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NHANES    National health and nutrition examination survey 
NHERF-1   Sodium-proton exchanger regulatory factor 1 
NICE    National Institute for Health and Care Excellence  
nNOS    Neuronal nitric oxide synthase 
NOS    Nitric oxide synthase 
NOSIP    Nitric oxide synthase interacting protein 
NSAID   Non-steroidal anti-inflammatory drug 
p53    Protein 53/tumour protein 53  
p-Akt    Phospho Akt 
PBS    Phosphate buffered saline 
(RT-)PCR   (Real time) Polymerase chain reaction 
PCT    Proximal convoluted tubule 
PD    Peritoneal dialysis 
PDE5I    Phosphodiesterase 5 inhibitor (zaprinast) 
PEP    Phenylephrine 
PKC    Protein kinase C 
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PKG    Protein kinase G 
PLCγ    Phosphoinositide phospholipase C γ  
PMSF    Phenylmethanesulphonyl fluoride 
PSS    Physiological saline solution 
PTH    Parathyroid hormone 
PWA    Pulse wave analysis 
PWV    Pulse wave velocity 
RA    The UK Renal Association 
RAAS    Renin-angiotensin-aldosterone system 
Redox    Reduction-oxidation reactions 
REIN    Ramipril in non-diabetic renal failure 
RIN     RNA integrity number 
RIPA     Radio-immunoprecipitation assay buffer  
ROS    Reactive oxygen species 
RPMI    Roswell park memorial institute 
RRT    Renal replacement therapy 
SD    Standard deviation 
SEEK    Study to evaluate early kidney disease 
SEM    Standard error of the mean 
SNP    Sodium nitroprusside 
SOD    Superoxide dismutase 
SP1    Specificity protein 1 
TAE    Tris-acetate electrophoresis 
TBS(T)   Tris buffered saline(with tween) 
TGF    Transforming growth factor 
TNF     Tumour necrosis factor  
TRPV5   Transient receptor potential vallinoid 5 
UPCR    Urinary protein to creatinine ratio 
VC    Vascular calcification  
VCAM   Vascular cell adhesion molecule 
VEGF    Vascular endothelial growth factor 
VSMC    Vascular smooth muscle cell 
WKY     Wistar-Kyoto rat strains 




Chronic kidney disease (CKD) is prevalent affecting 8.5% of the population in the UK and 
it is associated with premature cardiovascular disease (CVD) and death. The association 
between CKD and accelerated CVD arises as a consequence of traditional and non-
traditional cardiovascular (CV) risk factors, including serum phosphate. Currently, there is 
no therapeutic intervention which has been shown to effectively reverse the increased CV 
risk in CKD. Phosphate metabolism is disordered in CKD particularly in the advanced 
stages (CKD 4 and 5). Even at the upper limit of the normal reference range, serum 
phosphate has been shown to be associated with CV mortality and morbidity including left 
ventricular hypertrophy, vascular calcification (VC) and endothelial dysfunction (ED). 
These associations also extend to populations without CKD. Serum phosphate is an 
appealing CV risk factor because it can be modified by dietary and pharmacological 
therapies. However, there has been no study linking lowered phosphate with improved 
outcomes and whilst several small mechanistic studies have suggested a role of phosphate 
in VC, oxidative stress and more recently ED, the precise mechanism of action of 
phosphate as a CV risk factor remains elusive. Our lack of understanding of the 
mechanism of action of phosphate makes it difficult to ascertain how to best manage 
phosphate. 
 
The hypothesis of this thesis is that long term exposure to elevated phosphate is associated 
with endothelial and vascular dysfunction and it is this which contributes to the elevated 
CV risk seen in CKD. Endothelial and vascular dysfunction will be evident in individual 
cell lines and in blood vessels as well as in humans, who have been exposed to sustained 
oral phosphate. This hypothesis has been explored in a translational manner in three ways: 
 
1. The function of resistance vessels from rats and from humans, with and without 
CKD, has been studied. Experiments were performed looking at endothelium 
dependent and independent relaxation of vessels exposed to either normal or high 
phosphate concentration medium. The anti-oxidant, ascorbic acid and zaprinast, a 
phosphodiesterase 5 inhibitor were studied in the rat vessels to assess if these 
additions altered the vessels’ relaxation response. 
 
2. Cells were cultured in normal and high phosphate concentration medium from the 
outset to mimic the chronicity of the uraemic environment. The nitric oxide (NO) 
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pathway was studied considering eNOS expression, VEGF and cGMP production, 
intracellular calcium concentration and NO production. Proliferation and cell 
growth pathways have also been studied. 
 
3. A cross-over clinical trial was performed in 19 healthy volunteers, without CKD. 
Volunteers attended for three visits. Prior to each visit, they fasted for 12 hours and 
performed a 24 hour urine collection. Bloods were drawn and endothelial function 
was measured with flow mediated dilatation and vascular stiffness with pulse wave 
velocity and analysis. There was a baseline visit and then two further visits. Prior to 
visit two, volunteers were randomised to take phosphate supplementation or 
phosphate binding medication for two weeks, followed by a wash out period and 
then volunteers took the other tablet for two weeks, before attending for a final 
visit.   
 
In rat vessels, there was impaired endothelium dependent and independent relaxation in 
vessels exposed to high phosphate concentration medium. Vessels in high phosphate 
produced less basal NO and less cGMP. The impaired relaxation could be ameliorated with 
the addition of a phosphodiesterase 5 inhibitor. This suggests reversibility of the 
detrimental effects of phosphate. In human vessels from patients without CKD, there was 
similarly attenuated endothelium dependent and independent relaxation. In vessels from 
patients with CKD, there was impaired endothelium dependent relaxation but independent 
relaxation was preserved. The CKD vessels exposed to normal phosphate medium relaxed 
to the same degree as their counterparts from patients without CKD, again suggesting that 
the effects of phosphate may be reversible. These effects are independent of intracellular 
calcium concentration which was found to be similar in cells cultured in normal or high 
phosphate medium. There was evidence of disruption to the NO pathway with reduced 
eNOS expression in human and rat endothelial cells and reduced protein kinase G 
expression in vascular smooth muscle cells. NO measured by the Griess reaction was lower 
in cells cultured in high phosphate medium. NO has an inhibitory effect on growth and 
cells cultured in high phosphate proliferated more (measured with the MTT assay) and 
were bigger than cells cultured in normal phosphate medium. Gene expression studies 
showed alterations in growth genes and cell cycle regulators. 
 
ED was demonstrated in healthy volunteers exposed to sustained oral phosphate loading. 
This was independent of serum phosphate level which was unchanged. Urinary phosphate 
and fibroblast growth factor 23 level independently predicted ED and suggest that whilst 
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the normal homeostatic mechanisms maintain serum phosphate within the normal 
reference range, total body phosphate was elevated and urinary phosphate excretion was a 
surrogate for this. These relationships are novel and have not been demonstrated 
previously. 
 
It has previously been difficult to separate the effects of phosphate from other effects of the 
uraemic environment, including acidosis. The studies in this thesis have achieved this and 
the results provide strong evidence of an association between phosphate and ED. There is 
also evidence that these effects may be reversible. In contrast to conventional thinking that 
the effects of phosphate, like VC, are largely irreversible, these studies suggest that there 
may be dynamic effects of phosphate. This may be explained by alterations in intracellular 
phosphate. These findings have important implications for patients with CKD because they 
provide a sound explanation for the increased CV risk seen with phosphate and advocate 
further study of phosphate lowering (and outcome) as a therapeutic strategy to reverse this 
elevated CV risk.  
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1 Chapter One – Introduction 
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1.1 General Introduction 
This thesis will explore the mechanism of action of phosphate as a cardiovascular (CV) 
risk factor in a translational manner. Specifically, the effects of phosphate on the 
vasculature and the endothelium will be addressed in cell lines, in blood vessels and in 
humans both in the context of chronic kidney disease (CKD) and in the healthy population.  
In this introduction, CKD and CV risk will be discussed in sections 1.2 and 1.7. 
Endothelial dysfunction (ED) and vascular calcification (VC) seen in CKD are discussed in 
sections 1.3, 1.4 and 1.7. Phosphate homeostasis in health and dysregulation in CKD is 
described in sections 1.5, 1.6 and 1.8 with current management strategies for elevated 
phosphate discussed in section 1.9. Section 1.10 details work leading up to this thesis, 
section 1.11 the aims of this thesis and section 1.12 the hypotheses. 
The association between CKD and accelerated CV ageing arises as a consequence of both 
traditional and non-traditional CV risk factors. Phosphate metabolism is disordered in 
CKD, probably at all stages but especially in advanced CKD (stages 4 and 5) (1;2). In 
observational studies of CKD, elevated phosphate has been linked to VC, left ventricular 
hypertrophy (LVH), arrythmogenic death and ED (3-6). This increased CV risk seen with 
phosphate also extends to populations without CKD (7;8).  
Superficially, hyperphosphataemia is an appealing risk factor for cardiovascular disease 
(CVD) in CKD because it can be modified through diet and currently available 
pharmacological agents; phosphate binders. Yet, no firm evidence links lower serum 
phosphate levels with improved CV or patient outcomes (9;10). Furthermore, despite 
several mechanistic studies establishing that hyperphosphatemia plays a role in 
pathological processes including VC, ED and oxidative stress, the precise role and 
independent mechanism of action of phosphate as a CV risk factor remains elusive 
(4;6;11). It is very difficult to determine how best to manage elevated phosphate, whilst 
our understanding of the mechanism of action of phosphate as a CV risk factor remains 
limited. 
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1.2 Chronic kidney disease  
1.2.1 Staging of chronic kidney disease 
CKD is classified according to the measured or estimated glomerular filtration rate 
(eGFR). There are five stages: stage one indicates normal excretory function and stage five 
either severe impairment of renal function or the need for renal replacement therapy 
(RRT). The suffix p denotes the presence of significant proteinuria of more than 1g/day 
(12). 
1.2.2 Cardiovascular disease in chronic kidney disease 
CKD is increasingly prevalent, affecting 8.5% of the population in the U.K. and 10.9% of 
the population in the US (13;14). The burden of CVD in these patients is substantially 
higher than that of the general population. Moreover, patients with CKD are significantly 
more likely to die of CVD than to progress to end stage renal disease (ESRD) (15-17). 
Even with adjustment for age, the presence of diabetes mellitus (DM), racial and sex 
differences, CV mortality in end stage CKD is 10-30 times that of the general population 
such that a 25-year-old receiving haemodialysis (HD) maintenance has a mortality which is 
roughly equivalent to that of an 80-year-old in the general population (14;17). Dialysis is 
expensive costing approximately £35,000 per patient annually (18). Renal transplantation 
is currently the only definitive treatment available and offers a survival advantage over 
maintenance dialysis (19;20). Yet CVD mortality rates of at least twice that of the general 
population persist and the overall prevalence of CVD continues to be approximately four 
times higher (14;21). Furthermore there is a shortage of deceased donor kidneys and renal 
transplantation is not a viable option for everyone (22).  
Without transplantation, the five year survival for a patient aged around 60 years on 
dialysis is 46% which is equivalent to five year survival from ovarian cancer and 
significantly worse than five year survival from breast, colon or bladder cancer. Notably if 
a cancer sufferer survives, their chance of survival at ten years increases whereas in 
dialysis patients, it continues to reduce leading to a trend survival of less than 15% (Table 
1-1) (23-25).  Thus, CKD represents a significant, worldwide public health concern and 
socio-economic burden. 
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Table 1-1: Comparison of the five year survival in a patient aged between 60-64 years with 
different diagnoses. 
Adapted from Hutchison et al and based on statistics from Cancer Research UK and The UK Renal 
Registry (23-26).  
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1.2.3 Cardiovascular risk factors in chronic kidney disease 
The disproportionate CV risk seen in CKD is not adequately explained by the traditional 
atherosclerotic risk factors such as hypertension and DM, and the pattern of CVD differs 
with an excess of sudden death and death due to chronic heart failure rather than 
myocardial infarction (27;28). Some traditional risk factors including body mass index 
(BMI) and hypertension exhibit ‘reverse epidemiology’ in HD patients whereby low BMI 
and hypotension are risk factors for CVD compared to obesity and hypertension in the 
general population (29;30).  
In an attempt to explain the gap in risk between the CKD and the general population, ‘non-
traditional’ risk factors which may be unique to the CKD population have been described 
(2;14). In reality, excess CV risk probably reflects a combination of traditional CV risk 
factors, including hypertension and ‘non-traditional’ risk factors including serum 
phosphate level (Figure 1-1), ED and oxidative stress (31).  
Serum phosphate level, even within the normal range, has been shown to be an 
independent risk factor for CVD in the CKD population, including recipients of a renal 
transplant, and in healthy volunteers (2;8;32;33). It is of particular relevance in CKD 
because the normal homeostatic mechanisms are disrupted leading to disequilibrium with 
clinically significant consequences (3;4). Serum phosphate is inversely proportional to 
eGFR, although there is individual variation (34). The mechanisms of action of phosphate 
as a CV risk factor are not well understood and may relate to direct effects on VC 
(dependent upon the calcium phosphate product), effects on endothelial function and 
indirect effects mediated via regulators of phosphate homeostasis including fibroblast 
growth factor 23 (FGF-23) (6;35;36). 
1.2.4 Progression of chronic kidney disease 
Several risk factors have been demonstrated to increase the likelihood of progressive loss 
of renal function including poor control of hypertension and low eGFR at presentation 
(37;38). However, the best independent predictor of outcome in CKD is proteinuria (39). 
This is true in patients with both primary renal disease and diabetic renal disease (40;41). 
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Figure 1-1: Traditional and non-traditional risk factors for CVD in CKD. 
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Proteinuria is also a sensitive predictor of chronic renal transplant dysfunction and of long-
term graft survival (42-44) and also predicts all-cause and CV mortality in the general, 
renal transplant and CKD populations (45-48).   
1.2.5 Proteinuria 
Proteinuria indicates renal damage and reflects the increased permeability of the 
glomerulus as a consequence of renal disease and tubular losses (49). Evidence also points 
to a directly toxic effect of proteinuria causing stimulation of pro-fibrotic, inflammatory 
chemokines including interleukin (IL) 8 and transforming growth factor (TGF) β markers 
in the proximal convoluted tubule (PCT) and proximal tubule cell apoptosis (50). The 
extent of interstitial fibrosis (and associated tubular depletion), determined by renal biopsy, 
is the best histological correlate of risk of progressive renal decline (51). 
The increased CV risk seen with proteinuria is multi-factorial. In part it relates to its 
association with a more rapid decline in renal function and thus more rapid progression to 
the increased risk associated with low eGFR. Other postulated mechanisms include 
inflammation, hypertension and ED (52). Proteinuria might not only represent renal 
damage but increased endothelial permeability throughout the body. In 2003, Paisley et al 
demonstrated macro-vascular ED in individuals with proteinuria in addition to a low grade 
inflammatory response which was associated with impaired micro-vascular endothelial 
function (53). Stroes et al showed a similar impairment in macrovascular endothelial 
function and postulated that this might relate to defective nitric oxide (NO) release (54). 
Associations have been demonstrated between proteinuria and alterations in the NO and 
vascular endothelial growth factor (VEGF) pathways (52). No study demonstrates a 
causative link and whilst proteinuria may be directly toxic to the vasculature, it may simply 
be a marker reflecting widespread ED. 
1.2.6 Renin-angiotensin-aldosterone system  blockade 
The benefit of therapeutic strategies which reduce proteinuria to slow the progression of 
renal decline has been clearly established (55-58). The renin-angiotensin-aldosterone 
system (RAAS) plays a well recognised role in the pathogenesis of CV and renal disease 
with activation resulting in oxidative stress, a pro-inflammatory environment and fibrosis 
Chapter 1 XXX 30 
(59). Proteinuria may be a surrogate marker for the damage inflicted by activation of the 
RAAS. In the last decade, inhibition of RAAS with angiotensin converting enzyme 
inhibitors (ACEi) or angiotensin II receptor blockers (ARB) has become the mainstay of 
the management of the common manifestations and complications of CKD:  CVD, 
hypertension and proteinuria. The reno-protective effects of ACEi and ARB in CKD 
appear to extend beyond their blood pressure lowering capabilities (56). However, despite 
RAAS blockade, a proportion of patients will develop end stage renal disease and no study 
has demonstrated that these agents reduce CV risk or CVD in this population.  
One reason for the incomplete benefits of ACEi/ARB may be that neither agent blocks the 
RAAS completely and aldosterone may be independently regulated. The detrimental 
effects of aldosterone include ED and fibrosis (59). Blockade of the mineralocorticoid 
receptor may confer additional benefits in terms of reno-protection particularly when taken 
in combination with ACEi or ARB (60). Similarly, the direct renin inhibitor, aliskeren, 
blocks RAAS at an earlier point and may confer additional benefits (61). There is a paucity 
of trials looking at either renal or patient outcome with these drugs and any such study 
would require a large cohort and an extensive follow up period. 
1.2.7 Phosphate and progression of chronic kidney disease 
Interest in phosphate waned in the 1980s and 1990s with research focussing on proteinuria, 
hyperparathyroidism and VC in CKD progression and related mortality. However with the 
discovery of new factors involved in bone mineral metabolism in CKD, interest in 
phosphate has revived. 
Thirty years ago, Ibels et al demonstrated dietary phosphate restriction in a remnant-kidney 
rat model prevented histological change, reduced renal functional decline, ameliorated 
proteinuria and reduced mortality (62). A second study in the 5/6 nephrectomised rat 
confirmed that those animals fed a high phosphate diet were more likely to develop 
progressive renal impairment and myocardial hypertrophy (63). In the 1980s, a clinical 
study demonstrated that a phosphate and nitrogen restricted diet had a renoprotective effect 
(64). In 2006 and 2007, three further observational clinical studies highlighted an 
association between progression of renal disease and higher serum phosphate levels (65-
67). A further observational study in 2011 confirmed that elevated serum phosphate 
increased the likelihood of progression of renal disease independently of eGFR (68). 
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Observation does not confirm causality nor does it give insight into the mechanism by 
which higher phosphate levels might accelerate renal decline. 
 
1.3 The vasculature in chronic kidney disease 
The vasculature becomes progressively dysfunctional in CKD with evidence of increased 
stiffness and ED ubiquitously present from the large vessels down to the very small 
resistance vessels.  
1.3.1 Arterial stiffness, pulse wave velocity and the augmentation 
index 
In health, the arterial vessels are both elastic and compliant allowing forward and 
retrograde pressure waves to propel blood from and towards the heart. Their compliance 
affords the ability to smooth the transition of the pressure wave throughout the arterial tree 
ensuring a constant flow of blood to the tissues. Proximal arteries (eg ascending aorta) are 
comprised of a higher proportion of elastin and collagen and thus are more elastic than 
their distal counterparts (eg femoral artery). Compliance of an artery is the product of the 
vessel’s distensibility and the volume of blood contained within the vessel. In less 
distensible and therefore stiffer arteries, blood flow dynamics are affected; forward and 
retrograde pressure waves travel more rapidly through a stiffer vessel (69). Pulse wave 
velocity (PWV) therefore acts as a surrogate for arterial stiffness. It is derived from the 
distance between two recording sites in the line of pulse travel (typically the carotid and 
femoral arteries) and the time delay between the corresponding points of the pressure 
wave. PWV measurement is non-invasive, straightforward and reproducible and it is 
acknowledged to be the gold standard measure of arterial stiffness (70). 
PWV is higher in distal compared with proximal arteries. As a pulse wave travels through 
the distal vessels, its amplitude will increase such that in a fit, healthy, young individual 
with a normal heart rate, brachial pulse pressure may be up to 50%  higher than that of the 
aorta (71). Consequently, brachial pressure cannot be considered to be the same as aortic 
pressure. The augmentation index (AIx) measured by pulse wave analysis (PWA) is 
another reflection of arterial stiffness. In a stiffer artery, the PWV increases such that the 
pulse wave will arrive ‘early’ in systole (71). As a result, the forward pressure wave is 
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enhanced, systolic blood pressure rises and diastolic blood pressure is proportionately 
lower. The amount by which the reflected wave augments the forward pressure wave is the 
AIx. This is summarised in Figure 1-2. Any factor which tips the balance between 
production and degradation of elastin and collagen towards reduced quantities of the 
proteins can contribute to vascular stiffness; ageing, DM, inflammation, hypertension, 
CKD, hormonal and dietary factors (72). The more compliant proximal arteries are those 
predominantly affected by stiffening. As a consequence of arterial stiffness, arterial 
pressure rises, cardiac performance and coronary perfusion are compromised. Not 
unexpectedly, increased arterial stiffness is linked to ageing, CV morbidity and mortality, 
all cause mortality and dementia (72-74). Measurements of PWV and AIx are predictive of 
CV events and mortality in the general population and in CKD (75-78). In CKD, both also 
correlate with progression of renal disease (79;80). 
1.3.2 Arterial stiffness in chronic kidney disease 
Arterial stiffness increases as renal function declines. This is true even if changes in eGFR 
are minor and within the normal range (81;82) and may reflect the association of uraemia 
with factors which are known to contribute to arterial stiffness including inflammation, 
ED, oxidative stress, malnutrition, DM, insulin resistance and hypertension (35;72).  
However there are other factors, prevalent in CKD, which contribute to arterial stiffness- 
notably VC, the hallmark of which is calcium and phosphate deposition as hydroxyapatite 
(83). In the CKD population compared with the non-CKD population, extensive VC is 
often present. In those with advanced CKD this is classically calcification of the arterial 
media - Mönckeberg sclerosis - which occurs independently of atheromatous disease of the 
intima (4;84). Intimal calcification, in the context of atheroma, may also develop but 
medial calcification is significantly more common (4;85). 
Explanations for the increased prevalence of VC seen in CKD include disordered bone 
mineral metabolism and the recognition of a complex and active osteochondrogenic 
differentiation process whereby the vascular smooth muscle cell (VSMC) of the media 
undergoes phenotypic transformation into an osteoblast like cell (86;87). There is 
increasing evidence that phosphate plays a key role in the development of VC and this will 
be discussed more fully in section 1.7.3. 
 
Chapter 1 XXX 33 
 
Figure 1-2: Graphical representation of pulse wave velocity and derived functions. 
The augmentation pressure (AP) is the pressure difference between the maximal systolic peak and 
the inflection point. AIx is the augmentation index and is calculated by dividing AP by the pulse 
pressure (PP). To ascertain the pulse wave velocity:Δt is the difference in time between the 
upstroke in the common carotid artery and the upstroke in the common femoral artery, after the R 









Chapter 1 XXX 34 
1.4 The endothelium in health and chronic kidney 
disease 
The endothelium is a mono-layer of squamous cells which lines the inner surface of every 
blood vessel. It serves as a pivotal connection between the vascular wall and the blood 
circulating through the vessel lumen and plays a central role both in health and disease 
(89). In health, the endothelium is central to the maintenance of vascular tone and provides 
a non-thrombotic, smooth surface to line blood vessels and provide structural integrity. 
Additionally, directly or indirectly, the endothelium produces an abundance of mediator 
molecules involved in coagulation, VSMC growth and proliferation and inflammation 
(89;90).  
Endothelial cells (ECs) ‘sense’ and respond to mechanical signals created by blood flow 
(pressure, stretch and shear stress), as well as humoral eg adrenaline, noradrenaline, 
aldosterone, acetylcholine, angiotensin II and endothelin-I and chemical (glucose, reactive 
oxygen species (ROS) and homocysteine) factors (90-93). Detection of these signals, alone 
or in combination triggers ECs to release mediators, including NO, which modulate 
processes involving the blood vessel wall, including adhesion of leucocytes, release of pro-
thrombotic and antithrombotic factors and release of vasoactive substances (91). 
When the endothelium is damaged, ED develops and this refers to a pro-thrombotic and 
pro-inflammatory environment in which there is increased vascular reactivity with 
impaired endothelium dependent vasodilation, leucocyte adhesion and platelet aggregation 
(90;94). This can affect any area of the vasculature, and is the hallmark of all major 
vascular causes of mortality and morbidity: CKD, atherosclerosis, hypertension, 
pulmonary hypertension and DM (89;95-98). 
ED has been shown to be an independent predictor of CV events in patients with CV risk 
factors or pre-existing CVD (99;100). In healthy volunteers without DM or pre-existing 
CVD, it is independently predictive of progression of carotid arterial disease and of future 
CV events (101;102).  
ED may be partly reversed by statin therapy and with ACEi and ARBs, independently of 
any blood pressure lowering effect (103;104). Antioxidants may also be effective although 
the evidence is mixed with one study showing an improvement in endothelial function with 
treatment with a combination of vitamins C and E and α-lipoic acid in elderly but not in 
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younger patients (105). In women with polycystic ovarian syndrome, metformin and 
pioglitazone improve endothelial function (106). 
1.4.1 The nitric oxide pathway and endothelial dysfunction 
The major modulatory molecule released by ECs is NO. The NO pathway is summarised 
in Figure 1-3.  
NO is produced under basal conditions as well as in response to the mechanical, humoral 
and chemical stress as described above (107). Basal NO production is reduced in 
conditions including coronary artery disease, where ED is present (108). NO is a powerful 
relaxing factor which is synthesised from the oxidation of L-arginine by nitric oxide 
synthase (NOS). There are three isoforms of this enzyme: endothelial NOS (eNOS), 
inducible NOS (iNOS) and neuronal NOS (nNOS). The form predominantly present in 
endothelial cells is eNOS. eNOS has two phosphorylation sites: Ser1177 which activates 
eNOS and Thr495 which inhibits eNOS (90;109). eNOS produces NO continuously in the 
picomolar range. iNOS is present in VSMC and is not responsible for basal NO 
production; it needs to be ‘switched on’ by cytokines, mechanical stress or endotoxins; 
production of NO is delayed and levels produced are in the nanomolar range (110). 
NO is a paracrine mediator, diffusing from ECs to adjacent VSMCs where it triggers a 
signalling cascade mediated by activation of guanylate cyclase and the generation of cyclic 
guanosine monophosphate (cGMP). This promotes the stimulation of protein kinase G 
(PKG) and results in the activation of several transcription factors; the end result is 
inhibition of calcium mediated vasoconstriction (90;111). 
In addition to its role as a potent vasodilator, NO inhibits platelet aggregation, leucocyte 
adhesion (107) and VSMC proliferation (possibly by inhibition of the enzyme, ornithine 
decarboxylase which is essential for cell growth) (112). VEGF is produced by a number of 
different cells and promotes vasodilation. It acts on ECs to increase endothelial 
permeability and stimulates phosphorylation of eNOS thus increasing NO levels (113). 
Levels of VEGF have been shown to be reduced in the setting of ED (114). 
When ED is present, there is reduced NO release. This promotes a pro-inflammatory state 
and encourages leucocyte adhesion and platelet aggregation with increased expression of 
the cell adhesion molecules including soluble E-selectin and vascular cell adhesion 
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molecule (VCAM) (115). Elevated levels of soluble E-selectin have been shown to be 
independently predictive of mortality in patients with pre-existing CVD (116). In the pro-
inflammatory state of ED, the adenosine receptor, ADORA2A may be protective: it is 
activated which enhances production of the intracellular signalling molecule, cyclic 
adenosine monophosphate (cAMP) and reduces cell adhesion molecule expression (117). 
Thus, NO has a central role in the relationship between ED and coagulation which explains 
the importance of ED in CVD specifically occlusive coronary disease and stroke.  
1.4.2 Reactive oxygen species and oxidative stress 
Reduction-oxidation reactions (redox) occur in vivo to convert oxygen to water. 
Intermediates, termed ROS are produced as part of the reduction of oxygen. Free radicals 
are species with an unpaired electron. ROS include both free radicals (superoxide (O2
-
), 
peroxynitrite) and peroxides (hydrogen peroxide) (118).  
In health, ROS are products of normal cellular metabolism and the concentration of ROS is 
dependent upon the balance between production and removal. Removal occurs via ROS 
scavengers including traditional antioxidants like vitamins C and E as well as enzymes and 
proteins (118). An anti-oxidant is a substance which inhibits oxidation of oxidizable 
substrates by direct competition (119).  ROS stimulate expression of ‘defence genes’ eg 
NADPH oxidases and activate transcription factors to control endothelial function and 
maintain vascular tone (90;94;120). Oxidative stress occurs when there is impaired redox 
signalling and a pro-oxidant environment. In this circumstance, ROS induce cellular injury 
and play a pathological role in inflammation, hypertrophy, proliferation, angiogenesis and 
fibrosis, all of which contributes to ED. 
NO is highly reactive with free radicals and this is of benefit; it has been shown to 
scavenge peroxyl radicals and to inhibit lipid peroxidation. (121). However, a by-product 
of the reaction between NO and O2
-
 is peroxynitrite, which is itself a ROS. The superoxide 
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Figure 1-3: The nitric oxide pathway. 
Upon stimulation of an EC, the calcium regulatory protein, calmodulin (CaM) binds eNOS resulting 
in the production of NO. Additional stimulation of NO production comes via the vascular endothelial 
growth factor (VEGF) pathway. NO diffuses into the VSMC where it stimulates the production of 
cGMP from guanosine-5’-triphosphate (GTP) via activation of the enzyme, guanylyl cyclase. cGMP 
activates protein kinase G (PKG) which has a negative effect on calcium and causes subsequent 
relaxation of the muscle cell and vasodilatation of the blood vessel as a whole. cGMP is broken 
down to the guanosine monophosphate (GMP) by a group of enzymes, the phosphodiesterases. 
NO also prevents platelets and leucocytes from sticking to the blood vessel wall. Adapted from 
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1.4.3 Endothelial dysfunction in chronic kidney disease 
ED is present in CKD and the degree worsens with severity of renal disease. Low GFR, is 
linked to clinical measures of endothelial function and increased oxidative stress (123-
125). Many of the clinical studies in this area have used forearm plethysmography or flow 
mediated dilatation (FMD), measured in the brachial artery, to assess endothelial function. 
The differences seen demonstrate that in CKD, ED is widespread and not confined to the 
renal vascular bed. Thus ED is very likely to play a role in the increased premature CV risk 
seen in the CKD population which is unexplained by traditional CV risk factors. 
The mechanism of ED seen in CKD is not well understood, and much of the work in this 
area has been in animal models. ED may be either a cause or a consequence of CKD. In 
reality it is likely that there is an initial insult leading to endothelial damage which then 
self-propagates the problem with imbalances in redox as described in section 1.4.2. 
Alterations in eNOS and O2
-
 expression have been demonstrated as well as evidence of 
increased lipid peroxidation products, abnormalities in EC growth and impaired relaxation 
in human resistance vessels from patients with CKD (6;95;124;125). 
Renal EC dysfunction plays a central role in the pathogenesis of disorders including 
vasculitis, glomerulonephritis, DM and haemolytic uraemic syndrome (126;127). 
Proteinuria (sections 1.2.5 and 1.2.6), when present, is likely to be a marker of ED, 
specifically glomerular EC dysfunction as a marker of generalised ED (52;53) and may 
explain the link between ED and progression of CKD (126). 
ED is an early marker of CVD, facilitating the development of atherosclerosis and 
hypertension. An improved understanding of the mechanism of ED in CKD may allow for 
targeted therapies to reduce CV risk; the contribution of phosphate to ED is one possibility. 
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1.4.4 Flow mediated dilatation  
In vivo, FMD is the best validated, non-invasive technique for measurement of endothelial 
function and correlates closely with invasive measurements at coronary angiography 
following acetylcholine injection (128). A schematic representation of FMD is presented in 
the cartoon in Figure 1-4.  
Using high resolution B mode doppler ultrasound, the brachial artery can be imaged to 
quantify changes in artery diameter secondary to increased blood flow (Figure 2-7, Chapter 
2). This can provide an indicator of vasomotor function. A blood pressure cuff is inflated 
on the forearm to occlude the arterial inflow for five minutes. This causes ischaemia and 
dilation of downstream blood vessels as a result of auto-regulation. When the cuff is 
deflated there is a brief period of increased blood flow through the artery, reactive 
hyperaemia, which  in the healthy endothelium stimulates NO release from the 
endothelium with consequent vasodilation of the brachial artery – FMD (130). This 
measure has been validated in a number of populations including healthy volunteers and 
those with CKD (123;131). 
Endothelium independent vasodilation can also be measured with this technique. Glyceryl 
tri-nitrate (GTN) is a NO donor which causes dilation of the brachial artery independently 
of the endothelium. It allows determination of the maximum possible vasodilation response 
(seen approximately 3-4 minutes following administration of GTN) and provides an 












Figure 1-4: Schematic representation of FMD. 
Baseline brachial artery diameter is measured pre and post inflation of a blood pressure cuff and 
the % difference is calculated as a measure of endothelial function. When the endothelium is intact 
the vessel dilates when the cuff is released and blood flow is increased: ‘reactive hyperaemia’. The 
same measurements can be undertaken after administration of GTN spray to assess endothelium 
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1.5 Phosphate 
1.5.1 Phosphorus or phosphate 
Phosphorus, described as the ‘Devil’s element’ because of its use in explosives, poisons 
and nerve agents, was first discovered in 1669 by a German chemist, Hennig Brand. Brand 
was trying to produce ‘The Philosopher’s Stone’ by evaporating urine when he isolated a 
white substance which glowed in the dark - phosphorus. In ancient Greece, phosphorus 
was the name for the planet Venus and has its origins in the Greek words for ‘light’ and 
‘carry’ thus phosphorus translates roughly as light carrier (132). 
Phosphorous is a non-metal element which is part of the nitrogen group in the periodic 
table (atomic number 15). It is extremely reactive and does not exist as a free element,but 
rather in an oxidised state as phosphate (PO4
3-
), a component of many minerals (133). 
Throughout this thesis, the term phosphate will be used.  
Phosphate is a tetrahedral anion and is found within the human body in several forms. 
Approximately 80% of total body phosphate is stored in the teeth and bones as solid 
minerals, calcium phosphate, hydroxyapatite (and fluoroapatite, which is harder and 
created when hydroxyl groups are replaced by fluoride ions). 14% is found intracellularly 
and 1% in the serum (134).  
Serum phosphate acts as an important buffer system existing in four forms; the two main 
forms are hydrogen phosphate (HPO4
2-
) and dihydrogen phosphate (H2PO4 
-
). Briefly, the 
reaction scheme for this buffer system is: H
+
 + HPO4 
2-
   H2PO4
–
 
At a neutral pH of 7.4, the pK value of H2PO4
–
 is 6.8 and HPO4:H2PO4
–
 exist in a ratio of 
4:1.  In strongly acidic conditions, a third form, H3PO4 (phosphoric acid) predominates. In 
a strongly alkaline environment, the fourth form, the phosphate ion is the dominant form 
(PO4
3-
). Remaining serum phosphate (about 14%) is found bound to protein. Phosphate 
forms chains and rings with phosphoanhydride bonds (P-O-P bonds). Both adenosine 
triphosphate (ATP) and adenosine diphosphate (ADP) are polyphosphates (135;136). 
Although serum phosphate is only a small percentage of total body phosphate,  it can easily 
be measured and provides some insight into total phosphate stores (134). The 
concentration of phosphate is generally expressed as millimoles/litre (mmol/L or mM); in 
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the USA, it is often expressed as milligrams/decilitre (mg/dL). mM can be converted to 
mg/dL by dividing by 0.323 such that 1mg/dL is equivalent to 0.323mM (134). The 
reference range for serum phosphate measurements in our laboratory (Gartnavel General 
Hospital) is 0.7-1.4mM (2.2-4.3mg/dL) in an adult. 
1.5.2 Phosphate homeostasis in health 
 Despite the accolade of the sixth most abundant element present in the human body and 
playing a crucial role in several biological processes and functions including genetic 
coding, energy metabolism, oxygen carrying by haemoglobin, and intracellular signal 
transduction, the precise details of phosphate homeostasis are poorly defined (137).  
To maintain phosphate at physiological levels, there has to be a tightly regulated sensing 
and signalling mechanism. In phosphate homeostasis two types of cell sensing have been 
described: metabolic sensing which is how human cells sense inorganic phosphate to 
regulate cell metabolism and endocrine sensing which describes how extracellular 
phosphate is regulated via feedback systems (138). Mechanisms for phosphate sensing in 
yeast and bacteria have been well described leading to alterations in protein 
phosphorylation and transcription (139;140). In humans and other mammals, identifying 
the phosphate sensor(s) has proved elusive. The four main organs involved in phosphate 
regulation: kidney, bone, parathyroid gland and intestine all ‘talk’ to each other and there is 
now a sizeable body of evidence describing how this occurs and this in turn provides 
further evidence that a phosphate sensor must exist in humans although we have yet to find 
the sensor or its effector mechanisms. 
1.5.2.1 Phosphate and diet 
Phosphate is present in many foods, most importantly dairy products, meat, whole grains, 
fizzy juice and food additives. The phosphate content of selected foods is incorporated into 
Figure1-5 (141). In the Western world, average daily phosphate consumption approximates 
1000-1500mg. However, the modern diet is high in processed foods which often contain 
food additives including mono-calcium phosphate and sodium phosphate (9;141).  High 
consumption of processed food contributes up to 1000mg of additional phosphate per day 
(142). Currently, the amount of phosphate does not need to be quantified on product labels 
and thus the actual phosphate intake and the estimated phosphate intake might differ 
significantly (143). In health, bone contains an exchangeable pool of phosphate and 
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behaves as a reservoir (Figure 1-5). There is constant exchange of phosphate to and from 
this pool between bone and the serum; in combination with dietary absorption and renal 
resorption, this maintains serum phosphate levels within the normal range (144). 
1.5.2.2 Phosphate transport in the intestine 
The majority of phosphate from the diet is absorbed in the small intestine via two 
processes: a passive diffusional process and an active process via sodium dependent 
phosphate co-transporters. Passive absorption relies upon electrochemical gradients across 
the intestinal epithelial cells with phosphate diffusing through the junctions between 
adherent neighbouring cells. This process is dependent upon phosphate load in the intestine 
from ingested food (145). 
The type II sodium dependent phosphate co-transporters are responsible for active 
absorption of phosphate from the small intestine. There are three type II transporters: 
NaPi2a, NaPi2b and NaPi2c, encoded for by the SLC34A1, SLC34A2 and SLC34A3 
genes respectively(146). NaPi2a and NaPi2c are largely responsible for renal transport of 
phosphate and are discussed in section 1.5.2.3. 
NaPi2b is principally expressed in the brush border membrane of the small intestine and is 
responsible for the active absorption of phosphate here (147). Expression of this 
transporter is primarily regulated by vitamin D although FGF-23 is also thought to play a 
key role (145;147). Other factors including oestrogen, glucocorticoids and thyroid 
hormones may also be involved, and a study in a knock out mouse model demonstrated 
that phosphate itself may directly stimulate expression of the receptor independently of 
vitamin D (145;148). In this model, serum phosphate levels were unchanged which is 
likely to be explained by the observed increased expression of NaPi2a in the kidney with 
consequent increased renal reabsorption of phosphate. In humans with genetic mutations 
and resultant inactivation of NaPi2b, serum phosphate levels are unaltered which is at odds 
with NaPi2b playing an essential role in serum phosphate regulation (149). 
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Figure 1-5: Phosphate balance within the body. 
Phosphate is consumed within the diet and excreted mainly via the kidneys but also via the 
intestine. The bone acts as a reservoir and constantly exchanges phosphate with the serum. 
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1.5.2.3 Phosphate transport in the kidney 
Phosphate is filtered in the glomerulus and approximately 70% of filtered phosphate is 
reabsorbed in the PCT in the kidney (150). NaPi2a and NaPi2c are expressed in the PCT 
and facilitate phosphate transport across the apical brush border epithelial membrane of the 
PCT cells with efflux at the basolateral membrane (147). Parathyroid hormone (PTH) is 
the major regulator of transporter expression (discussed in detail in section 1.5.2.6). High 
phosphate concentration in the glomerular filtrate also directly stimulates release of these 
transporters from brush border vesicles to reduce phosphate reabsorption (144). 
NaPi2a appears to play a more prominent role in phosphate reabsorption than NaPi2c and 
might be responsible for up to 70% of phosphate reabsorption (147;150). Several 
differences between the transporters have been identified. NaPi2a transports three sodium 
ions with phosphate whereas NaPi2c carries only two (146).  PTH reduces expression of 
NaPi2a and therefore reduces renal phosphate reabsorption. In a knock out mouse  
(NaPi2a-/-), proven to express NaPi2c, PTH does not have this effect and thus PTH does 
not seem to be able to alter renal phosphate reabsorption by altering the expression of 
NaPi2c (150).  
In animal studies, NaPi2c seems to be more abundantly expressed in the neonatal period 
and expression reduces thereafter (151). Humans with hereditary hypophosphataemic 
rickets have profound hypophosphataemia, rickets and short stature. In this condition, loss 
of function mutations in the SLC34A3 (encodes NaPi2c) have been sequenced (152). It is 
likely therefore that, at least in humans, NaPi2c plays a more important role than initially 
appreciated in renal phosphate transport. 
1.5.2.4 Phosphate transport in other tissues and organs 
PiT1 and PiT2 are type 3 phosphate transporters encoded for by SLC20A1 and SLC20A2. 
Both transport phosphate with a high affinity and are widely expressed throughout the 
body (145;150). Current thinking assumes that these transporters are ‘housekeepers’ 
responsible for intracellular transport of phosphate to provide cells with their basic 
phosphate requirements. These transporters have not been as well studied as the type II 
phosphate transporters and there is little cellular data to support the ‘housekeeper’ theory. 
Recent evidence suggests that the importance of PiT1 and 2 may have been overlooked. In 
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an animal model, PiT1 has been shown to have a pivotal role in liver development (153). 
In human cell lines depleted of PiT1, cell proliferation is markedly reduced and cells are 
more sensitive to the pro-apoptotic effects of tumour necrosis factor (TNF) α  which 
implies a role in cell growth and possibly in cancer pathogenesis (154;155). These 
observed effects are independent of phosphate transport function.  
1.5.2.5 Hormonal regulators of phosphate homeostasis 
Maintaining phosphate balance centres upon regulation of phosphate excretion by the 
kidney. This is controlled by three major regulatory factors; PTH, vitamin D and FGF-23. 
Homeostasis depends upon co-ordination between these factors and not upon on any one 
factor individually.  
1.5.2.6 Parathyroid hormone 
PTH is produced by the parathyroid glands and its main role relates to calcium homeostasis 
(150). In health it is produced primarily in response to reduced serum calcium but also to 
increased serum phosphate levels. PTH exerts its effects on bone and the kidney via the 
type 1 PTH receptor with several consequences: increased urinary phosphate excretion, 
reduced urinary calcium excretion, increased production of vitamin D and increased 
calcium release from bone (36;147;156). This serves to maintain serum calcium and 
phosphate at physiological levels. The role of PTH in phosphate homeostasis is 
summarised in Figure 1-6. 
PTH binds to the type 1 PTH receptor in the PCT cells and reduces the expression of 
NaPi2a. This occurs via one of three pathways: protein kinase C (PKC) signalling, the 
cAMP dependent phospholipase C pathway and the mitogen activated protein kinase 
(MAPK) pathway. Correct targeting of PTH and NaPi2a seems to require the presence of 
an additional factor: sodium-proton exchanger regulatory factor 1 (NHERF1) which 
interacts with the PTH receptor and phospholipase C (146;147;150). Thus PTH reduces 
renal phosphate transport and increases urinary phosphate excretion. 
PCT expression of 25-hydroxyvitamin D 1-α-hydroxylase is increased by PTH resulting in 
the conversion of inactive vitamin D, 25-hydroxyvitamin D (25-OH-D) to active vitamin 
D, 1,25- dihydroxyvitamin D3 1-25-(OH)2-D. Vitamin D acts on the renal distal 
convoluted tubule (DCT) to increase calcium reabsorption although its major effect is on 
the intestine where it increases both calcium and phosphate absorption (36). The 
Chapter 1 XXX 47 
contrasting effects of vitamin D and PTH on the kidney and intestine serve to balance 
serum phosphate levels whilst maintaining calcium homeostasis. PTH also increases bone 
resorption by osteoclasts thereby stimulating calcium release from bone (157). Lastly PTH 
may increase the expression and production of FGF-23, which is discussed in section 
1.5.2.8 (36). 
1.5.2.7 Vitamin D 
Vitamin D circulates in an inactive form, 25-OH-D which is filtered by the kidneys and 
reabsorbed in the PCT (158). The active form, 1-25-(OH)2-D, is secreted in the kidney 
following conversion of 25-OH-D by 25-OH-D 1-α-hydroxylase and it mediates its effects 
via the vitamin D receptor (159). Elevated serum phosphate and lowered serum calcium 
levels enhance the activity of 25-OH-D 1-α-hydroxylase. PTH stimulates transcription of 
25-OH-D 1-α-hydroxylase (147). Active vitamin D increases calcium and phosphate 
absorption in the small intestine. FGF-23 reduces expression of 25-OH-D 1-α-hydroxylase 
thereby reducing 1-25-(OH)2-D production (158). 
1-25-(OH)2-D has a negative regulatory effect on PTH and on itself by reducing expression 
of 25-hydroxyvitamin D 1-α-hydroxylase and increasing expression of 24-hydroxylase 
(24-OH-ase) which converts active vitamin D into an inactive form. 1-25-(OH)2-D 
increases production of FGF-23 from bone and increases gene expression of Klotho, the 
FGF-23 co-factor. This promotes additional negative feedback on 1-25-(OH)2-D 
production (158;159). 
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Figure 1-6: Effects of parathyroid hormone release on bone, kidney and intestine. 
Hypocalcaemia and hyperphosphataemia stimulate release of parathyroid hormone which acts on 
bone to increase bone resorption and stimulate FGF-23; on kidney to reabsorb calcium, synthesise 
vitamin D and excrete phosphate; and on the intestine to increase calcium and phosphate 
absorption (mediated via vitamin D) 
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1.5.2.8  Fibroblast growth factor 23  
FGF-23 is a phosphaturic hormone which was discovered in 2000 following genetic 
studies in patients suffering from autosomal dominant hypophosphataemic rickets (ADHR) 
(160). ADHR is one of a handful of genetic conditions, including tumour induced 
osteomalacia, characterised by hypophosphataemia, hyperphosphaturia and disrupted bone 
mineralisation. An additional circulating factor was suggested to have a role in these 
conditions to explain the surprising finding that serum phosphate concentrations are altered 
without observing any significant changes in serum calcium level, PTH or vitamin D 
(161). Subsequent genomic work led to the discovery of FGF-23. In ADHR, there is a 
genetic defect in PHEX, a metalloprotease with a role in FGF-23 breakdown. The 
consequence is elevated serum levels of FGF-23 (162). 
FGF-23 is a 251 amino acid protein with a molecular weight of 26kDa which is produced 
in bone by osteocytes and osteoblasts in response to increases in serum phosphate and 1-
25-(OH)2-D levels (36;150;163). It is encoded for by the FGF-23 gene located on 
chromosome 12 (147). There are seven FGF families; FGF-23 is a member of the FGF-19 
sub-family (163). FGF-23 shares a common structure, an ‘FGF-like sequence’ at amino 
acid residues 25-180, with other FGFs but it has a unique 72 amino acid sequence 
extension (residues 179-251) at the carboxyl C terminal tail (164). Full length FGF-23 is 
the biologically active form but the C terminal is essential for its biological effects 
(147;164). Only full length FGF-23 causes a reduction in serum phosphate levels (165). 
However there is evidence in rats that the C terminal of FGF-23 retains significant 
phosphaturic activity separate from the ‘FGF-like’ main amino acid sequence (166). 
Inactivation of FGF-23 occurs by cleavage of the FGF-like domain from the C terminal tail 
of the intact protein (147). The enzyme responsible has not been identified.  
FGF-23 acts mainly to alter renal tubular handling of phosphate by reducing the expression 
of NaPi2a and NaPi2c and thus reducing phosphate re-absorption and increasing urinary 
phosphate excretion. This action is mediated in the kidney via the interaction of FGF-23 
with Klotho, its co-factor and the FGF receptor (36). The molecular mechanism underlying 
the phosphaturic effects of FGF-23 remain elusive but there is evidence that FGF-23 
activates ERK 1 / 2 and serum-glucocorticoid-regulated kinase-1 resulting in 
phosphorylation of NHERF-1 leading to downregulation of NaPi2a (167). 
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Although 1-25-(OH)2-D levels increases the mRNA levels encoding FGF-23, FGF-23 
itself is a counter-regulatory hormone for 1-25-(OH)2-D – it reduces expression of 
Cyp27b1 which encodes 25-OH-D 1-α-hydroxylase and upregulates Cyp24 which encodes 
24 (OH)ase (168). FGF-23 reduces 1-25-(OH)2-D production and inactivates available 1-
25-(OH)2-D. In patients with normal renal function, if there is excess FGF-23 in the serum, 
hypophosphataemia occurs; this relates to the effects of FGF-23 on the renal sodium 
phosphate co-transporters and 1-25-(OH)2-D with consequent renal phosphate wasting.  
FGF-23 binds to and activates FGF receptors (FGFRs) 1c, 3c and 4 (168). Most FGF 
molecules use heparin sulphate as a cofactor to facilitate binding to the FGFRs. However, 
FGF-23 and other members of the FGF-19 sub-family possess a disulfide bond, not found 
in other FGFs, and this confers a conformational change in the core structure such that 
FGF-23 has a low affinity for heparin (163;169). However when an FGFR forms a 
complex with Klotho, the FGFR becomes specific for FGF-23 (168). 
1.5.2.9 Klotho 
 Klotho is an anti-ageing, trans-membrane protein, named after one of the daughters of the 
Greek god, Zeus. Klotho spins the thread of life whilst her sisters determine life’s length 
and end (163;170). Accelerated ageing and widespread atherosclerosis is observed in 
Klotho deficient mice and mice who over-express Klotho experience an extended lifespan 
and reduced levels of oxidative stress (171-173). The mice also develop 
hyperphosphataemia (168).  
FGF-23 null mice develop hyperphosphataemia and display a similar accelerated ageing 
phenotype to Klotho deficient mice but with the addition of elevated vitamin D levels and 
resultant metastatic calcification and abnormal bone mineralization (174). In both knock-
out models, a low phosphate diet slows the ageing process and in the FGF-23 null mouse 
corrects hyperphosphataemia and VC although elevated vitamin D and calcium levels 
persist (169;175). This supports the notion of a shared signalling pathway. Klotho makes 
the FGFR specific for FGF-23 and the biological effects of FGF-23 are mediated in a 
Klotho dependent fashion; the Klotho/FGFR complex binds FGF-23 with much higher 
affinity than the receptor or Klotho alone (176). The FGFR is expressed throughout the 
body, yet Klotho is expressed at high levels only in the DCT of the kidney, the parathyroid 
gland, the sino-atrial node of the heart, the choroid plexus, the testis, the ovary and the 
pituitary gland (168;177). There is also evidence of expression in the PCT of the kidney 
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but to a far lesser extent (167). This limited expression of Klotho has not yet been 
explained but it supports the notion of a targeted, organ specific effect of FGF-23. 
However, in the kidney the disparity between the expression of Klotho and the site of 
action of FGF-23 is not easily explained.  
There are two hypotheses: FGF-23, via Klotho, acts on the DCT and induces a paracrine 
signal (perhaps secreted Klotho) which acts at the PCT to downregulate expression of 
NaPi2a and NaPi2c permitting the phosphaturic effects of FGF-23 or FGF-23 acts directly 
on the PCT and the role of Klotho in the DCT is unclear. In a mouse study by Farrow et al, 
following injection of FGF-23, the FGF-23 signalling pathway was activated only in the 
DCT (178). This supports the former hypothesis. 
Furthermore there is a secreted form of Klotho which arises from the extracellular portion 
of the protein. This is cleaved by membrane proteases and secreted in blood, urine and 
cerebrospinal fluid (169). Secreted Klotho is phosphaturic, independently of FGF-23, and 
can directly inhibit NaPi2a and NaPi2c (179). Additionally it has the ability to act upon the 
DCT calcium channel,TRPV5, promoting calcium reabsorption and reducing calciuria 
(180). 
There is increasing evidence that Klotho plays a part in maintaining endothelial function; 
reducing vascular inflammation and attenuating oxidative stress. In human ECs, Klotho 
has been shown to up-regulate ACE activity via the cAMP pathway, and in mice Klotho 
increases endothelial derived NO production (181-183). Thus Klotho may have some 
involvement in the regulation of vascular tone mediated via the interplay between NO and 
the RAAS. Angiotensin II negatively regulates Klotho expression via an angiotensin 1 or 2 
receptor dependent pathway (184;185). Inhibition of insulin like signalling is a recognised 
as a mechanism for conserving life span and in VSMCs, Klotho inhibits the insulin/IGF-1 
signalling cascade and reduces oxidative stress induced apoptosis (170;182). Removal of 
ROS is facilitated by Klotho which induces manganese superoxide dismutase expression 
thus reducing oxidative stress (170). Furthermore, the ED displayed in Klotho deficient 
mice can be attenuated by adenovirus mediated Klotho gene delivery (183). Cell adhesion 
molecules including VCAM and E-selectin are up-regulated when the vascular 
endothelium is activated (186). In human umbilical vein ECs (HUVECs), Klotho reduces 
TNFα induced VCAM expression, possibly acting via NF-κB. TNFα induced suppression 
of eNOS phosphorylation is also attenuated by Klotho (177).  
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1.5.2.10 Emerging phosphatonins 
Kumar defined a phosphatonin as a substance which fulfils four criteria: it inhibits renal 
phosphate tubular reabsorption; it inhibits vitamin D; it is produced by tumours in tumour 
induced osteomalacia; and it is elevated in the serum of these patients (187). 
Current literature suggests that FGF-23 is the major phosphatonin. However there are 
others whose importance may not yet be recognised. They have not been well studied but 
include frizzled-related protein 4 (FRP4), matrix extracellular protein (MEPE) and 
stanniocalcin. FRP4 inhibits renal phosphate transport, mediated by effects on on the 
Wnt/β-catenin pathway within kidney and bone (161). MEPE induces renal phosphate 
wasting and is over-expressed in tumour induced osteomalacia. It is unclear if effects on 
renal phosphate wasting are independent or the result of an interaction with FGF-23 (150). 
Stanniocalcin is a calcium regulating hormone thought to exert paracrine effects affecting 
intestinal absorption and renal transport of phosphate (137). 
1.5.2.11 Phosphate homeostasis summary 
Current understanding of phosphate homeostasis is summarised in Figure 1-7. The 
maintenance of serum phosphate within a tightly controlled range is the result of a complex 
interplay between PTH, vitamin D, FGF-23, Klotho and a multi-organ system: the bone-
parathyroid-kidney axis. Our understanding of these factors, their interaction and their 
precise regulation is incomplete but it is continuing to evolve. In CKD, the homeostatic 
mechanisms described are disrupted leading to hyperphosphataemia. The emergence of 
serum phosphate as a CV risk factor has prompted increased study of this dysregulation 
and has helped to enhance our understanding of phosphate balance. 
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Figure 1-7: Phosphate homeostasis in health. 
Bold black arrows indicate a stimulatory effect and the bold red arrow, an inhibitory effect. 
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1.5.3 Dysregulation of phosphate in chronic kidney disease 
Patients with advanced CKD experience disarray of the systems described in section 1.5.2 
which are designed to regulate phosphate balance. This leads to a clinical syndrome 
characterised by hyperphosphataemia, elevated FGF-23, reduced vitamin D, reduced 
Klotho and hyperparathyroidism and with widespread detrimental effects on the bone, the 
heart, the vasculature and the endothelium. Furthermore, hyperphosphataemia itself is 
linked independently with progression of CKD and thus not only contributes directly to 
CV risk, it also perpetuates it by promoting renal decline. 
1.5.3.1 The intact nephron hypothesis 
In 1960, Bricker described the concept of the intact nephron hypothesis whereby in CKD 
as the number of functioning nephrons reduces, the workload of the remaining nephrons, 
which are believed to be functionally intact, must increase so that any individual nephron 
must perform a greater fraction of renal excretion (188;189). In the case of phosphate, 
individual nephrons must excrete an increased amount of phosphate to maintain serum 
phosphate balance. In CKD, serum phosphate levels are initially preserved within the 
physiological range via the regulators described in sections 1.5.2.5 to 1.5.2.10 and it is not 
until advanced CKD that homeostasis is no longer possible and hyperphosphataemia 
inevitable (Figure1-8) (190). 
1.5.3.2 The extent of the problem 
There are limited data looking at the prevalence of phosphate dysregulation in patients 
with CKD and not on dialysis. Kestenbaum et al published observational data from a 
cohort of approximately 3500 patients and reported serum phosphate levels to be 
maintained within the reference range until eGFR fell below 30ml/minute; serum 
phosphate then began to rise above the upper limit of normal (2). This happens insidiously 
but it has not been determined exactly at which point in CKD phosphate levels start to rise 
within the normal reference range. There is, however, some evidence to support a gradual 
rise from mild CKD (1). Between 40 and 70% of patients with ESRD on dialysis have a 
serum phosphate elevated above the reference range (191-193). An Indian study found that 
65% of patients with CKD stage 4 had a phosphate higher than the reference range (191). 
In German live kidney donors evaluated 11±7 years from nephrectomy, Gossman et al 
found creatinine rose significantly from the time of donation, serum phosphate to be 
0.9±0.19mmol/L, PTH to be elevated in 19% of donors and 30% to have reduced tubular 
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Figure 1-8: Dysregulation of phosphate in CKD. 
Initially phosphate levels are maintained within the normal range but as nephrons are lost and CKD 
advances, the normal homeostatic mechanisms are overwhelmed and there is 
hyperparathyroidism, elevated FGF-23 and hyperphosphataemia whilst vitamin D and Klotho levels 









Chapter 1 XXX 56 
reabsorption of phosphate. They did not compare phosphate values at the time of donation 
and at the time of evaluation (194). 
1.5.3.3 The current ‘trade off’ hypothesis 
This was described by Gutierrez in 2010: in order to maintain serum phosphate levels by 
increasing phosphate excretion per nephron there has to be a ‘trade off’ between normal 
serum phosphate and alterations in circulating levels of key regulatory factors (195). Prior 
to the discovery of FGF-23, the standard thinking was that in CKD reduced nephron mass 
led to a reduction in phosphate excretion and thereby an increase in serum phosphate 
causing a reduction in vitamin D and calcium. All three of these factors then stimulate PTH 
release and this was believed to be the key hormone responsible for phosphate 
homeostasis. We now know that there is much more to the phosphate story and the current 
updated ‘trade off’ hypothesis acknowledges the role of FGF-23 in maintaining serum 
phosphate levels and a second consequent ‘trade off’ between elevated FGF-23 and 
lowered vitamin D levels (Figure 1-9).  
1.5.3.4 FGF-23 in CKD 
FGF-23 levels are elevated from early in CKD; initially this maintains phosphate within 
the physiological range (36;195). Increased FGF-23 secretion from bone is the first 
compensatory step for the reduced number of functioning nephrons in the kidney and by 
enhancing renal excretion and reducing intestinal absorption of  phosphate (directly and 
indirectly via reduced vitamin D) allows serum phosphate levels to be maintained. 
Lowered vitamin D levels are a very important consequence of elevated FGF-23. FGF-23 
levels rise before phosphate and before PTH leading to widespread conclusion that FGF-23 
may be a useful biomarker to detect disorder in phosphate homeostasis early in CKD 
(196). By advanced CKD, FGF-23 levels can be more than 1000 fold above the normal 
range (197;198). FGF-23 remains biologically active even at these supra-physiological 
levels (199). It has been postulated that FGF-23 at such high levels may have effects in the 
absence of Klotho. The phenotype of mice without Klotho and FGF-23 is no different to 
that of those lacking only Klotho (despite very high FGF-23 levels) which does not support 
the notion of FGF-23 effects independent of Klotho (200). However, there is an association 
between FGF-23 and LVH (section 1.7.5) and Klotho is not expressed in myocardial cells. 
Faul et al demonstrated evidence of a Klotho independent pathway (acting via the PLCγ 
pathway) leading to LVH in mice. 
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Figure 1-9: The original and updated 'trade off' hypotheses. 
 The updated version acknowledges the previously unrecognised role of FGF-23. Adapted from 
Gutierrez et al (195). 
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 This does support the hypothesis that FGF-23 may be able to exert effects on atypical 
target organs, including the myocardium (201). Elevated FGF-23 can down-regulate 
Klotho expression in mice which may contribute to target organ resistance to FGF-23 in 
CKD and consequently encourage further FGF-23 release to perpetuate this cycle (202). In 
another animal study, FGF-23 (when injected) was seen to up-regulate Klotho expression 
(203). The explanation for the difference may be that short term exposure to and the long 
term effects of elevated FGF-23 are different.  
1.5.3.5 Klotho in CKD 
Klotho has been reported to be reduced in CKD (169). Koh et al, in 2001, demonstrated 
that in patients on HD, there is a reduced number of functioning nephrons and in the 
remaining nephrons, membrane bound Klotho expression (protein and mRNA) is reduced 
to approximately 5% of the level seen in healthy control specimens (204). In hyperplastic 
parathyroid glands from patients with CKD including recipients of a renal transplant, 
expression of Klotho is reduced along with expression of FGFR1. The expression of both 
correlates with renal function and declines as renal function declines (205). The study 
populations in both studies were small but there is support for the notion of reduced Klotho 
expression in CKD from animal studies (169;206). Klotho expression is difficult to 
measure in humans when it requires a tissue sample. However, Yamazaki et al have 
developed a commercially available ELISA kit which allows measurement of secreted 
Klotho in blood and urine (207). Use is not yet widespread but evidence is now becoming 
available that, like membrane bound Klotho, secreted Klotho is also reduced in CKD. 
There is evidence of reduced secreted Klotho in the urine of those with CKD compared to 
urine from controls without CKD. This reduction is evident from CKD stage 1 and in a 
similar fashion to FGF-23 has led to speculation that Klotho is one of the earliest 
biomarkers for disordered phosphate metabolism (208). In dialysis patients, serum Klotho 
is lowered compared with control serum and is positively correlated with serum phosphate 
levels and negatively correlated with serum calcium levels (209). In contrast, Seiler et al 
looked at patients with CKD stages 2-4 and found no association between secreted plasma 
Klotho and declining renal function or with any parameter of calcium-phosphate 
metabolism. There was only a weak association with age (210). This study did not look at 
Klotho as a continuous variable but rather in tertiles, it did not look at urinary Klotho and 
by excluding patients with CKD 1, there is the possibility that a very early reduction in 
Klotho was missed and, of course, in dialysis patients the story may be different. 
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In rats with acute kidney injury induced by ischaemia reperfusion injury, expression of 
membrane Klotho and levels of secreted Klotho (blood and urine) are reduced. The 
administration of recombinant Klotho after induction of acute kidney injury, increased 
Klotho levels and minimised the extent of kidney damage (211). Similarly, in a mouse 
model, angiotensin II infusion down-regulated Klotho and induced kidney damage; gene 
transfer of Klotho in an adenovirus vector ameliorated much of this damage (212).  
Thus, whilst there is some evidence of Klotho deficiency in CKD, studies present 
conflicting findings. We do not yet have a full understanding of this and further studies 
should help to clarify the relationship between membrane bound Klotho, secreted Klotho 
and CKD. Membrane bound Klotho may decline progressively in CKD with progressive 
urinary decline of secreted Klotho. Plasma secreted Klotho may decline in early CKD and 
then may remain fairly constant until the later stages of CKD or it may decline 
progressively as FGF-23 rises progressively. The rise in FGF-23 may in part be the result 
of end organ resistance secondary to a decline in Klotho, its co-factor. However,  in a 
mouse model of renal disease, the reduction in Klotho arises prior to the rise in FGF-23, 
raising the possibility that Klotho and not FGF-23 is the earliest biomarker for CKD and a 
potentially causative factor in the accompanying phosphate dysregulation as CKD 
advances (169). 
1.5.3.6 PTH and Vitamin D in CKD 
Prior to the interest in phosphate as a CV risk factor, PTH and vitamin D were believed to 
be the primary regulators in phosphate homeostasis as explained by the classical ‘trade off’ 
hypothesis (Figure 1-10) (195). Reduced nephron mass leads to phosphate retention and a 
deficiency of 1α-hydroxylase which in turn leads to a deficiency of active vitamin D, 1,25-
(OH)2-D3. Both these factors simulate production of PTH. The discovery of FGF-23 and 
other molecules changed this thinking. However, the reduction in vitamin D levels and the 
elevation of parathyroid hormone seen in CKD undoubtedly remains an integral part of the 
phosphate story. 
FGF-23 reduces vitamin D synthesis; low vitamin D levels stimulate PTH release and 
secondary hyperparathyroidism develops. In early CKD, when phosphate levels are 
normal, reduced vitamin D levels and elevated PTH levels are observed (213). Under 
normal circumstances vitamin D should suppress PTH but the reduced levels of vitamin D, 
perpetuated by the raised levels of FGF-23 prevent this. When parathyroid cells are 
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exposed to FGF-23 in vitro, there is suppressed PTH expression and secretion (203). PTH 
is elevated in CKD, and reduced Klotho expression in the parathyroid gland in CKD may 
explain why FGF-23 does not suppress PTH release in CKD. In addition to the possible 
effects of FGF-23 on Klotho expression, Vitamin D up-regulates Klotho expression and 
therefore reduced vitamin D levels in CKD also attenuate Klotho expression (214). 
Removing the parathyroid gland in a rat model of uraemia reduces FGF-23 levels. This 
raises the possibility that PTH itself may stimulate FGF-23 production (215).  
We still do not fully understand the various complex interactions between Phosphate, FGF-
23, Klotho, vitamin D and PTH either in health or in CKD. In CKD, it is evident that the 
relationships become disordered and that the extent of this increases with eGFR decline. In 
CKD stages 4-5, increased levels of FGF-23 are no longer able to compensate for dietary 
phosphate intake with consequent hyperphosphataemia, vitamin D deficiency and 
hyperparathyroidism and parathyroid hyperplasia. 
1.5.3.7 Summary 
Klotho plays an important role in ageing and expression levels naturally decline with age 
(216). CKD can be considered a condition of accelerated ageing with life expectancy 
markedly reduced, most commonly secondary to premature CVD (16). The phenotype seen 
in humans with CKD including early CVD, infertility and VC is very similar to the 
phenotype of the Klotho deficient mouse (173). CKD accelerated ageing is associated with 
a syndrome of hyperphosphataemia, hyperparathyroidism and hyper-FGF-23-aemia; this 
may be a cause or a consequence of altered Klotho expression. It may be adaptive or it may 
be maladaptive. Regardless this syndrome, arising from disordered phosphate balance, 
leads to widespread detrimental effects throughout the body and is associated with a 
significantly shortened life expectancy and progression of CKD. 
 
1.6 Guidelines for phosphate control in chronic kidney 
disease 
In CKD, phosphate can be lowered by modification of dietary intake or with readily 
available pharmacological therapies which bind phosphate in the gut (phosphate binders) 
before it can be absorbed (section 1.9). Additionally in dialysis patients, the dialysis 
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process itself facilitates phosphate removal; this can be improved by optimising the quality 
and quantity of dialysis received. Thus, guidelines have been produced to target phosphate 
levels in CKD. 
The Kidney Disease Improving Global Outcomes (KDIGO) work group produce 
international guidelines for various aspects of management of CKD including phosphate 
control (217). KDIGO focus the guideline on minimising risk, based on most up-to-date 
evidence. Some countries, including the UK and the USA produce their own guidelines, 
taking into account the recommendations from KDIGO. The rationale for the difference in 
the UK relates to ensuring that the guideline allows ‘targeting ideal clinical practice 
targets for biochemical parameters.’ (218) 
The UK guideline is produced by The Renal Association (RA) and the USA guideline by 
The National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) 
(218;219). Traditionally guidelines present recommendations and grade these according to 
the strength of evidence as per the GRADE approach (220). The strength of 
recommendation is graded according to the strength of the evidence A (strong), B 
(moderate) C (low) D (very low). Grade A is randomised controlled trial evidence whereas 
grade D is often simply opinion.  
All guidelines suggest that in patients with CKD stage 3-5 (not on RRT) serum phosphate 
should be maintained within the normal range (graded C). In dialysis patients the 
recommendation is to lower elevated serum phosphate levels toward the normal range 
(graded C). The guidelines for target phosphate level in CKD are arbitrary and are not 
evidence based. There is no recommendation in any guideline pertaining to phosphate 
control, a target serum phosphate level or how to achieve a target serum phosphate which 
is graded above level C.  
One large retrospective study in HD patients showed an association between attaining a 
phosphate within the normal range and a reduction in all cause mortality of between 5 and 
33% depending upon the number of phosphate results within target (221). The study was 
retrospective and was not able to look at adjusted mortality.  
There is no evidence that lowering phosphate to a specific target translates to an 
improvement in clinical outcomes and there is no evidence to point to a phosphate level at 
which the detrimental effects seen with phosphate are attenuated.  
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1.6.1 UK Renal Association Guideline 
In the UK, the RA advise that, in CKD stages 3-5 (not on RRT), serum phosphate levels 
should be maintained at 0.9-1.5mM. In patients on dialysis, pre-dialysis phosphate levels 
should be maintained at 1.1-1.7mM. Both of these recommendations are graded at C. In 
March 2013,  The National Institute for Health and Care Excellence (NICE) issued its first 
guideline for the management of hyperphosphataemia in CKD (222). The aim of the 
guideline was to standardise management across the UK, and they suggest that a calcium 
based phosphate binder be offered as first line management in conjunction with dietetic 
input. They acknowledge that the evidence for this is poor but taking account of what 
evidence there is and on the basis of a thorough cost analysis, this was the most robust 
recommendation they could make. 
 
1.7 Phosphate and cardiovascular risk 
In 1998, Block et al demonstrated a link between aberrant phosphate homeostasis and 
adverse clinical outcomes. This association remained present after adjustment for other 
variables including co-morbidity (192). Prior to this, hyperphosphataemia was a recognised 
problem in CKD but focus centred on its causative role in hyperparathyroidism and 
consequent metastatic VC rather than on any directly toxic effects of phosphate itself. This 
was the first study to demonstrate an independent effect of phosphate on mortality in 
patients on dialysis and led to renewed interest in the effects of phosphate and indirectly to 
a better understanding of phosphate homeostasis in health and CKD. Naturally with better 
understanding, more questions have arisen which remain unanswered. 
1.7.1 Mortality, CV risk and phosphate: in chronic kidney disease 
and in health 
In 1997, Narang et al studied a population of patients undergoing elective coronary 
angiography. They found a strongly positive correlation between serum phosphate levels 
and severity of occlusive coronary disease. On the basis of their data they concluded that 
“A moderate change in the serum level of....phosphorus confers a risk similar to that 
associated with smoking, as estimated by the odds ratios.”(223). Smoking, and the risks 
associated with it, is a highly publicised public health concern. This study put a serum 
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phosphate level, elevated within the normal range, in the same risk category as smoking, a 
major killer in the Western world. Many observational studies since 1997 have 
demonstrated that Narang et al did not overestimate the relevance of serum phosphate as a 
risk factor for CVD. Fifteen years on, however, a causative link underlying the observed 
association between serum phosphate and outcomes remains elusive. Higher serum 
phosphate levels even within the ‘normal’ range are linked with a significant increase in all 
cause mortality, CV mortality and CV risk in the CKD population, in the general ‘healthy’ 
population and in recipients of a renal transplant. The risk is present regardless of pre-
existing CVD and is maintained following adjustment for standard CV risk factors (Table 
1-2) (7;8;32;67;224-227). Increased risk remains present when adjustments are made for 
GFR and thus it is not an anomaly attributable to reduced renal function. 
In 2009, a systematic review identified seventeen studies, published between 1990 and 
2007, which assessed the association between hyperphosphataemia and death in dialysis 
patients (228). Sixteen of these studies concluded that hyperphosphataemia was a risk 
factor for death in patients on dialysis. Stevens et al demonstrate an increase in risk of 56% 
for each 1mM rise in serum phosphate (229). This holds true in the pre-dialysis population 
with an increase in risk of death of 62% (67). Six studies identified by the same review 
considered the effect of serum phosphate on CV mortality in dialysis patients; all six 
reported an increase in risk of up to 13% per 0.32mM rise in serum phosphate (228). The 
increase in CV mortality was evident in patients using peritoneal dialysis (PD) or HD as 
their mode of RRT (230). 
The Western diet is high in phosphate rich foods and in preservatives but effects of 
phosphate certainly in the non CKD population might be unrelated to dietary consumption. 
The NHANES III study with just over 15,500 participants (1,500 of whom had CKD) 
found only a very weak association with phosphate and dietary intake and an inverse 
relationship between higher serum phosphate levels and Framingham coronary heart 
disease risk scores (based upon traditional risk factors for CVD including smoking and 
hypertension) (231). This supports an independent effect of phosphate on CV risk rather 
than an effect mediated through either dietary phosphate intake or an already unfavourable 
CV risk profile. It remains unclear if these results can be extrapolated to the CKD 
population. 
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Table 1-2: Associations between serum phosphate and outcome in different populations.  
A selection of eight clinical studies demonstrating an association between serum phosphate level 
and mortality, CVD or VC in patients with and without pre-existing CVD and with and without CKD 
(7;8;32;67;224-227). 
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The mechanism by which phosphate confers this increased CV risk is not understood: 
association does not always imply causality and thus a plausible mechanism of action for 
phosphate as a CV risk factor is crucial. 
1.7.2 Phosphate and left ventricular hypertrophy  
LVH is a common manifestation of CVD in CKD with a prevalence of 40% in pre-dialysis 
patients increasing to 75% for those on dialysis (232). Several studies have shown an 
association between serum phosphate level and left ventricular mass (LVM) which is 
independent of blood pressure (225;233). No causative relationship has been demonstrated 
but Ayus et al showed that improving phosphate control in HD patients by 12% over a 12 
month period resulted in a reduction in LVH, which was independent of other confounders 
(233). In individuals without CKD, higher dietary phosphate intake has been shown to 
correlate with greater risk of LVH in women but not men, without CKD (234).  
The increased CV risk seen with phosphate levels even within the normal range may be in 
part explained by the association with LVM. However an appreciation of the mechanisms 
by which phosphate might contribute to the risk of LVH is essential. Phosphate may be 
directly toxic to the myocardium or it may be that it triggers its effect via disruption of the 
usual regulators of phosphate homeostasis: FGF-23, PTH or vitamin D. That LVH is seen 
in early CKD, before significant alterations in serum phosphate are evident, lends 
plausibility to this hypothesis.  
1.7.3 Phosphate and vascular calcification  
Patients with CKD have diffuse arterial calcification; this begins before the onset of end 
stage renal disease, may be unrelated to the degree of renal impairment and is present at 
least at moderate level in up to 70% of patients with CKD stages 3-5 (235). More than 60% 
of dialysis patients have significant VC (236). Medial arterial calcification is a strong 
prognostic marker of CV mortality in dialysis patients (237). In patients with CKD stage 3-
5, progression of coronary artery calcification, measured by total calcium scoring on CT 
scan, was more prominent than in control subjects without CKD (238). Serum phosphate 
level was correlated with coronary artery calcification. In another study of patients with 
mild CKD (mean eGFR 51ml/min) after adjustment for confounders, for each 1mg/dL 
(0.323mmol/L) increase in serum phosphate within the normal range, there was a 21% 
greater prevalence of coronary artery calcification and a 62% increase in mitral valve 
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calcification (239). This relationship holds within the general population, where Foley et al 
showed that a higher phosphate, within the normal range, led to a >50% increase in risk of 
coronary artery calcification 15 years later (8). Demonstration that phosphate at the high 
end of the normal range is associated with risk of VC lends support to the concept that 
phosphate load and abnormal regulation of phosphate are important mediators of ectopic 
VC. Further support for this comes from Russo et al (240). In 90 patients with CKD stage 
3-5 not on dialysis, a comparison was made between three interventions: low phosphate 
diet alone or in combination with one of two phosphate binders, sevelamer or calcium 
carbonate. (Phosphate binders are discussed in section 1.9.2). Total calcium score was the 
outcome measure as a marker of VC. The groups on the low phosphate diet alone or in 
combination with calcium carbonate had significant progression in VC over the course of 
the study (one year). In contrast, in the sevelamer group total calcium score did not change 
significantly. Serum phosphate levels were unchanged from baseline in all three groups but 
urinary phosphate reduced in the groups taking calcium carbonate or sevelamer (240). This 
suggests that lower phosphate absorption might reduce progression of VC. Additionally, 
perhaps other measures of phosphate load or excretion should be made; serum phosphate is 
probably not a reflection of total body phosphate. 
In animal and cell models, a significant number of studies have demonstrated that VC is an 
active, regulated process much like the formation of bone (5). Under normal 
circumstances, a balance is maintained between pro and anti calcification factors such that 
VC does not occur. In pathological conditions, such as CKD, ectopic calcification occurs 
because this normal homeostasis is upset (241). A number of different risk factors, 
including elevated phosphate level can tip this balance in favour of ectopic VC (242). 
Reynolds et al showed that calcification can be induced in human VSMCs maintained in 
culture with medium containing high calcium or high phosphate concentration; treatment 
with medium containing both high calcium and phosphate concentration had a synergistic 
effect (243).  However, they showed that in VSMCs exposed to elevated phosphate and 
calcium, apoptosis was induced and cells released vesicles with high concentrations of 
both phosphate and calcium. Usually, factors including fetuin A and matrix GLA protein 
inhibit matrix mineralisation, but in CKD, these factors are reduced creating a pro-
calcification environment (244). Concomitantly, VSMCs undergo phenotypic change and 
essentially become bone cells with osteochondrogenic differentiation (245). Li et al have 
shown that blocking phosphate uptake into cells (via the type 3 sodium dependent 
phosphate co-transporter, Pit1) in vitro can ameliorate phosphate induced VC (246). 
Similarly, Mathew et al, demonstrated that controlling hyperphosphataemia in an animal 
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model of CKD reduced VC (247). There is a lack of evidence that strategies to reduce 
serum phosphate prevent or reverse VC or impact upon hard clinical endpoints like patient 
survival. 
1.7.4 Phosphate and endothelial function 
In the past, most clinical and laboratory studies have focussed on VC as an explanation for 
the observed increase in CV risk with hyperphosphataemia. In many clinical studies, VC is 
used as the surrogate outcome measure. However, there is growing evidence that 
phosphate has a direct detrimental effect on endothelial function. Much of the evidence 
comes from isolated cell and animal studies, the detailed molecular mechanism remains 
elusive and whether phosphate is a direct or indirect endothelial toxin is not clear. 
Furthermore, cells are usually treated with phosphate for a short period (24 hours or less) 
testing acute, rather than long term exposure to elevated phosphate. Patients with CKD are 
exposed to higher levels of phosphate for a prolonged period and thus long term effects of 
phosphate in vitro and in vivo are of more clinical relevance. 
Several studies have shown effects of phosphate on the expression of eNOS, NO and ROS 
production in cell culture (6;248-250). Peng et al showed that elevated phosphate in culture 
media (3mmol/L) reduced cell number and caused apoptosis, associated with reduced 
eNOS phosphorylation at residues Ser-1177 and Ser-615 and reduced NO. Intracellular 
calcium levels were also lower and they found evidence of alterations in phospho-Akt and 
NF-κB-p65 signalling (249). Shuto et al, found elevated phosphate increased 
phosphorylation of eNOS at Thr
497
(inactivates eNOS) and increased ROS production in a 
bovine cell line (6;248). This effect was ameliorated by phosphonoformic acid, a specific 
inhibitor of sodium dependent phosphate transporters (6). They also found that PKC was 
increased, and postulated that phosphate may mediate its effects via PKC but unlike Peng 
et al, they did not demonstrate a change in intracellular calcium concentration.  
Several studies suggest an effect of phosphate on cell growth and cell death with elevated 
phosphate causing increased apoptosis (249;250), the cause of which is not clear, although 
may involve cell cycle regulators. Of interest, similar effects have been seen with low 
phosphate (0.5mmol/L) with increased expression of p53 and cyclin dependent kinase 2 
(CDK2), a cell cycle regulator known to induce apopotosis (249). Di Marco et al, found 
that apoptosis and increased ROS production was present in ECs at phosphate 
concentrations of 2.5mmol/L and above, concluding that high phosphate caused 
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mitochondrial dysfunction and that increased ROS production was the trigger for apoptosis 
(250).  
In studies of isolated blood vessels in vitro, rat aortic rings incubated for one hour in a high 
phosphate concentration medium (2.4mmol/L) showed impaired endothelium dependent 
vasodilatation to acetylcholine (6). This effect on endothelium dependent vasodilatation 
has also been shown in resistance vessels from rats with induced renal impairment and fed 
a high phosphate diet (2 fold increase in phosphate content compared with normal rat 
chow) over several weeks (251). In the same study, the use of L-NAME also suggested 
that there were lower levels of basal NO than in control animals and levels of serum 
phosphate, brain natriuretic peptide (BNP) and PTH were higher than in control animals 
(251). BNP level is known to be an independent predictor of endothelial function in man 
(252). 
Morris et al, showed that resistance vessels form patients with CKD stage 5 showed 
impaired endothelium dependent relaxation when compared with healthy controls with 
preserved endothelium independent relaxation (95). Whilst there are many studies 
evaluating ED in renal disease, there is paucity of studies looking at phosphate and its 
effects specifically the effects of long term exposure to elevated phosphate. 
In healthy subjects, acute phosphate loading with a meal containing 1200mg of phosphate 
significantly reduced FMD two hours post ingestion when compared with a meal 
containing 400mg of phosphate (6).  
There are no outcome data in clinical trials demonstrating a beneficial effect of lowering 
phosphate, although we have the tools to do so (section 1.9). In a rat model of adenine 
induced CKD, rats fed a low phosphate diet (0.2% compared with 1% in standard rat 
chow) for 16 days exhibited significant improvement in markers of bone biochemistry 
(phosphate, calcium, PTH, vitamin D and FGF-23). Phosphorylation of eNOS (Ser-1177) 
was significantly increased and the impaired endothelial dependent vasodilatation seen in 
aortic rings with animals fed standard rat chow was ameliorated in those fed chow 
containing low phosphate (253).  
Part of the difficulty with clinical studies of phosphate lowering is the endpoints tend to be 
surrogate outcomes, for example VC, rather than mortality or CV events. Additionally 
many of the studies compare different phosphate lowering agents with each other rather 
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than against a placebo or no intervention. No single study has demonstrated that phosphate 
lowering reduces mortality. 
1.7.5 Mortality, cardiovascular risk and phosphate regulation 
Abnormal regulation of phosphate is likely to be as detrimental to CV risk as 
hyperphosphataemia itself. The consequences of hyperphosphataemia and resultant 
abnormalities in phosphate regulation are summarised in Figure 1-10. 
In the general population, and in CKD, vitamin D deficiency is linked with ED, vascular 
stiffness and increased mortality (254-256). In animal models, vitamin D deficiency has 
been shown to induce myocardial hypertrophy and myocyte proliferation and reduce 
myocardial contractility (257;258). Treatment with vitamin D inhibits both myocyte 
proliferation and hypertrophy (259;260). In HD patients, treatment with vitamin D 
(calcitriol) for 15 weeks, led to a marked reduction in LVM (261) although evidence of 
long term reduction in CVD or mortality is lacking. 
The dialysis outcomes and practice patterns study (DOPPS) an observational study in 
>25,000 patients showed that patients with phosphate levels >7mg/dl (2.3mM) or PTH 
levels >600pg/ml were at increased risk of death and if both were present the risk was 
highest (262). Additionally higher PTH levels predict worse renal outcomes (263). In 
animal models, elevated PTH has been linked with myocardial hypertrophy and fibrosis 
(264). In dialysis patients, higher levels of PTH predict increased rate of all cause and CV 
hospitalisation (11). 
There has been much focus on FGF-23 and its co-receptor Klotho. FGF-23 levels inversely 
correlate with renal function (197). Gutierrez et al demonstrated an independent 
association with elevated FGF-23 and mortality in patients commencing dialysis (198). 
There is evidence that this relationship is true across the spectrum of CKD and that 
elevated FGF-23 is a predictor of ESRD (265). Additionally, higher FGF-23 levels are 
associated with increased arterial stiffness in CKD and with ED in the healthy population 
(266). In dialysis patients, FGF-23 levels correlate with carotid artery atherosclerosis and 
with LVM (267;268). Increased LVM is also seen with higher FGF-23 levels in the CKD 
population (236). Faul et al showed in a cohort of >3000 patients with CKD, FGF-23 level 
was an independent predictor of LVH (201). In >1200 patients with largely preserved renal 
function, dietary phosphate intake, PTH level and standard CV risk factors including  
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Figure 1-10: Unwelcome consequences of hyperphosphataemia. 
Hyperphosphataemia results in abnormal regulation of phosphate in CKD. The consequences of 
this include elevated FGF-23, elevated PTH and reduced vitamin D. Each of these four factors 
impacts upon CV risk and has detrimental effects on the vasculature and the heart. 
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triglyceride level, smoking status and hypertension were all independently predictive of 
higher FGF-23 level (269). 
At a molecular level, FGF-23 is believed to need Klotho, its co-receptor to mediate its 
effects (36). The observational studies described above do not determine whether FGF-23 
is directly toxic or if it is simply a biomarker for myocardial damage and hypertrophy. Faul 
et al demonstrated that not only is FGF-23 directly toxic to the myocardium causing LVH 
in an animal model but that it does this via a Klotho independent pathway (the calcineurin-
NFA signalling pathway) (201). They went on to show that treating animals with 
established CKD with an FGF receptor blocker (PD173074) could attenuate LVH whilst 
making no alteration to blood pressure; supporting a blood pressure independent effect of 
FGF-23 on LVH. FGF-23 and its receptor may therefore be promising therapeutic targets 
in early CKD before the detrimental effects are observed. 
  
1.8 Clinical consequences of altered phosphate 
homeostasis 
1.8.1 Chronic kidney disease mineral bone disorder  
A new clinical syndrome was defined by KDIGO in 2006 in recognition of the strong 
association between phosphate and diseases of the bone-vascular axis: chronic kidney 
disease mineral bone disorder (CKD-MBD) (270). Previously the term renal 
osteodystrophy was used to explain the histological bone changes and the abnormalities in 
phosphate and calcium metabolism seen in CKD (271). However, CKD-MBD 
encompasses the systemic nature of the problems seen in bone and soft tissue including the 
clinical features and is defined by an abnormality of any of the following (or a 
combination): serum calcium, phosphate, PTH, or vitamin D levels; alterations in bone 
turnover, mineralization, volume, linear growth, or strength; and calcification in the 
vasculature or soft-tissue. This has raised the profile of phosphate and highlighted its 
pivotal role in what is now known to be a multisystem disorder. The creation of CKD-
MBD as a separate disease entity has further emphasised the importance of establishing the 
ideal target for phosphate lowering, whether phosphate lowering translates to improvement 
in clinically relevant outcomes (reduced hospitalisation, improved mortality and CV risk 
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rather than surrogate outcomes like VC) and focussed attention on establishing a 
mechanism to explain the observed effect of phosphate on CV risk and mortality. 
1.8.2 Symptoms and signs attributable to elevated phosphate 
Hyperphosphataemia is similar to hypertension in that the symptoms tend to be those of the 
consequences rather than directly attributable to hyperphosphataemia itself. The lack of 
visible symptoms, early on, is likely to make patients less compliant with treatment, 
particularly if that treatment has side effects. Education may improve adherence, however 
it is difficult to educate and to justify intervention when there is not a target phosphate 
level. Our understanding of the mechanism is limited and evidence of a beneficial effect 
with treatment is lacking.  The consequences of hyperphosphataemia experienced by the 
patient include calciphylaxis, bone disease, VC and CVD. 
Calciphylaxis has a prevalence of around 4% in HD patients and is a debilitating skin 
condition caused by calcification in the small arteries with consequent necrosis and 
panniculitis (272). It is difficult to treat and increases the mortality of HD patients by 
eightfold usually secondary to sepsis (272;273). The development of calciphylaxis is 
linked to serum phosphate levels and treatment options are limited and often futile, usually 
centring around improved control of PTH and phosphate (273). 
There is a spectrum of bone disease which occurs in CKD-MBD with altered bone 
turnover rate and altered mineralisation (271). Clinical features tend to develop when 
abnormalities in phosphate and calcium metabolism have been present for some time. At 
which point, clinical features may include symptomatic hypocalcaemia, fractures, bone and 
joint pain and muscle weakness (271;274). In paediatric patients, there may be consequent 
abnormalities of growth (271) 
VC occurs via the processes outlined in section 1.7.3 and is initially asymptomatic. 
Ultimately, the patient can experience a number of problems as a consequence of VC. 
Transplant is the best method we have currently of lowering CV risk in CKD (19). 
However, with significant VC it can become technically impossible to perform a transplant 
operation. When the vessels are heavily calcified, vascular access can become problematic 
and impossible in extreme cases leaving no method of undertaking HD (275). If other 
forms of RRT are not an option, a patient will die. Calcified valvular heart disease is more 
common in CKD and associated with elevated phosphate and increased all cause mortality 
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(276;277). Arrhythmias and sudden cardiac death are more common, and VC within the 
cardiac conducting system may contribute (278-280). 
ED is not currently included in the manifestations of CKD-MBD. This may relate to the 
multi-factorial nature of ED in CKD, the small current evidence base for the link between 
abnormalities and ED and to the lack of routine measurement in clinical practice. However 
the ‘symptoms’ of ED experienced by the patient include CVD and its consequences 
including death. 
1.8.3 Progression of CKD: phosphate and proteinuria 
Higher serum phosphate levels and proteinuria have been shown to promote progression of 
CKD. Blockers of the RAAS system are a key strategy to reduce proteinuria and slow 
progression of CKD. Zoccali et al showed in a post hoc analysis of 331 patients from the 
REIN study population that not only is phosphate an independent risk factor for 
progression of CKD (1mg/dl (0.323mM), (increase in serum phosphate translated to an 
84% excess risk for progression to ESRD, requiring RRT) but a high phosphate load may 
limit the renoprotective effect of ACEi (ramipril) (281). The relationship between 
phosphate and risk of progression of renal disease was present even with phosphate levels 
within the normal range (albeit at the upper limit). Whilst these findings require 
confirmation in further study populations, they support the need to establish exactly how 
phosphate acts to increase CV risk, mortality and risk of progression of renal disease. 
Optimising our understanding of the mechanism of action of phosphate as a risk factor 
would allow for targeted and more effective interventions in an attempt to improve 
outcomes. This is necessary not least because serum phosphate appears to weaken one of 
the only strategies we currently have to slow progression of proteinuric CKD. It is also 
plausible to hypothesise that in the presence of a higher serum phosphate, the protective 
effects of ACEi and ARB on the CV system seen in non-CKD populations might be 
ameliorated (282).  
 
1.9 Management of CKD-MBD 
Phosphate increases CV risk and is associated with ED and VC. Thus there is a drive, 
which is perhaps misplaced, to lower phosphate in CKD. There is no evidence to support 
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that lowering phosphate translates to improved outcomes and furthermore there is no 
evidence that any of our currently available phosphate lowering methods confer any 
benefit to patients. The two currently available management strategies are dietary 
modification to reduce the phosphate load and phosphate binders to reduce phosphate 
bioavailability within the body. Mostly, these methods are poorly tolerated and perhaps, if 
we better understood the mechanism of action of phosphate as a CV risk factor, the 
opportunity to develop novel, more effective strategies for reducing phosphate would 
become available. Ultimately this might translate to improved clinical outcomes. Dietician 
input and phosphate binders are expensive and yet using these resources patients 
consistently fail to achieve the targets we have set. Although the current targets set for 
phosphate lowering are opinion rather than evidence based, in the 1,814 participants of the 
SEEK study only 15% had a serum phosphate below or at the target set by the KDOQI 
guidelines (190). Our focus should be on better understanding the in vivo effects of 
hyperphosphataemia, the consequences of lowering phosphate and then using this 
information to tailor patient management. This may include the development of novel 
phosphate lowering strategies.   
1.9.1 Diet 
Phosphate is present in many common foods (section 1.5.2.1). By altering cooking 
methods, reducing quantities of or eliminating certain foods it is possible to lower the 
dietary phosphate content. However, using diet as a management strategy for 
hyperphosphataemia poses several problems: there is no clear consensus on when dietary 
advice should be instigated, access to dietetic services varies between centres, and even the 
most motivated patients find it difficult to drastically change their diet and to maintain 
compliance with these changes in the long term. 
Phosphate containing foods are often protein rich and thus there is a theoretical risk of 
malnutrition in patients on a phosphate restricted diet (283). This is over and above the 
malnutrition often present with uraemia in advanced CKD (284). In a review article, Sigrist 
et al provide a standard phosphate containing diet and a low phosphate alternative; both 
contain similar quantities of protein (283). This demonstrates it is possible to limit dietary 
phosphate content without compromising protein intake but it requires thought, effort, 
motivation and planning from patients. Even in the most motivated patient, this can prove 
challenging particularly if there are other dietary restrictions in place. This includes 
patients with DM or coeliac disease or those following a low potassium diet which often 
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runs in parallel with a phosphate restricted diet. The advice and food choices can be 
conflicting and difficult to follow as well as socially isolating and could lead to a reduced 
quality of life for some - limiting social engagements where often food is a focus. In HD 
patients, up to 75% struggle to adhere to dietary guidelines (including low phosphate 
dietary advice) (285).  
Additionally, patients with CKD are more likely to be depressed than the general 
population, and in the CKD population, those who are malnourished are most at risk of 
depression (286). In patients with CKD, as in many chronic conditions, there is evidence 
that improving nutritional status generally improves quality of life (284). However, 
nutrition, depression, quality of life and phosphate restriction are closely linked and present 
an impossible situation in patients with advanced CKD. Restricting already limited food 
choices may worsen nutritional status, exacerbate depression and worsen quality of life. 
Worrying about non-adherence and non-compliance may contribute additional pressures. 
Thus in the management of hyperphosphataemia, dietary phosphate restriction is not the 
Holy Grail and alternative strategies for management would be useful and may prove 
superior. 
1.9.2 Phosphate binders 
Phosphate binders are drugs which bind phosphate in the intestine to prevent its absorption 
and thus lower serum phosphate levels when CKD prevents normal phosphate metabolism 
and excretion. They were first introduced in the 1970s and initially were used to prevent or 
slow the complications of secondary hyperparathyroidism (287). Currently, following the 
recognition of the importance of phosphate as a CV risk factor, these drugs are used in 
conjunction with dietary measures (and dialysis in patients with ESRD) to lower phosphate 
to a specific therapeutic target with the aim of reducing CV risk. This is despite no study 
showing a benefit of lowering serum phosphate to a specific level. These drugs are 
prescribed to over 90% of patients with CKD at a cost of approximately $750 annually (9). 
Whilst there is evidence that phosphate binders effectively lower serum phosphate in CKD, 
in the 40 years since they were first introduced there has been no randomised controlled 
randomised trial which proves benefit of phosphate lowering in terms of meaningful 
patient outcomes like mortality or CVD (288). 
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Broadly speaking there are two categories of phosphate binder: calcium and non-calcium 
containing. The most effective would be one which lowers phosphate with few side effects 
and the minimum number of tablets. 
1.9.2.1 Calcium containing phosphate binders 
The two main binders in this category are called calcium carbonate and calcium acetate. 
Up to 50% of patients may develop hypercalcaemia with this class of drug (288). The 
binding ability of calcium carbonate is pH dependent and can be reduced by concomitant 
use of proton pump inhibitors. Calcium acetate has superior binding abilities and 
theoretically could be used in smaller doses, reducing calcium content. However it causes a 
higher proportion of gastrointestinal side effects and is less well tolerated (23). 
1.9.2.2 Non-calcium containing phosphate binders 
Aluminium was the first binder in this category. It was effective at lowering phosphate but 
is no longer widely used because of an extensive side effect profile as a result of systemic 
aluminium toxicity (289). 
Sevelamer hydrochloride is an anion exchange resin (9). It was the first non-calcium and 
non-aluminium containing binder to become available (290). Studies have shown that it 
lowers serum phosphate levels but perhaps less effectively than calcium containing binders 
(288). Much of the trial evidence in this area is conflicting but sevelamer seems to reduce 
VC when compared to calcium containing phosphate binders and may have positive effects 
on low density lipoprotein (LDL) cholesterol levels, inflammation and endothelial 
dysfunction (291-294). In terms of mortality, the DCOR trial with over 2000 participants 
(on HD) showed no difference in mortality when compared with calcium containing 
phosphate binders except in a subgroup analysis of patients aged over 65 years where a 
survival benefit was observed (295). There was a significant reduction in all cause 
hospitalisations in the sevelamer treated group. However, almost half of the original study 
population did not complete the study. In CKD patients, not on dialysis, a pilot study 
showed a possible mortality benefit with sevelamer compared with calcium carbonate 
(296). Oliveria et al showed that in CKD stages 3 and 4, whilst both calcium containing 
binders and sevelamer reduce serum PTH and urinary phosphate levels, only sevelamer 
reduced FGF-23 levels significantly (297). 
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The problems with sevelamer include optimal phosphate binding occurring at a pH higher 
than that of the intestinal tract, large pill size, a high pill burden and possible interference 
with the absorption of fat soluble vitamins including vitamin D (290;298). Additionally 
there is some evidence that sevelamer may aggravate acidosis (it lowers bicarbonate levels 
possible because of its hydrochloride content) and hyperkalaemia in dialysis patients (299).  
The only placebo controlled blinded randomised trial in this area compared sevelamer to 
placebo over a 40 week period in patients with mild CKD (stage 3) and found no 
improvement in LVM, left ventricular systolic or diastolic function nor in arterial stiffness 
(300). They did not measure endothelial function and compliance was poor. 
Lanthanum carbonate (this will be referred to as lanthanum throughout this thesis) is the 
newest non-calcium containing phosphate binder. Advantages compared to sevelamer 
include a smaller pill burden and reduced risk of acidosis and hyperkalaemia, optimal 
phosphate binding at a broad pH range (thus it is effective in both the stomach and small 
intestine) and no effect on the absorption of fat soluble vitamins (290). Lanthanum may be 
better at attaining serum phosphate targets and at a reduced cost (301;302). Lanthanum is a 
heavy metal with the potential for accumulation in a similar fashion to aluminium. 
However, it is mainly excreted by the liver and has a low bioavailability (303). It may be 
absorbed; bone biopsy specimens from patients treated with lanthanum for approximately 
five years show rising levels of lanthanum over time (9;304). Despite this, there is no 
evidence that it causes direct bone toxicity and unlike aluminium it does not seem to cross 
the blood brain barrier (303). Lanthanum is manufactured in different tablet strengths 
unlike any other phosphate binder and so helps with pill burden (23). In CKD stages 4 and 
5, lanthanum effectively lowers FGF-23 levels (305). 
Magnesium has been studied as a potential phosphate binder and may have therapeutic 
potential (306;307). However, there is sparse data on safety and efficacy and more work is 
needed with larger patient numbers (9).  
1.9.2.3 Conclusion 
There is good evidence that all currently available phosphate binders work: they all lower 
serum phosphate. However, despite many studies, none has been shown to be superior in 
terms of meaningful patient outcomes. Furthemore a study by Isakova et al in 10,000 HD 
patients showed that those prescribed a phosphate binder had improved survival compared 
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with those not prescribed a binder. This survival benefit was seen independently of serum 
phosphate levels and regardless of which phosphate binder was prescribed (308). If the 
effect is not related to serum phosphate is that because serum phosphate is not a true 
marker of total body phosphate and a different surrogate e.g. urinary phosphate would have 
been a better measure of true body phosphate levels? Or is it that the phosphate binder has 
an effect on something else e.g. FGF-23 and it is alterations in that which may confer a 
benefit? 
The pill burden in patients with CKD, particularly those on dialysis is high and higher than 
that of many other chronic diseases. A recent study by Chiu et al found that in 233 dialysis 
patients, the average total daily pill burden was 19 with 25% taking in excess of 25 pills 
per day (309). Phosphate binders account for 50% of the pill burden. A higher pill burden 
correlated independently with poorer quality of life, and increasing the number of 
phosphate binder pills did not seem to improve hyperphosphataemia and in fact came at the 
expense of poorer quality of life. 40 – 60% of dialysis patients admit to non-adherence 
with phosphate binding medication (309;310).  
Furthermore according to registry data, almost 50% of patients on dialysis fail to achieve 
targets for phosphate control (with the caveat that optimal phosphate levels are not known) 
(311). When we consider the cost of phosphate binders, the poor compliance and the lack 
of evidence for improved patient outcomes surely for now we should concentrate on 
determining why phosphate increases CV risk?  
1.9.3 Dialysis 
The dialysis process removes phosphate. This works best with long, slow HD sessions 
(eight hours) as is the case with nocturnal dialysis which removes up to 40% more 
phosphate than conventional dialysis (four hour session) (312).There is diurnal variation in 
serum phosphate levels in healthy patients and this variation is maintained in CKD with 
phosphate levels at their highest in the evening (313). This might contribute to the success 
of nocturnal dialysis in reducing phosphate. Nocturnal, home HD is the only dialysis 
modality which has been shown to normalise serum phosphate levels (314). Most patients 
are however not on nocturnal nor on home but on conventional in-hospital HD as dictated 
by resource, patient preference and co-morbid factors. For PD, depending upon an 
individual’s ability to transport different solutes, continuous dialysis with manual 
exchanges may more effectively remove phosphate than automated PD performed over-
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night (315). Neither HD nor PD alone lower phosphate sufficiently to meet the set targets; 
this is particularly true in patients with residual renal function (316). Thus, patients are 
prescribed dietary advice and phosphate binders in conjunction with dialysis.  
1.9.4 New treatments 
The problems with current methods of lowering phosphate as outlined above have led to 
the study of alternative management strategies. Wang et al showed that oral activated 
charcoal effectively reduces serum phosphate n HD patients. 90% of patients achieved a 
serum phosphate below 5.5mg/dL(1.78mM) with the average reduction in serum phosphate 
being 2.6mg/dL (0.83mM) over the 24 week treatment period (317). However this was a 
small pilot study and not a randomised control trial; the safety and efficacy of activated 
charcoal would need to be studied in a larger population and over a longer time period. 
Vitamin B3 or niacin has been shown to improve lipid profiles and slow the progression of 
atherosclerosis in patients, without CKD, with CV risk factors (318;319). It exerts its 
effects by inhibiting adipocyte lipolysis and raising high density lipoprotein (HDL) 
cholesterol levels (320-322). In animal studies, niacin metabolites have also been shown to 
have effects on the type 2 sodium dependent phosphate co-transporters in the intestine 
(323;324). The problem with niacin is that it stimulates prostaglandin release and thus one 
of the major side effects is facial flushing which has the potential to markedly reduce 
patient tolerance (318). Nicotinamide is a circulating form of niacin which does not induce 
prostaglandin release to the same extent and thus has fewer side effects (325). 
Nicotinamide does not act through the nicotinic acid receptor, activation of which is 
thought to be essential for observed effects on HDL cholesterol levels (326). It does, 
however exert effects on the intestinal phosphate transporters as well as in PCT cells where 
it has been shown to inhibit phosphate uptake (327). 
The observed effects of niacin and nicotinamide on phosphate transporters have sparked 
interest in the potential phosphate lowering effects of these drugs. In HD patients, Muller 
et al studied an oral modified release preparation of niacin and Takahashi et al studied oral 
nicotinamide in a similar population (325;326). Both studies showed that the drugs 
lowered serum phosphate levels. Niacin was not well tolerated with 35% of patients not 
completing the study secondary to side effects and a further 29% experiencing flushing or 
diarrhoea but not to the extent that they discontinued the drug. Although serum phosphate 
was lowered, this was not significant and the mean phosphate level following treatment 
Chapter 1 XXX 80 
was 5.8mg/dL (1.87mM). With nicotinamide, serum phosphate was significantly lowered 
to a mean of 5.4mg/dL (1.74mM) and only 9% of patients experienced side effects. Both 
drugs raised HDL cholesterol levels. Neither drug has been studied in meaningful numbers 
in patients with CKD not yet on dialysis. To limit the side effects of niacin, Muller et al 
concomitantly administered a non- steroidal anti-inflammatory drug (NSAID) to inhibit 
prostaglandin release. NSAIDs have a detrimental effect on kidney function and thus 
whilst safe in patients on dialysis, they can accelerate renal decline in those who do not yet 
have ESRD and are thus not a viable option in these patients. Other small studies have 
confirmed a modest phosphate lowering effect with both drugs but the side effect profile 
and tolerability seems to be variable (328;329). Both niacin and nicotinamide can be taken 
once daily and do not need to be taken with meals (9). Neither drug is currently a serious 
contender in the management of hyperphosphataemia without further large multi-centre 
studies including outcome and pharmacokinetic studies in CKD. 
Patients with CKD secrete more phosphate in the saliva than the general population and 
this correlates with renal function and serum phosphate levels (330). Chitosan, a natural 
polymer, has a good binding capacity for phosphate. In 2007, Savica et al showed that if 
chitosan gum was chewed in between meals and sevelamer was taken with meals, a lower 
phosphate could be achieved in dialysis patients previously established on sevelamer 
regularly (331). No adverse effects were reported. In a separate study, the same 
investigators found that the chitosan containing chewing gum significantly reduced CRP 
levels in HD patients and that this reduction correlated with serum phosphate reduction 
(332). This supports a pro-inflammatory effect of phosphate which might be modifiable if 
serum phosphate is lowered. This is pilot data only but it does suggest that salivary 
phosphate might be a therapeutic target. 
No information is available as to whether any of the above therapies impact upon VC, 
endothelial function, mortality, rate of hospitalisation or bone histology. 
1.9.5 Potential therapeutic targets 
In order to establish novel therapeutic targets, the exact mechanism of action of phosphate 
as a CV risk factor needs to be established and an improvement in patient outcome has to 
be demonstrated with lowered phosphate. Rather than binding phosphate in the intestine, 
one possibility might be to block the uptake of phosphate into cells. There may be more of 
a role for FGF-23 and the use of medication to alter the level. 
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1.10 Work leading up to this thesis 
Although, renal transplantation improves quality of life and offers a survival advantage 
over maintenance dialysis (19;20), the prevalence of CVD still remains 3-4 times that of 
the general population (21). An association has been demonstrated between elevated serum 
phosphate and increased mortality post renal transplantation (32) and I, therefore, sought to 
ascertain if this relationship was evident in our local renal transplant population. 
1.10.1  Methods 
The electronic patient record was used to identify patients who received a first deceased 
donor renal transplant between January 1999 and December 2008. Patient demographics, 
laboratory parameters, cause and date of death and of transplant failure were recorded at 
one year post transplantation. A history of smoking, DM or CVD was recorded. The 
primary endpoint was death with a functioning transplant. 
1.10.2   Results 
377 transplant recipients were followed up for a median of 1798 days (337-3919 days). 
62% (n=235) of patients were male, 10% (n=38) were diabetic and 18.8% (n=71) had a 
history of vascular disease at the time of transplantation. Characteristics of the patients are 
shown in Table 1.3. Forty-four patients had died at the time of analysis: 11 from a CV 
cause. Survivors and non-survivors were compared; survivors were younger, less likely to 
be diabetic, had a higher eGFR and a lower phosphate at one year post transplantation. 
Figure 1-11 shows Kaplan-Meier analysis for transplant recipient survival stratified by 
serum phosphate at one year post transplantation. A serum phosphate in the range of 0.9 to 
1.11mM afforded the best survival outcome; serum phosphate which was greater than 
1.11mM was associated with all cause mortality (p=0.006). When adjusting for history of 
DM, history of smoking, age at the time of transplantation and eGFR, serum phosphate at 
one year post transplantation remained a significant predictor of all cause mortality (HR 
3.36 (1.26-8.97), p=0.016). 
 
1.10.3  Discussion 
There is an independent association between serum phosphate at one year post renal 
transplantation and death from all causes. Optimal serum phosphate appears to be between 
0.9mM and 1.11mM; levels above or below confer increased risk of death. This 
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observation, for the first time, of a possible J shaped relationship between serum phosphate 
and all cause mortality, suggests that addressing the impact of phosphate is more 
complicated than the use of phosphate binders and phosphate supplementation. A history 
of CVD was not significantly associated with mortality. In our centre, patients undergo CV 
screening prior to being listed for transplantation; high risk patients are selected out which 
may explain this finding (333). 
This study is a single centre study with small numbers and its retrospective nature means 
there is incomplete data on important CV risk factors. However, the association of 
phosphate with all cause mortality concurs with other data of CV risk and ED associated 
with increased phosphate (6;32). Understanding the mechanism is a crucial step in 
allowing us to identify phosphate targets and management strategies to lower CV risk in ‘at 
risk’ populations, particularly those with CKD. 
 
The prevalent view is that elevated serum phosphate increases CV risk by promoting VC. 
An alternative possibility is that phosphate directly causes ED. Phosphate may act alone or 
in conjunction with its regulators, eg FGF-23. These possibilities are explored in detail, 
throughout this thesis, by examining vascular function in vitro and in vivo, gene 
expression, and quantitative and functional changes in signal transduction pathways. 
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Table 1-3: Characteristics of the study population. 
p values refer to comparison between survivors and  deceased patients.  * n=190 at 5 years and 
**at time of transplantation. 
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Figure 1-11: Transplant recipient survival stratified by serum phosphate at one year post 
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1.11 Aims of this thesis 
The aims of this thesis are to determine the effects of phosphate in vitro and in vivo. The 
specific questions that I have answered are: 
 Whether phosphate and FGF-23 level correlate with LVM in patients with CKD 
and whether this may be explained by an effect on cell adhesion molecules? 
 Does elevated phosphate concentration affect the function of resistance vessels 
from healthy rats and from humans with and without CKD? 
 What are the effects of culturing different cell lines, long term, in high phosphate 
concentration medium particularly whether long term exposure to high phosphate 
causes endothelial dysfunction and altered growth patterns? 
 Whether intracellular calcium concentrations are altered when cells are cultured in 
high phosphate medium? 
 In healthy volunteers, what are the effects of phosphate supplementation and 
phosphate binding on endothelial function, vascular stiffness, urinary phosphate 
excretion, urinary cGMP levels and serum phosphate and FGF-23 levels? 
 
1.12 Hypothesis 
The hypothesis of this thesis is that long term exposure to elevated phosphate is associated 
with direct endothelial and vascular dysfunction and it is this which contributes to the 
elevated CV risk seen in those with CKD. Endothelial and vascular dysfunction will be 
evident in individual cell lines, in blood vessels and in humans exposed to prolonged oral 
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Figure 1-12: Summary of thesis - the interaction between phosphate and FGF-23 and effects 
on the vasculature and the endothelium and the pertinent chapters. 
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2 Chapter Two – Materials and Methods 
Chapter 2 XXX 88 
2.1 Introduction 
This chapter contains a comprehensive guide to the methods used in the work contained 
within this thesis. The effects of phosphate were studied in a translational manner and the 
findings described in the individual results chapters involved the use of cell lines (chapters 
three to six), resistance vessels from rats (chapter four), resistance vessels from humans 
(chapter five) and a cross over trial in human volunteers (chapter seven).    
2.2  General laboratory practice 
A laboratory coat and latex free gloves were worn during all experimental work. The 
highest available grade of laboratory reagents and equipment was used. When handling 
hazardous materials, laboratory glasses and/or a fume hood were utilised in accordance 
with The Control of Substances Hazardous to Health Regulations (COSHH). 
Gilson pipettes (Gilson Medical Instruments) were used to dispense volumes between 
0.1µl and 1,000 µl whilst a Gilson battery powered pipetting aid with sterile disposable 
pipettes (Corning Inc., NY, USA ) allowed dispensing of larger volumes between 1 ml and 
25 ml. When appropriate, a multi-channel pipette (Eppendorf) was used. Pipettes were 
calibrated annually. 
Centrifugation of samples at 4-20 ºC was performed in either a Sigma 1-15K microfuge 
(volumes up to 2 ml) or a Beckman GS-6KR centrifuge (volumes up to 50 ml). Vortexing 
was undertaken with a FSA Laboratory Supplies WhirliMixer. A plate shaker, ‘Belly 
dancer’ was used where indicated (Denville Scientific, Inc.). A Mettler Toledo digital pH 
meter was used to determine the pH of solutions. This was calibrated regularly with 
solutions of pH 4.0, 7.0 and 10.0 prepared from buffer tablets (Sigma-Aldrich Ltd, Poole, 
UK). To weigh reagents, use was made of either an Ohaus portable advanced balance 
(sensitive to 0.01 g) or a Mettler HK160 balance (sensitive to 0.0001 g).  
For protein quantification, a Beckman DU640B spectrophotometer was utilized. An 
automated microplate washer (LT-3500, Labtech) was used where indicated. A hot block 
was used to heat substances up to 70°C (Dri-Block DB-2A Techna) and a Heidolph 
Polymax 1040 plate shaker was used to mix solutions when appropriate. 
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In the preparation of aqueous solutions, distilled water was used unless otherwise stated 
and a Jenway 1000 hotplate/stirrer aided dissolving and mixing.  
Sterile, disposable plastic ware from Corning Inc., NY, USA was utilised including: 0.5ml, 
1.5ml and 2ml microcentrifuge tubes (Greiner Bio-One); 15ml and 50ml centrifuge tubes; 
5ml and 20ml universal containers (Sterilin); assorted sterile, disposable pipette tips; 







 culture flasks with vented caps. 
Glassware was cleaned in Decon 75 detergent (Decon Laboratories Ltd.), rinsed in distilled 
water and finally dried in a 37°C cabinet. If laboratory equipment required to be sterilised 
this was undertaken in an autoclave (Priorclave Tactrol 2). All cell culture took place under 
sterile conditions in a laminar flow hood. Unless otherwise stated, all chemicals and 
reagents were purchased from Sigma-Aldrich Ltd, Poole, UK. 
2.3 Vessel studies 
Two separate series of studies were undertaken looking at the function of animal and 
human vessels in vitro. The vessels used were: rat mesenteric resistance vessels from 12 
week old male Wistar-Kyoto rats (WKY) and human resistance vessels from subcutaneous 
abdominal adipose tissue from patients with and without CKD. The West of Scotland 
Research Ethics Committee 4 approved the human studies.   
2.3.1  Animals 
Work with experimental animals was in accordance with the Animals Scientific 
Procedures Act 1986. Pre 9/11/2011 this was under the project licence held by Professor 
A.F. Dominiczak (60/3618) and post 9/11/2012 under the project licence held by Dr 
Delyth Graham (60/4286). Inbred colonies of WKYs were maintained “in-house” by 
brother-sister mating. Microsatellite screening was used to confirm homozygosity of all 
loci within a random group from the strain.  
WKYs were sacrificed (schedule one) and the mesentery removed and placed into a chilled 
normal phosphate concentration physiological saline solution (PSS). The constituents of 
PSS are defined in Table 2-1. This was undertaken by trained staff. Prior to sacrifice, all 
animals were housed under controlled environmental conditions: temperature maintained 
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at 21C with 12 hour light/dark cycles. Rats were fed standard rat chow (rat and mouse 
No.1 maintenance diet, Special Diet Services) and water was provided ad libitum. The 
mesentery was stored in the fridge for up to one hour before it was pinned on a petri dish 
containing fresh PSS as illustrated in Figure 2-1. 
2.3.2 Selection of human subjects  
Patients without CKD undergoing nephrectomy for living kidney donation and patients 
with CKD undergoing live donor renal transplant were identified and provided with a 
participant information sheet (section 9.2, Appendix).  
Informed consent was obtained (section 9.2, Appendix). Blood samples were collected the 
day prior to the operation and in the case of patients with CKD, prior to dialysis where 
possible. Samples were sent for full blood count and routine biochemistry including bone 
biochemistry, urea and electrolytes, CRP and PTH. EDTA plasma was stored for FGF-23 
analysis and serum was stored for vitamin D measurement. 
At the time of the operation, and prior to the use of either diathermy/harmonic scalpel, a 
piece of skin approximately 5mm wide and 70mm long was dissected with adherent 
subcutaneous abdominal fat. The sample was immediately placed into chilled PSS and 
transported to the laboratory. 
2.3.3 Wire myography and dissection of vessels 
Blood flow to tissues is controlled by resistance vessels including all small arteries with an 
internal diameter of less than 500µm. Arterioles have an internal diameter of less than 
80µm. Wire myography allows the study of the function of all pre-arteriolar arteries: tiny 
resistance vessels with an internal diameter of 100-500µm as defined by Mulvany (334).  
In 1972, Bevan and Osher described the first wire myograph which allowed segments of 
arterial vessels with internal diameters as small as 100µm to be mounted on two wires 
fixed under tension at both ends (335). The isometric response of a vessel to an agonist 
could then be recorded. Prior to this, detailed study of the properties of vascular smooth 
muscle was confined to ring preparations of large vessels using the traditional organ bath 
method. Technical difficulties prevented direct study of smaller vessels and thus 
information about their mechanical and pharmacological properties could only be 
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extrapolated from these large vessel studies or gleaned from perfusion experiments or 
histological examination (336).  
In the mid-70s, Mulvany and Halpern honed the technique further. Vessel segments of 
approximately 2mm in length are mounted on fine wires (40µm) with both wire ends fixed 
under tension onto two stainless steel jaws. One jaw is attached to an isometric force 
transducer and the other to a micrometer, allowing the vessel wall tension to be measured 
at a pre-determined circumference (Figure 2-2) (337;338). This method differs from others 
where only one end of the wire is fixed, necessitating manipulation of the vessel on the 
wire with dissecting equipment with almost inevitable consequent damage to the vessel 
(339). Additionally, when only one end of the wire is fixed, for contractions to be 
isometric, the wire has to be thicker (100-200µm) precluding the use of smaller vessels. 
Mulvany and Halpern performed their original experiments using rat resistance vessels 
from the mesentery. Human omental vessels were first examined with wire myography in 
1981 (337;338;340). Human vessels are taken from subcutaneous fat usually from buttock 
biopsies or at the time of a surgical procedure or from the myometrium in pregnancy 
(95;108;340;341). In the rat, mesenteric vessels are commonly studied (338). 
Once vessels are mounted, the contractile response can be studied with the addition of 
phenylephrine (PEP) or noradrenaline and acetylcholine and its mimetics (e.g. carbachol) 
can be administered to trigger NO production in the endothelium. NO donors including 
sodium nitroprusside (SNP) allow the study of endothelial independent vasodilation by 
donating NO to VSMCs, bypassing the need for a functioning endothelium. N-nitro-L-
arginine methyl ester (L-NAME) is an inhibitor of NO synthesis and thus can be used in 
the study of NO and its effects, particularly to study basal NO production. 
All vessels were dissected, on a petri dish with 5mm thick layer of sylgaard to hold fixing 
pins and fresh PSS, under a dissection microscope (Zeiss). Micro dissection instruments 
were used (World precision instruments). Dissection was performed at room temperature 
without oxygenating PSS. Following dissection, vessels were stored in standard PSS 
before being transferred to universal containers containing either normal (1.18mM) or high 
(2.5mM) phosphate concentration PSS. The composition of these solutions is shown in 
Tables 2-1 and 2-2. The solutions were stored at 4
o
C for 16 hours prior to use in 
experiments. For the human vessels, EDTA was also added to both the normal and high 
concentration PSS at a concentration of 0.023mM. 
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Figure 2-1: Dissected rat mesentery pinned out onto a petri dish. 
The resistance vessels (example indicated by the black arrow) are easily identified under a 
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Figure 2-2: A typical four chamber wire myograph (top) with the micrometer indicated by the 
black arrow and oxygen supply by the red arrow.  
Inside each of the four chambers are stainless steel jaws (middle) between which two wires can be 
fixed to hold a vessel in place. One wire is indicated by the blue arrow (bottom). 
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Table 2-1: Composition of normal and high phosphate concentration solutions. 
The solutions were aerated with a 5% CO2/95% O2 mixture and had a pH of 7.4 
 
 
Table 2-2: Final electrolyte concentration of standard and high phosphate PSS. 
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2.3.3.1 Rat mesenteric vessels 
Third order resistance vessels were identified according to the technique described by 
Mulvany and dissected under a dissecting microscope with all adherent fat removed (336). 
2.3.3.2 Human subcutaneous vessels 
Resistance vessels were usually identified running from the skin. Dissected vessels along 
with a small amount of attached fat were transferred to a second petri dish also containing 
PSS and pinned at either end. The surrounding fat was carefully removed taking care not to 
damage the vessel. The vessels were then transferred to a universal containing PSS and 
stored in the fridge for between three and four hours. At time zero, the vessels were 
transferred to two further universals containing normal (1.18mM) or high (2.5mM) 
phosphate concentration PSS. 
 
2.3.4 Mounting of vessels on the wire myograph 
All myography experiments were performed on a four chamber wire myograph 
(multimyograph model 610, Danish Myo Technology). This is illustrated in Figure 2-3. 
Experiments were conducted after storage of the vessels at 4°C in normal (1.18mM) or 
high phosphate (2.5mM) concentration PSS for 16 hours. Each chamber of the myograph 
was filled with PSS; two chambers contained normal phosphate and two high phosphate 
concentration PSS. Stainless steel wires, forty microns in diameter, were cut into lengths of 
approximately 2.5cm. One wire was attached by one of the two available fixing screws 
onto one jaw of the myograph thus leaving a free straight segment of wire onto which a 
vessel lumen could be threaded. Under the dissecting microscope, the vessels were, using 
micro-forceps, fed onto the wire attached to the myograph. The free end of the wire was 
then attached to the second fixing screw on the myograph jaw. A second wire was then 
carefully threaded, through the vessel lumen, under the first wire. The jaws were closed 
clamping both wires. The second wire was secured to each fixing screw on the opposite 
jaw of the myograph and the jaws were carefully opened putting a small amount of tension 
on the vessel. This allowed the wires to be levelled in a horizontal plane. Any part of the 
vessel protruding beyond the jaws was cut away taking care not to damage the remaining 
vessel. Using a micrometer eyepiece attached to the dissecting microscope, the length of 
the vessel segment was measured and recorded. The wires were then just touching and the 
micrometer reading recorded at that point. Figure 2-3 incorporates a cartoon of a vessel 
mounted on a myograph. 
Chapter 2 XXX 96 
 
 
Figure 2-3: A four chamber wire myograph system (top) and a cartoon of vessel mounted on 
two wires, attached to the two jaws of a wire myograph (bottom). 
One jaw is attached to a micropositioner allowing the vessel to be put under tension and the other 
jaw attaches to a force transducer which is connected to a computer. Adapted from Mulvany et al 
(336). 
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2.3.5 Normalisation and experimental procedure - rat mesenteric 
vessels 
Mulvany’s original work described a process by which to standardise third order rat 
resistance vessels on a myograph (338). This is necessary for three reasons: the active 
response of a vessel is dependent upon the degree of stretch which it is under, the 
sensitivity of a vessel to pharmacological agents is dependent upon the degree of stretch 
which it is under and the size of an elastic vessel is influenced by trans-mural pressure and 
this requires to be defined. Normalisation establishes the internal circumference that a 
vessel would have when relaxed under a trans-mural pressure of 100mmHg (L100). This is 
undertaken by gradually distending the vessel using the micrometer and recording the 
micrometer and force readings. The Laplace equation is then used to calculate the L100. The 
internal circumference is then set to 90% of the L100 (342) 
 
Vessels were mounted as described and then following normalisation subjected to a 
‘waking up’ protocol where KPSS (PSS with potassium chloride substituted for sodium 
chloride on an equimolar basis) was added to the bath and the vessels contracted. This was 
repeated. The vessels were then contracted with phenylephrine (PEP) and relaxed with 
carbachol. Vessels which failed to contract to KPSS or PEP or failed to relax >50% to 
carbachol were discarded. The vessels were then left for 30 minutes prior to concentration 
response curves being calculated. The specific protocols are discussed in more detail in the 
relevant results chapters; four (rat vessels) and five (human vessels). Briefly, vessels were 
contracted with PEP in the presence and absence of N-nitro-L-arginine methyl ester (L-
NAME).  Following contraction with PEP, they were relaxed with carbachol or with 
sodium nitroprusside (SNP). Vessels were also contracted and relaxed in the presence of 
ascorbic acid or zaprinast, a phosphodiesterase-5-inhibitor (PDE5I) (Tocris bioscience, 
Bristol, UK). 
 
2.3.6 Standardisation and experimental procedure – human 
subcutaneous vessels 
Mulvany’s process of normalisation refers specifically to third order rat resistance vessels 
and there is debate as to the applicability to other types of vessel (343). Therefore, for the 
human resistance vessels, active and passive tension curves were constructed as described 
by Van den Akker (343). The force on the vessels was standardised at the point where the 
constructed active and passive tension curves crossed: 0.8g of tension. Approximately 0.2g 
of tension was added to the vessels every 15 minutes to reach 0.8g. The vessel diameter 
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was measured manually by taking the micrometer reading when the wires were just 
touching and subtracting this from the reading when the wires were touching the vessel 
wall and adding 80 microns (wires 40microns). The vessel length was measured also. The 
vessels were ‘woken’ with KPSS. They were then contracted with PEP to achieve what 
was considered to be a maximal response. After wash out the vessels were contracted with 
PEP to 60% of the maximum response and then relaxed with carbachol. Following a wash 
out period, the vessels were then contracted again with PEP and relaxed with SNP. Only 
vessels which did not contract to KPSS were discarded. 
 
2.3.7 Statistical analysis 
For each vessel, a concentration response curve was calculated for each drug added to the 
bath. Area under the curve (AUC) was then calculated in Microsoft Excel using the 
formula: AUC = (X1/2)+X2+X3+X4+X5+X6+X7+(X8/2). Xn is the % relaxation or 
contraction at each point on the concentration curve. A Student’s T test or one-way 
analysis of variance (ANOVA) (if comparison of more than two groups) was then used to 
compare the AUC values. Maximum contraction and vasodilatation responses were 
compared directly with a Student’s T test.  EC50 values were also calculated. This is the 
concentration where 50% of the maximal drug effect is observed. The median L100 (rat 
vessels only) and the median vessel lengths were compared with a Mann Whitney U test. 
Statistical analysis was performed in SPSS v 19 (IBM, UK) and results are expressed as 
mean ± standard error of the mean (SEM). 
2.3.8 cGMP ELISA 
This was measured according to the manufacturer’s instructions using an ELISA kit (Cell 
Signaling technology, distributed by New England Biolabs Ltd, Hertfordshire, UK). A 
standard curve was plotted using the samples provided and plotted in Microsoft Excel on a 
logarithmic scale with a logarithmic trendline and the appropriate equation (y=a*ln(x) + b). 
Each measure was made in duplicate and an average absorbance taken, the average 
background absorbance was subtracted from this to allow cGMP calculation (nM). Results 
were then expressed as cGMP pM/µg protein. Analysis was by Mann Whitney U test in 
GraphPad Prism, CA, USA .  
Chapter 2 XXX 99 
2.3.9  Preparation of rat vessel samples for cGMP ELISA 
Rat mesenteric resistance vessels were incubated in 1.18mM or 2.5mM PSS for 24 hours 
and then snap frozen using a combination of dry ice and methanol and stored at -80°C until 
use. The vessels were thawed at 4°C, sonicated and the protein concentration quantified 
using the Bradford’s assay (section 2.4.7). The solution (180µl) was washed with a 10% 
(v/v) excess of 1:1 tri-n-octylamine and 1,2,2-tri chlorofluoroethane (198µl) vortex mixed 
and centrifuged (14,000rpm at 4°C for three minutes). The top layer (150µl) was removed 
and washed a second time as above. The top layer was removed (120µl) and stored at -
80°C until use. 
2.3.10  Superoxide measurement in whole blood 
This was undertaken by Ms Elaine Friel (Technician, Institute of Cardiovascular and 
Medical Sciences). Whole blood samples were collected from patients with and without 
CKD. The samples were placed on ice immediately after collection. Electroparamagnetic 
spin resonance (EPR) spectroscopy allows measurement of chemical species which have 
one or more unpaired electron, like O2
-
. The Bruker e-scan EPR machine was calibrated 
using a reduced form of the spin probe, CP (3-carboxyl-proxyl radical) at concentrations of 
1µM, 5µM and 10µM. Each was read ten times and the mean, standard deviation (SD) and 
coefficient of variation were calculated from these results. A HEPES buffer containing 
100mM DTT (dithiothreitol) and 20% (v/v) Tween-20 was used to keep the pH of the 
solutions constant at 7.4. Deferoxamine (DF) and diethyldithiocarbamic acid (DTEC) were 
used as chelators at final concentrations of 25µM and 5µM respectively. CPH (1-hydroxy-
3-carboxy-2,2,5,5-tetramethylpyrrolidine) was then used as a spin probe, labelling the 
superoxide present in the sample (final concentration 1mM). Everything was kept on ice 
throughout. Blood was added to HEPES buffer and chelators and finally CPH was added 
immediately before processing. The solution was drawn up by a 15µl capillary tube and 
sealed with ‘cristoseal’ sealant. After ten minutes on the EPR machine, the sample was 
removed and disposed of. Each blood sample was processed three times. The results were 
analysed in Microsoft excel using a linear equation and plotted in GraphPad Prism.   
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2.4 Cell culture 
Four cell lines were utilised: HUVECs, rat thoracic aortic ECs, rat myoblasts and human 
cardiac myocytes. All cultures were incubated at 37°C in 5% CO2. For all cell types, two 
types of media appropriate to the cell line were used. Media was either standard phosphate 
concentration media (0.5mM) or custom formulated with a phosphate concentration of 
3mML from PromoCell, Heidelberg, Germany. Table 2-3 details the cell line supplier, the 
media supplier, the appropriate catalogue number and the passage range at which each cell 
type was used in experimental work. All media were supplemented with 10U/ml penicillin 
and 10µg/ml streptomycin (Gibco by Life technologies Ltd., UK). In order to check the 
electrolyte composition of the media, the biochemistry department at Gartnavel General 
Hospital analysed sodium, potassium, phosphate, magnesium and calcium concentrations 
in each of the medium utilised (Table 2-4). 
On arrival, cells were seeded into flasks and grown in standard phosphate concentration 
medium until they reached 90% confluence. At the first passage in our laboratory, they 
were divided into normal phosphate (0.5mM) and high phosphate (3mM) concentration 
cells and grown in the appropriate phosphate concentration media from that point until 
they were discarded. HUVECs were used between the second and fifth passages, rat ECs 
were used between the fourth and sixth passages and cardiac myocytes between the fourth 
and sixth passages. The rat myoblasts used, A10s, are an immortalized cell line with many 
properties of VSMCs and thus throughout this thesis will be referred to as VSMCs.  
2.4.1 Trypsinization and cell storage 
At 90% confluence, all cell lines were trypsinized and transferred to new flasks or onto 
plates at a density appropriate to the plate size. Media was removed from flasks and 10mls 
of phosphate buffered saline (PBS) (Gibco by Life technologies Ltd., UK) was added to 
wash away trypsin neutralisers. Trypsin-EDTA (Gibco by Life technologies Ltd., UK) was 
added and the flask was incubated at 37°C for five to ten minutes (cardiac myocytes were 
incubated at room temperature as per manufacturer’s instructions). Immediately after 
detachment of cells, media was added to neutralise the trypsin, and the solution was 
transferred to a universal container and centrifuged at 1500rpm for five mins at 20°C. The 
cell pellet was re-suspended in media. 10µl of this solution was put onto a haemocytometer 
to allow the cells to be counted. Cells were left to adhere at least overnight before any 
experimental work was undertaken. Unless otherwise stated, the cell densities used were: 
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 Six well plate and glass bottom dish: 1x104/well or dish. 
 Twelve well plate: 1x105/well. 
 Ninety-six well plate and four chamber glass slides: 1.8x103/well or chamber. 
 Passage into new culture flasks: a 1 in 10 dilution. 
For cell storage, cells were trypsinised and then re-suspended in standard growth medium 
for those cells, i.e. 0.5mmol/L or 3mmol/L phosphate concentration, containing 10% (v/v) 
DMSO and 20% (v/v) FCS. One ml of this cell suspension was frozen containing 1x10 
6
/ml cells and frozen in an isopropanol containing cryopreservation container (‘Mr Frosty’) 
at a rate of -1°C/minute to -80°C before being transferred to liquid nitrogen after 24 hours.   
 
2.4.2 Cell based ELISA for E-selectin and VCAM 
This was performed in HUVECs cultured in 0.5mM phosphate and 3mM phosphate.  The 
cells were plated onto a 96 well plate and left for 24 hours before being treated with FGF-
23, at a final concentration of 3.5x10
-7
M (ProSpec, Tany TechnoGene Ltd, Israel) and 
Klotho, 2x10
-10
M (R&D Systems, Abingdon, UK) either alone or in combination; controls 
were untreated. After a four hour incubation with FGF-23 and Klotho, some wells were 
also treated with IL1β, and all plates left for a further six hours. The wells were washed 
with PBS and then the cells were fixed with 4%  (w/v) paraformaldehyde and incubated at 
4°C overnight. The wells were washed with a PBS (purchased from Sigma Aldrich) and 
0.1% (w/v) bovine serum albumin (BSA) solution for one hour to block non specific 
protein binding. For E-selectin, mouse anti-human antibody (AbD Serotec, Oxford, UK) at 
a 1/2000 dilution was added to each well. For VCAM sheep anti-human antibody (R&D 
Systems, Oxford, UK) at a 1/2000 dilution was added to each well. After a one hour 
incubation, the wells were washed and the secondary antibody added (horseradish 
peroxidase (HRP) rabbit anti-mouse for E-Selectin and rabbit anti-goat for VCAM). This 
was washed off after incubation for one hour and developer was added. The wells were 
read at 630nm absorbance on a microplate reader (SpectraMax M2, Molecular Devices, 
Sunnyvale, CA, USA). Stripping buffer was added to the wells which were then probed for 
mouse anti-human GAPDH (R&D Systems, Abingdon, UK).  
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Table 2-3: Details of cell line and media suppliers and the passage range at which cell lines 
were used in experimental work. 
*Indicates custom made media formulation with 3mmol/L phosphate concentration and ** indicates 
the supplement mix added to the media. 
 
 
Table 2-4: The concentration of electrolytes in each type of media used; endothelial cell 
(EC), smooth muscle cell (SMC) and cardiac myocyte (CM). 
Standard media phosphate concentration for all cell lines is listed by Promocell as 0.5mM. The 
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Cell based ELISA for E-Selectin and VCAM was performed in three separate experiments 
with each group represented in triplicate in each experiment, and results were normalized 
to GAPDH. For cell based ELISA comparisons, the different groups were compared using 
a two way ANOVA and post-hoc analysis was carried out with Tukey’s test. 
2.4.3 Cell staining and imaging 
All cell lines were plated onto four chamber glass slides (Nunc Lab-Tek Chamber Slide). 
The following day they were stained with haematoxylin (0.1% w/v) and eosin (0.2% v/v) 
(H&E). Initially, the cells were washed twice with PBS and then they were fixed with 
paraformaldehyde (4% (w/v) dissolved in a 5% (w/v) sucrose solution) and incubated for 
ten minutes. The cells were washed again with PBS and then the slide was placed into 
haematoxylin for two minutes. After washing for five minutes with tap water, the slide was 
transferred to eosin for a further minute and then dipped into tap water to remove the 
excess for ten seconds. Slides were then taken to the fume hood where they were left for 
five minutes each in 70% (v/v) ethanol, 90% (v/v) ethanol and 100% (v/v) ethanol. The 
slides were then placed in histoclear for ten minutes. A cover slip was placed onto the slide 
and the cells were then imaged and photographed with an Olympus BX40 microscope and 
a Micropublisher 3.3 RTV camera (Q Imaging, UK) using Image Pro Software (Media 
Cybernetics, UK).  
 
2.4.4 MTT Proliferation assay 
Yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), a 
tetrazolium salt is reduced to blue/purple formazan in the mitochondria of living cells via 
mitochondrial dehydrogenase. NADH is thought to be responsible for the majority of MTT 
reduction and MTT reduction is associated with the cytoplasm, the plasma membrane and 
other non-mitochondrial membranes in addition to the mitochondria. This process requires 
active mitochondria, and even freshly dead cells do not cleave significant amounts of 
MTT. The formazan product is insoluble and the crystals therefore need to be solubilised 
(344). Absorbance can then be measured at a wavelength of 590nm with a reference filter 
of 620nm on a microplate reader. An increased cell number results in an increased amount 
of formazan and therefore increased absorbance (345). 
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MTT was used at a concentration of 5mg/ml, filtered through a 0.2µm filter and stored at -
20°C, protected from light. A series of experiments using the MTT assay was performed in 
HUVECs, rat ECs, cardiac myocytes and rat VSMCs. Cells were incubated in twelve well 
plates and assayed for mitochondrial dehydrogenase activity by MTT. For the basic 
proliferation assay, cells were plated onto twelve well plates on day one. On days two and 
three the media was carefully changed. On day four, 20µl MTT/100µl media (final 
concentration 1mg/ml) was added to HUVECs, rat ECs and VSMCs. 10µl MTT/100µl 
media (final concentration 0.5mg/ml) was added to cardiac myocytes. The cells were then 
incubated at 37°C for three and a half hours (HUVECs and rat ECs), two hours (VSMCs) 
and one hour (cardiac myocytes). The media/MTT solution was carefully removed and 150 
µl of MTT solvent was added (1:1 ethanol/DMSO mixture). The plate was wrapped in 
aluminium foil and agitated on an orbital plate shaker for fifteen minutes. The plate was 
then read on a microplate reader. In each plate there were control wells which contained 
media (both 0.5mM and 3mM as appropriate) and no cells. The basic proliferation assay 
was performed a minimum of three times for each cell line. Within each plate, four wells 
contained cells cultured in 0.5mM phosphate concentration and four wells, cells cultured in 
3mM phosphate concentration. The remaining four wells were control wells. 
The proliferation assays were repeated with the cells exposed to different chemicals: L-
NAME (1x10
-4
M), IL1β (5ng/ml), FGF-23 (3.5x10-7M) and Klotho (2x10-6M). The cells 
were plated as described above and then on day two, one of these substances, with the 
exception of IL1β, was added when the media was changed. This was repeated on day 
three. IL1β was only added to the cells six hours before the addition of MTT. Comparisons 
were made using Graph Pad Prism (San Diego, CA) and the Student’s T test, one way 
ANOVA or Kruskall-Wallis test with post hoc (Dunn’s multiple comparison test) analysis 
as appropriate. 
2.4.5  Griess reaction 
Measurement of NO is difficult because it has short half life and reacts rapidly with other 
molecules including oxygen radicals (346). Nitrate and nitrite are the main NO 
metabolites. The Griess reaction detects nitrites; when Griess reagent is added to a sample 
containing nitrite, a red-pink colour develops. Griess regeant contains sulphanilic acid 
which forms a diazonium salt with nitrites and an azo dye (N-alpha-naphthyl-
ethylenediamine) which results in the red-pink colour. On day one, cells were plated onto a 
96 well plate. After 24 hours fresh media was added to each well. Simultaneously cells 
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were treated with L-NAME (1x10
-4
M) or L-Arginine (1x10
-5
M); controls were left 
untreated. L-NAME was used as a NOS inhibitor and thus a reduction in NO would be 
expected. L-arginine was added to increase the available substrate for eNOS with an 
anticipated subsequent increase in NO production. The media was replaced daily with 
fresh L-NAME or L-arginine as appropriate until day four when a Griess reaction was 
performed. Sodium nitrite was used to generate a standard curve in each plate at a 
concentration of 0-100µM. 50µl of Griess was added to each well, the plate was then 
wrapped in tinfoil and replaced in the incubator for 30 minutes before being read at an 
absorbance of 540nm on a microplate reader. This was performed in duplicate and a 
minimum of six replicates were used for each condition. 
2.4.6 Preparation of cell lysates 
Supernatant was removed from cells and either discarded or stored in Eppendorf tubes at  
-80°C. On ice, cells were washed three times in ice cold PBS, before 70µL of radio-
immunoprecipitation assay buffer (RIPA) was added to individual wells. RIPA was made 
in house (150mM NaCl, 1mM EDTA, 1% (v/v) TX100, 0.5% (w/v) deoxycholic acid and 
50mM Tris pH7.4; concentrations are final concentrations)and stored at 4°C.  Prior to use, 
RIPA was supplemented with the protease inhibitors benzamidine and soya bean trypsin 
inhibitor, sodium orthovanadate and PMSF (phenylmethanesulphonyl fluoride). A pipette 
tip was used to scrape the adherent cells and the plate were placed in the freezer (-20°C) 
for 20 minutes. Lysates were collected after thawing and stored at -80°C until use. 
Repeated freeze-thaw was avoided. 
 
2.4.7  Quantification of protein concentration 
The Bradford assay was used to quantify protein concentration; it is a colormetric protein 
assay. Under acidic conditions, the red form of Coomassie brilliant blue G-250 dye is 
converted to a blue form to bind to the protein being assayed. The blue form of the dye is 
stabilised when it binds to the protein and the protein concentration can then be estimated 
by measuring absorbance at 595nm. The increase of absorbance at 595nm is proportional 
to the amount of bound dye, and therefore to the concentration of protein present in the 
sample. BSA standards were used to construct a standard curve at a concentration of 0-
0.225µM. 0.5ml of Bradford reagent (BioRad Laboratories, Germany) was added to a 
cuvette containing 5µL of sample. The samples were read using a spectrophotometer 
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(Beckman DU 640D) at an absorbance of 595nm. The standards and samples were 
routinely measured in duplicate and an average taken.  
 
2.4.8  Polyacrylamide gel electrophoresis and immunoblotting 
Proteins were resolved using the NuPAGE 4-12% Bis-Tris pre-cast gel system (Life 
technologies, Paisley, UK formerly Invitrogen). Minimum sample protein content was 
10ug per well. Protein samples were denatured in NuPAGE LDS (lithium dodecyl sulphate 
at a pH of 8.4) sample buffer (Life technologies, Paisley, UK) by heating to 70°C for 10 
minutes. In order to reduce proteins, 50mM DTT was added immediately prior to sample 
denaturing (unless otherwise stated). Proteins resolved by polyacrylamide gel 
electrophoresis were transferred to Protran nitrocellulose membranes using the NuPAGE 
XCell II blotting apparatus and the manufacturer’s transfer buffer which was supplemented 
with 20% (v/v) methanol. Transfer was performed at 40V for 60mins. Transfer efficiency 
was assessed by staining membranes with Ponceau S solution followed by washing with 
TRIS buffered saline (TBS) (20mM Tris-HCl pH 7.4, 135mM sodium chloride sterilized 
by autoclave) containing 0.1% (v/v) Tween 20 (TBST). The nitrocellulose membranes 
were then blocked in either 5% (w/v) non-fat powdered milk (Marvel) or 5% (w/v) BSA 
for 1 hour at room temperature. Blots were incubated with primary antibodies at the 
optimal concentration in either milk or BSA overnight at 4°C. Five washes of five minutes 
with TBST were then carried out prior to incubation with the appropriate horseradish 
peroxidise conjugated secondary antibody for two hours in milk or 5% (w/v) BSA at room 
temperature. Blots were then washed with TBST for five minutes five times. Proteins were 
visualised by enhanced chemiluminescence (Amersham, GE Healthcare, UK) and 
autoradiography. The antibodies used are detailed in Table 2-5. 
 
2.4.9 VEGF ELISA 
VEGF was measured on cell supernatants. The cells were cultured in six well plates and 
the supernatant from each well of one six well plate was combined and then concentrated 
and used to represent one replicate for each phosphate concentration. Three replicates were 
used for each condition and stored at -80°C. After a single thaw, the supernatant was 
concentrated using appropriately sized Amicon® ultra centrifugal filters (Merck Millipore, 
Abingdon, UK). A solid phase ELISA kit purchased from R&D systems was used and the 
ELISA was performed and analysed in accordance with the manufacturer’s instructions. A 
Chapter 2 XXX 107 
standard curve is generated by plotting absorbance versus VEGF concentration for each 
standard. The concentration of VEGF in each sample is subsequently read from this curve. 
VEGF is known to be induced when cells are exposed to hypoxic conditions (347). Cells 
exposed to hypoxic conditions were therefore used as a positive control.  
Cells were put into an air tight chamber for 24 hours to induce hypoxia. The reliable air 
tight seal and the fast gas exchange properties of the chamber, allow for the rapid and 
economical creation of a non-fluctuating hypoxic environment. Once sealed, this is a 
closed air tight system. The gas is a mixture of 5% CO2 and 95% N2. The cells are placed 
into the chamber in six well plates in the hood. The gas is bubbled through for four minutes 
then the chamber is sealed and put into the incubator. The lids are left off the plates (there 
is O2 in media). After 12 hours, fresh gas was bubbled through to ensure hypoxia was 
maintained. After 24 hours, the cells were removed and the supernatant and lysates 
obtained and stored. 
2.4.10 Epi-fluorescence and FURA -2-AM 
Intracellular calcium concentration was measured in HUVECs, rat VSMCs and rat ECs 
with epifluorescence using a dual-wavelength spectrophotometric method and the 
fluorescent dye FURA-2-AM (FURA-2-acetoxymethyl ester). 
FURA-2-AM is a membrane permeable derivative of the ratiometric calcium indicator, 
FURA-2. FURA-2-AM crosses into a cell through the membrane and the acetoxymethyl 
groups are cleaved by cellular esterases; this process regenerates FURA-2, the 
pentacarboxylate calcium indicator. Cells imaged under fluorescence can be measured at 
two wavelengths, 340nm and 380nm. Intracellular calcium concentration can then be 
calculated based on 340/380 ratios. Using the ratio automatically cancels out variables 
which may lead to artefact when imaging intracellular calcium concentration; including 
local differences in FURA-2 concentration and variations in cell thickness (348). The 
intracellular calcium value (R) which corresponds to a particular 340/380 ratio is 
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Table 2-5: Immunochemicals used in experimental work. 
Includes manufacturer information, the host species and the concentration at which the antibody 













M is the dissociation constant of FURA-2-AM. The minimum ratio (Rmin) is the 
fluorescence obtained using a zero calcium solution (10mM EGTA). The maximum 
calcium ratio (Rmax) is the fluorescence ratio obtained when the cell is lysed, thus releasing 
all of the intracellular FURA-2.
 
Cells were plated in glass bottomed plates and allowed to adhere overnight. The following 
day, cytosolic loading of FURA-2-AM (Life technologies, Paisley UK, formerly 
Invitrogen) was achieved by incubating the cells with FURA-2-AM (10µM endothelial 
cells and 5µM SMCs) at 37
o
C for 40 minutes (ECs) or 15 minutes (VSMCs). The cells 
were then washed with 1ml of media and incubated at 37
o
C for a further 15 minutes. Plates 
were mounted on an inverted microscope and isolated cells were imaged. Using an 
oscilloscope and the Clampex data acquisition software (pCLAMP, Molecular Devices 
LLC, USA), baseline fluorescence was recorded. 2µM calcium ionophore (non-fluorescing 
form, A23187) was added to prove that a calcium sensitive signal could be generated. On 
addition of calcium ionophore, the 340/380 fluorescence ratio rises and plateaus. 
Following this the cell lyser, saponin was added (10µM) to trigger cell lysis. A recording 
was made until the 380 nm wavelength began to fall. The Clampfit programme (Molecular 
Devices LLC, USA) was used to analyse the data and to determine the baseline 
fluorescence and the Rmax values. An example recording is shown in Figure 2-4. 
To calculate the Rmin of the cells and the dissociation constant (Kd) of FURA-2-AM, a 
three point calibration curve was constructed using HUVECs. Cells were plated in three 
dishes as described above and then incubated with 10µM FURA-2-AM for 40 minutes at 
37
o
C. The cells were washed and incubated for a further 5 minutes. 2µM calcium 
ionophore was added and the plates were left at 37
o
C for a further 2 minutes. A zero 
calcium HEPES (100mM KCl, 1mM MgCl2, 25mM HEPES, 10mM NaCl)  solution was 
used to wash the cells and then a 10mM EGTA HEPES solution was added to one plate, a 
5mM/5mM calcium EGTA/HEPES solution was added to the 2
nd
 and to the 3
rd
 a 10mM 
calcium EGTA solution was added. 
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Figure 2-4: A fluorescence recording from ECs using the Clampfit analysis package.  
The red arrow indicates the addition of calcium ionophore and the blue, saponin. The top row 
shows the 340/380 fluorescence ratio, the middle row the 340nm raw data and the bottom the 
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The plates were incubated for 10 minutes at 37
o
C. The fluorescence ratio was measured on 
the oscilloscope. The free calcium concentration of each of the three added solutions was 
calculated using REACT software (10nM, 37.5µM and 61.7µM respectively). The free 
calcium concentration was then plotted on a log scale on the X axis and the fluorescence 
ratio (Rmin) recorded for each solution was plotted on the Y axis. A sigmoidal curve was 
drawn. The 50% value is equivalent to the Kd of FURA-2-AM and the Rmin value for the 
cell line is equivalent to the fluorescence ratio seen with the 10mM EGTA solution. 
2.4.11 EPR superoxide measure from cell supernatant 
This was undertaken in HUVECs using a similar method to that described in section 
2.3.10. The cells were cultured and plated onto six well plates. Upon reaching confluence, 
the cells were washed twice with PBS and then incubated with a Krebs-HEPES buffer 
(118.4mM NaCl, 4.7mM KCl, 1.2mM MgSO4.H20, 11.1mM glucose, 2.5mMCaCl2, 
25mM HEPES)and the CPH spin probe for one hour at 37°C. The CPH spin probe and 
Krebs-HEPES buffer were also incubated in a well without cells for the same time period. 
The supernatant was then removed and immediately put onto ice before being run through 
the EPR machine in triplicate. The CPH without exposure to cells was used to assess the 
natural oxidation of the spin probe. The protein content of each well was quantified using 
the Bradford’s assay. For analysis, Microsoft excel was used. The figures obtained from 
the spin probe alone were subtracted from those attained with cells present and then 
normalised to the protein content of each well. Thus the final value is superoxide 
production/ng of protein/minute.  
 
2.5  Molecular biology 
2.5.1 RNA extraction and complementary DNA synthesis 
Cytoplasmic RNA was extracted from trypsinised cells according to the manufacturer’s 
instructions with the Qiagen RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA 
concentration was determined by measuring absorbance at 260nm and purity estimated by 
checking the 260nm:280nm absorbance ratio using the ThermoScientific NanoDrop® ND-
100 Spectrophotometer (Ratio >1.6). RNA was stored at -80°C until use and repeated 
freeze thaw was avoided. 
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cDNA was synthesised using the Invitrogen M-MLV reverse transcriptase kit. A mix 
comprising 1µg of RNA, 1µl hexamers (0.5µg/µl), 1µl 10 mM dNTP mix and sterile water 
to a final volume of 12µl was heated to 65°C for 5 minutes and then chilled on ice. 4µl of 
5x First-Strand buffer, 2µl 0.1M DTT and 1µl RNaseOUT (recombinant ribonuclease 
inhibitor) were added to the mix and samples were incubated for 2 minutes at 37°C before 
adding 1µl of reverse transcriptase (M-MLV RT (200U/µl). Thereafter, samples were 
incubated first at 37°C for 50 minutes and then at 70°C for 15 minutes. Each sample was 
also amplified without reverse transcriptase to assess for DNA contamination. Samples 
were subsequently diluted 1:5 with distilled water to a final volume of 100µl and stored at 
-20°C. 
2.5.2 Polymerase chain reaction: primer design 
The Roche universal probe library was used to design intron spanning primers. 
(https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000). Primers 
were subsequently ordered from Integrated DNA Technologies (Belgium). Table 2-6 lists 
the primers and their characteristics. 
2.5.3 Polymerase chain reaction 
The polymerase chain reaction (PCR) was performed using a PTC-100 programmable 
thermal controller with the Invitrogen Superscript III™ first strand system for RT PCR. A 
1µl of template (0.2ng), 0.25µl, 100nM forward and reverse primers, 0.5mls of 10mM 
dNTPs, 0.25µl Taq polymerase (5U/µl), 5µl 10x buffer (200mM Tris-HCl (pH 8.4), 
500mM KCl) and PCR-grade water were combined to give a 25µl reaction volume. 
Samples were denatured at 94°C for 30 seconds then primers annealed at 55°C for 45 
seconds and DNA extended at 68°C for 1 minute. This thermal cycling profile was used 
for 35 cycles. 
  
2.5.3.1  Agarose gel electrophoresis of DNA 
The DNA samples were mixed with blue loading buffer (Promega) and 15µl of 
sample/loading buffer mix was loaded onto the agarose gel. The DNA samples were run at 
100V for 1 hour with tris-acetate electrophoresis (TAE) buffer (0.04M Tris-acetate, 
0.001M EDTA). The 2% Agarose gels were made using 0.8g agarose for molecular 
biology, 40ml of TAE buffer and 4µl ethidium bromide. An ultraviolet transilluminator 
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was used to visualise bands and images were recorded on a BioRad ChemiDoc XRS digital 
imaging system. 
2.5.3.2 TaqMan® real time polymerase chain reaction 
Following reverse transcription, TaqMan® real time PCR (RT-PCR) was used to ascertain 
the relative quantity of the mRNA transcripts. The Roche Universal Probe Library was 
used in a probe-based detection scheme to allow time sensitive quantification rather than 
endpoint detection of the PCR template: ‘real time’. The fluorescent reporter signal is 
detected and quantified at the end of every PCR cycle and this signal increases 
proportionally to the amount of PCR product present in the reaction. A fixed fluorescence 
threshold is set above baseline called the threshold cycle (Ct) and this is the cycle number 
at which the fluorescence emission exceeds the threshold and is exponential. The Taqman 
probe is an oligonucleotide which is shorter than primers and has a fluorescent dye at the 
5’ base and a quenching dye on the 3’ base. When the probe is intact, no fluorescence is 
emitted. The probes are designed to anneal to a region of the PCR product. When 
polymerase replicates a template on which a Taqman probe is bound, the 5’exonuclease 
activity cleaves the 5’ end of probe which contains the reporter dye and the reporter emits 
fluorescence – this increases with each cycle proportional to the rate of cleavage. The 
accumulation of product is detected by monitoring the increase in fluorescence compared 
with a passive reference dye e.g. ROX. An internal control gene which remains constant in 
proportion to the total RNA is also amplified e.g. GAPDH. The mRNA target can be 
normalized to this control gene to allow for differences in the total RNA added to each 
reaction. Relative quantification of gene expression is determined using the comparative Ct 
method, where the difference between the Ct values of two PCRs for the same initial 
template amount varies. This is normalised to a baseline reference sample for comparison 
to be made (ΔΔCt method). 
Chapter 2 XXX 114 
 
Table 2-6: Oligonucleotide gene targets and characteristics. 
ENSEMBL gene identification number, oligonucleotide sequences (forward and reverse primers), 
optimal annealing temperature (Ann. temp), paired Universal Probe number (Probe No.) and 
amplicon size (Amp. Size). 
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2.5.3.3 TaqMan® RT-PCR protocol 
384 well PCR plates were utilized with each sample run in triplicate. 10µL was added to 
each well (2µL of 0.2ng of template, 0.1µL of 100nM probe, 0.4µL of 100nM forward and 
reverse primers, 2.1µL of PCR-grade water, 5µL QPCR mix containing 120nM ROX). The 
control gene was GAPDH. Control wells were run with non reverse transcribed template 
and mastermix without template. The plate was loaded onto a TaqMan® RT-PCR cycler 
where the block was heated to 50°C for two minutes then samples heated to 95°C for 10 
minutes followed by 40 cycles of denaturing at 95°C for 15 seconds and one minute 
annealing / extension at 60°C. To assess specificity of amplified product and to avoid 
spurious results from primer-dimer formation and amplification, dissociation curves 
showing product melting points were assessed. 
 
2.5.4 Microarray 
Microarray technology allows exploration of the expression levels of multiple genes 
simultaneously and thus provides insight into disease processes, regulatory pathways and 
gene function through comparison of mRNA transcript levels in cells or tissues. 
Biotinylated, amplified complementary RNA (cRNA), for hybridisation with Illumina 
Sentrix® arrays, was generated using the Illumina® TotalPrep RNA Amplification Kit 
according to the manufacturer’s protocol. 
2.5.4.1 Cell culture, RNA extraction, quantification and validation 
HUVECs were cultured in standard or high phosphate concentration medium on 96 well 
plates. Total RNA was extracted, DNase treated and quantified using the NanoDrop® ND-
100 Spectrophotometer. Total RNA sample integrity was verified by electrophoresis of 500 
ng on an Agilent Bioanalyzer 2100. 
2.5.4.2 cDNA synthesis and double strand cDNA purification 
First strand cDNA was synthesised by reverse transcription. Nuclease free H2O was added 
to 500 ng of total RNA to a final volume of 11 μl. 9 μl of reverse transcription master mix 
was then added. The master mix was prepared at room temperature and contained 1 μl T7 
Oligo(dT) primer, 2 μl 10 X first strand buffer, 4 μl dNTP mix, 1 μl RNase inhibitor and 1 
μl ArrayScript for each single 20 μl reaction.  After thorough mixing the samples were 
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incubated at 42ºC for two hours. Subsequently, second strand cDNA was synthesised 
immediately by adding 80 μl second strand master mix to each sample; prepared on ice and 
containing 63 μl nuclease-free H2O, 10 μl 10 X second strand buffer, 4 μl dNTP mix, 2 μl 
DNA polymerase and 1 μl RNase H for a single 100 μl reaction. After mixing thoroughly 
and flicking the tube 3-4 times, tubes were centrifuged briefly to collect the reaction in the 
bottom of the tube. Samples were then incubated for two hours at 16ºC in a thermal cycler 
and following this, cDNA purification was carried out immediately. cDNA was purified to 
remove RNA, primers, enzymes and salts which would inhibit in vitro transcription. 250 μl 
cDNA binding buffer was added to each sample and the mixture mixed thoroughly with 
pipetting and flicking the tube prior to being applied to the centre of a cDNA filter 
cartridge seated in a wash tube. Cartridges were centrifuged for a minute at 10,000x g, the 
flow-through was discarded and the cartridges replaced in wash tubes. 500 μl wash buffer 
was added to each cDNA filter cartridge and cartridges centrifuged at 10,000x g for a 
minute. Flow-through was discarded and the cartridges centrifuged for a further minute to 
remove all traces of wash buffer. The cDNA filter cartridges were then transferred to 
cDNA elution tubes and 10μl of pre-heated (50-55ºC) nuclease-free H2O added to the 
centre of the filters. The samples were incubated at room temperature for two minutes and 
then centrifuged at 10,000x g for 90 seconds. 9μl preheated nuclease-free H2O  was added 
to the filters and samples before a final centrifugation at 10,000 x g for two minutes to 
elute the double-stranded cDNA in an approximate volume of 17.5 μl. In vitro 
transcription (IVT) to synthesise cRNA was carried out immediately. 
2.5.4.3 In vitro transcription for cRNA synthesis, purification and validation 
To generate biotinylated RNA from the cDNA template firstly, 7.5μl IVT master mix was 
added to each sample. Master mix was prepared at room temperature with 2.5 μl T7 10 X 
reaction buffer, 2.5 μl T7 enzyme mix and 2.5 μl biotin-NTP mix for each single 25 μl 
reaction). Samples were thoroughly mixed and subsequently centrifuged briefly to collect 
the reaction mixture at the bottom of the tube. Samples were then incubated at 37ºC for 
between four and 14 hours before the reaction was stopped by adding 75μl of nuclease-free 
H2O. Purification of cRNA was carried out immediately. Each sample of cRNA was 
purified to remove unincorporated NTPs, salts, enzymes and inorganic phosphate by the 
addition of 350μl cRNA binding buffer followed by 250μl 100% ethanol. Samples were 
mixed, added to the centre of a cRNA filter cartridge placed in a cRNA collection tube and 
centrifuged for one minute at 10,000 x g. The flow-through was discarded and the 
cartridges replaced in new collection tubes. 650μl wash buffer was added to each cartridge 
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and samples were centrifuged for one minute at 10,000 x g. Flow-through was once again 
discarded and the samples centrifuged for a further minute to ensure complete removal of 
wash buffer. Cartridges were transferred to fresh cRNA collection tubes and 100μl of pre-
heated, nuclease-free H2O was added. The samples were left at room temperature for two 
minutes and then centrifuged for 90 seconds at 10,000 x g to elute the purified cRNA. 
Purified cRNA was quantified using the NanoDrop® ND-100 Spectrophotometer and 
quality assessed via electrophoresis of 500ng on an Agilent Bioanalyzer 2100. 
2.5.4.4 Microarray Hybridisation & Data Collection 
The Illumina® Whole-Genome Expression Direct Hybridization Assay was used to 
prepare cRNA for hybridisation with The Illumina® HumanWG-6 v3.0 Expression 
Beadchips. The Illumina® Beadchips contain 48,804 probes which target >25,000 
annotated genes. RNase-free H2O was added to 1.5μg of cRNA to a final volume of 10μl. 
Samples were mixed and then to re-suspend cRNA, incubated at room temperature for 10 
minutes. The hybridization reagents, GEX-HYB and GEX-HCB were incubated at 58ºC 
for 10 minutes to dissolve any salts which may have precipitated in storage. 20μl GEX-
HYB was added to each cRNA sample and 200μl GEX-HCB was added to each 
hybridisation chamber and the beadchips inserted into the chambers. cRNA samples were 
preheated at 65ºC for five minutes then vortexed and centrifuged. Samples were cooled to 
room temperature before 30μl was added to each array. The samples were randomised on 
the chips and technical duplicates were included. The hybridization chambers were 
incubated for overnight in a 58ºC oven rotating at 60 rpm. 
The following day, the beadchips were removed from the chambers and submerged in 250 
ml of the wash solution, E1BC (3mls E1BC buffer in 1L RNase-free H2O).  1 x high-temp 
wash buffer (50ml of 10 x stock in 450ml RNase-free H2O) was preheated to 55ºC and the 
beadchips were then incubated in this buffer for 10 minutes. Following this, the beadchips 
were transferred, at room temperature, to fresh E1BC wash solution and placed on an 
orbital shaker at maximum speed for 5 minutes. The beadchips were transferred to a 
250ml100% (v/v) ethanol solution and again placed on the orbital shaker for 10 minutes. A 
two minute wash in E1BC wash solution was performed before each chip was blocked in 
4ml Block E1 buffer for 10 minutes at medium rocking speed and room temperature. 
Beadchips were then placed in 2ml Block E1 buffer with streptavidin-Cy3 (2μl 1 mg/ml 
stock per chip) and covered to protect from light before rocking at medium speed for 10 
minutes. Beadchips were washed in 250ml E1BC wash solution and then placed on the 
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shaker for five minutes. The chips were dried by centrifugation at room temperature for 4 
minutes at 275 x g. Finally the beadchips were scanned and the images extracted using 
specific protocols on an Illumina® BeadArray Reader. Illumina® Gene Expression 
Beadchips have internal control features to monitor both sample-independent and sample-
dependent data quality. Control data results were visualised with BeadStudio software. 
2.5.4.5 Gene Expression Data Analysis 
Initial analysis of microarray data was performed using Illumina® BeadStudio software. 
Quantile normalisation of the data was carried out without background subtraction. Each 
probe is represented by multiple beads on an Illumina® Gene Expression Beadchip. 
Normalised values for each bead representing a given probe were averaged to obtain the 
estimate of expression for that probe. Unpaired two sample T tests were then performed on 
these averaged values using the Illumina® custom error model. Differentially expressed 
probes were identified using a difference score cut-off of +/- equating to a p value ≤ 0.05. 
Differentially expressed probes with a fold increase or decrease of  ≥2 and a false 
discovery rate (FDR) of ≤ 0.05 were uploaded to ThomsonReuters MetaCore™ software 
and analysed to identify pathways of interest containing the most significantly 
differentially expressed genes. Pathways analysis identified the pathways from the 
MetaCore™ library of pathways that were most significantly associated with the data set. 
Genes from the data set which met the p value cut-off of 5% and were associated with a 
canonical pathway in the MetaCore™ database were considered for the analysis. The 
significance of the association between the data set and the pathway was measured in two 
ways. Firstly, a ratio of the number of genes with differentially expressed probes from the 
data set that mapped to the pathway divided by the total number of genes with probes in 
the data set that mapped to the pathway was displayed. Secondly, in addition to this ratio, 
Fisher’s exact test was used to calculate a p value determining the probability that the 
association between the significant genes in the data set and the canonical pathway could 
be explained by chance alone, the FDR. TaqMan® RT-PCR as described in section 2.5.3.2 
was utilised to confirm differential expression observed in microarray experiments. The 
same total RNAs isolated for microarray experiments were used as templates for the 
synthesis of cDNA. Applied Biosystems Custom TaqMan® Gene expression assays or 
SYBR® Green based detection assays (Invitrogen) were used for RT-PCR. 
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2.6 Clinical Studies 
2.6.1 Study 1: FGF-23 and left ventricular mass in chronic kidney 
disease 
The lead investigator for this study was Dr Emily McQuarrie (formerly clinical research 
fellow, University of Glasgow) who kindly allowed me to make use of her data and her 
stored samples to measure FGF-23 levels and study any association with LVM.  
The Renal Unit at the Western Infirmary, Glasgow provides renal services to 2.8 million 
patients in the West of Scotland. Adult patients attending renal clinics in The West of 
Scotland were recruited with a diagnosis of either diabetic nephropathy or biopsy-proven 
IgA nephropathy and CKD stages 3–4. Patients with essential hypertension in the absence 
of CKD were recruited from the Glasgow blood pressure clinic. Patients who were 
receiving immunosuppression, had evidence of active infection or who were unable to 
undergo cardiac magnetic resonance imaging (CMRI) scanning were excluded. Written 
informed consent was obtained from all patients and the study was approved by the local 
ethics committee. 
Patients attended the Glasgow Clinical Research Facility. Demographic data including 
height, weight and waist circumference were recorded. The lowest of three blood pressure 
measurements was recorded. Investigations included measures of renal function, bone 
biochemistry (PTH, vitamin D, calcium and phosphate levels), haemoglobin and CRP). 
Proteinuria was estimated from a spot protein:creatinine ratio (UPCR), and 24-h 
proteinuria quantification. All prescribed medications were continued throughout the 
study.  Visits were undertaken by Dr Emily McQuarrie who also performed cMRI on each 
patient. The cMRI protocol has previously been described (349;350). Briefly, non-contrast 
cMRI was performed to determine left ventricular mass index (LVMI) using 8mm thick 
short-axis cine slices from a 1.5-Tesla Siemens (Erlangan) CMRI scanner, and a fast 
imaging with a steady-state precision (FISP) sequence. LVM was analysed by a blinded 
observer from short-axis cine loops using manual tracing of epicardial and endocardial 
end-systolic and end-diastolic contours. End-systolic volume, end-diastolic volume and 
LVM were calculated using commercial software (Argus; Siemens). Values were adjusted 
for body surface area (Mosteller formula, BSA (m
2) = √((weight (kg) × height 
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(cm))/3600)), and LVH was defined as LVMI > 84.1 g/m
2
 for men and >76.4 g/m
2
 for 
women; LV systolic dysfunction was defined as LV ejection fraction <55% (351).  
Statistical analysis was carried out using the IBM SPSS statistics package version 18.0 (IL, 
USA). Normality of the data was determined using Kolmogorov-Smirnoff analysis with 
normally distributed data expressed as mean ±SD and non-normally distributed data as 
median (interquartile range (IQR)). Parametric correlations were calculated using 
Pearson’s correlation, non-parametric using Spearman’s. Variables were log transformed 
to obtain a normal distribution as required. Comparisons were made using Student’s T test, 
Mann Whitney U test and one way analysis of variance as appropriate. Multivariate 
analysis was performed using binary logistic regression to determine independent 
predictors of LVH.  
2.6.2 Study 2: Effects of sustained phosphate loading on 
endothelial function 
In subjects without CKD, phosphate levels at the higher end of the normal range and acute 
phosphate loading (with a phosphate rich meal) can result in ED which corrects once 
loading has ceased (6). This study looked at the effects of manipulating physiological 
phosphate levels, using two different drugs and over a longer time course, on endothelial 
and blood vessel function in human subjects without CKD. The two drugs utilised to 
manipulate phosphate levels were phosphate (Sandoz UK, subsidiary of Novartis), a 
phosphate supplement and lanthanum (Shire Pharmaceuticals, UK), a phosphate binding 
medication. One 500mg phosphate tablet contains 16.1mM of phosphate which is roughly 
equivalent to the quantity of phosphate found in one can of fizzy juice (352). 
Hyperphosphatemia in the short term is not known to cause any adverse long term effects. 
Long term effects of prolonged hyperphosphataemia include VC and increased CV risk; 
these are seen in people who have been exposed to elevated phosphate over a significant 
period of time (35;192). It was anticipated that phosphate levels would be lowest with the 
binding mediation, highest with the phosphate supplement and in the middle at the baseline 
visit, visit one. 
This study was approved by The West of Scotland Research Ethics Committee two. All 
participants read a copy of the participant information sheet (section 9.2, Appendix) and 
were given the opportunity to ask questions and discuss the study further before informed 
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consent was obtained (section 9.2, Appendix). With the participant’s agreement, a letter 
was sent to inform the General Practitioner of their participation (section 9.2, Appendix). 
 
2.6.2.1 Inclusion Criteria 
Adult patients were recruited via email and word of mouth from University and National 
Health Service Staff (section 9.2, Appendix). 
  
 Patients/Volunteers without CKD (eGFR>60mls/min) 
 Individuals with capacity 
 Age≥18 years 
 
2.6.2.2 Exclusion Criteria 
 Patients on any form of RRT (HD, PD or renal transplant) 
 eGFR<60mls/min 
 History of peripheral vascular, cerebrovascular or coronary artery disease 
(symptoms, positive excercise tolerance test, CT/MRI brain findings, angiography 
findings) 
 Individuals without capacity 
 Age<18 years 
 Pregnant or lactating women 
 Known drug abuse 
 
2.6.2.3 Study Design 
This was a single blind, cross-over study with participants acting as their own control. 
Each participant attended The Glasgow Clinical Research Facility (fasted) at 9am for three 
visits. Prior to each visit, for the preceding 24 hours, participants performed a 24 hour 
urine collection; following bladder emptying, first thing in the morning, all urine was 
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collected during the 24 hour period finishing on the morning of the visit. From this, three 
aliquots of 20ml of urine were stored at -80°C for urinary FGF-23 and cGMP analysis and 
the remainder was sent for routine laboratory measurement of urinary protein and 
electrolytes including urinary phosphate and calcium level.  
 
At visit one, a history was taken to ascertain current health, medications, smoking history 
and history of CVD. At all visits, simple anthropometric measurements of height, weight 
and waist circumference were recorded along with blood pressure and an ECG. Endothelial 
function was measured using FMD and vascular stiffness using SphygmoCor® Vx system 
(Atcor Medical, Sydney, Australia). Blood samples were collected for routine analysis, 
storage for future analysis and extraction of white blood cells. At visit one, patients were 
randomised to receive either one phosphate tablet (500mg) or 1000mg of lanthanum 
(phosphate binder) three times daily for two weeks. The participant knew which tablet they 
were taking but the investigator did not. After consultation with the Medicines and 
Healthcare Products Regulatory Agency, neither phosphate nor lanthanum was being used 
as an investigative medicinal product simply as a means of altering serum phosphate 
concentration in vivo. After two weeks, patients attended for visit two. After a further two 
week wash out period, patients received the other drug for two weeks, before attending for 
the third and final visit. Figure 2-5 illustrates the study visit protocol. 
 
2.6.2.4 Randomisation, power calculation and statistical analysis 
Dr Patrick Mark (Senior Clinical Lecturer, University of Glasgow) generated a 
randomisation list in Microsoft Excel. This was given to the Pharmacy Preparation Unit at 
the Western Infirmary who put the drugs into an inner box and an outer bag. The inner box 
was labelled with details of the drug and the outer bag with participant identifiers but no 
drug identifiers. (Figure 2-6). The Western Infirmary pharmacy dispensed the drugs. 
Statistical advice with regards to sample size and power calculations was taken from an 
independent statistician, Professor Stephen Senn (formerly of The School of Mathematics 
& Statistics, University of Glasgow). We anticipated that FMD measures would differ 
between the highest and lowest phosphate measures. For a clinically relevant difference of 
3% in FMD, and a within-patient standard deviation of three (which corresponds to a 
standard deviation for the difference between repeated measures of about 4.25) 
approximately 18 patients would be needed to have 80% power for a 5% significance level 
(two sided).  The aim was to recruit between 18 and 24 patients, to be randomised in equal 
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numbers, per sequence. This would provide 90% power should all patients complete but 
allowed some margin in the event of drop-out. In fact 20 patients were recruited and 
randomised in equal numbers, 10 per sequence. Data were assessed for normality and log 
transformed where appropriate. Correlations were carried out using either Pearson’s or 
Spearman’s Rho. An ANOVA with post hoc analysis using Tukey’s honestly significant 
difference test was employed. Univariate and multivariate linear regression models were 
constructed with outcome (change in FMD from baseline) fitted as a function of treatment, 
patient and period but in such a way that the relevant contrasts could be specified. The 
issue of multiple testing was addressed in the protocol using the global F-test followed (if 
significant) by three pairwise comparisons. One third of the images were selected at 
random and re-analysed to test reproducibility and intra-observer variability. Intra-class 
correlation coefficient was computed using a two factor mixed effects model (type: 
consistency) for baseline diameter, post cuff diameter and FMD.  
Results for urinary phosphate are presented as the fractional excretion of phosphate 
calculated as follows:  
(Urinary phosphate * Serum creatinine) / (Urinary creatinine * Serum phosphate) % 
By taking into account urinary creatinine, this is more likely to be an accurate reflection of 
true urinary phosphate excretion. 
2.6.2.5 Blood pressure measurement 
After 15 minutes of supine rest, blood pressure was measured twice in each arm using the 
Omron MX2. An average of three readings was obtained and used in further analysis. 
 
2.6.2.6 Blood sampling 
After 30 minutes of supine rest, 50ml of blood was taken for routine biochemistry (urea 
and electrolytes, bicarbonate, bone profile, liver function tests, CRP, urate, glucose, lipids 
and PTH) and haematology (full blood count). Serum samples were obtained for vitamin D 
analysis and EDTA plasma samples for FGF-23 analysis. These were stored at -80°C until 
analysis. Additional plasma samples were obtained for extraction of white blood cells and 
an EDTA sample was obtained for genotyping. 
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Figure 2-5: Study Protocol. 
Volunteers attended for a baseline visit followed by two further visits. Prior to visit two, volunteers 
took either lanthanum carbonate or phosphate supplements and after a wash out period took the 
other drug before attending for the final visit .Patients were randomised at visit one to follow arm 
one (red arrows) or arm two (purple arrows). 
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Figure 2-6: Labels affixed to the outer bag (top) containing study medication and the inner 
box (bottom) of the medication. 
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2.6.2.7 Measures of vascular stiffness - the SphygmoCor® Vx system 
This is a non-invasive system which uses the gold-standard carotid-femoral PWV and the 
AIx. SphygmoCor® Vx is based upon the process of applanation tonometry whereby the 
artery is compressed against a rigid structure (usually bone) and the tonometer detects 
alterations in pressure as each pulse wave is generated. The system utilises a Millar 
tonometer which records and feeds these waves back to an attached computer for analysis. 
All measurements were undertaken following an ECG, to confirm sinus rhythm, and blood 
pressure recording. In certain settings, PWV cannot be performed, for example non-sinus 
rhythm. Measurements were standardised according to recommendations published By 
Van Bortel et al (69).  
 
Participants were assessed in the morning. There is diurnal variation in arterial vessel 
diameter and vessels are usually bigger in the evening. Participants were semi-recumbent 
for at least 10 minutes prior to any measurements. All usual medications were continued 
and because eating reduces reduces systemic vascular resistance, participants were fasted 
for 12 hours before measurements. Participants also abstained from caffeine for at least 12 
hours beforehand. There were no smokers amongst the study population; smokers should 
refrain from smoking for a minimum of three hours pre measurement because smoking 
increases sympathetic tone and arterial stiffness. Finally room temperature was kept at a 
consistent 21-23°C to standardise peripheral vasoconstriction. 
 
2.6.2.8 Acquisition and analysis of pulse wave velocity 
Three ECG electrodes were attached to the participant’s chest and the recording inspected 
to ensure that the R waves were upright and to confirm that the rhythm was sinus. The 
right carotid and right femoral arteries were identified and the distances between each 
artery and the suprasternal notch were measured in millimeters. The distal distance is that 
of the sternum to the femoral artery (via the umbilicus) and the proximal that of the 
sternum to the carotid. These values are entered into the SphygmoCor® Vx which 
calculates overall length by subtracting the proximal distance from the distal. 
Measurements were performed by one of four supervised, trained research nurses or by the 
researcher. Pulse wave velocity was recorded in metres/second and an average of three 
readings was used in analysis. An example carotid-femoral pulse wave velocity recording 
is shown in Figure 2-7. 
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Figure 2-7: Example of the SphygmoCor® Vx system PWV recording.  
This illustrates, in the top row, the femoral (distal) and on the bottom carotid (proximal) pulse wave 
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Recordings were taken at the right carotid and femoral arteries with the patient supine. 
Three readings, with a standard deviation of less than 10% of the mean, were obtained for 
each subject. The SphygmoCor® Vx measures the time between ventricular systole 
(represented by the R wave of the ECG) and the foot of the pressure wave at each site; 
carotid and femoral. The transit time is the time of travel of the foot of the wave over a pre 
determined distance. To ascertain the transit time, the time between the R wave and the 
proximal upstroke (carotid) is subtracted from the time between the R wave and the distal 
upstroke (femoral). 
  
2.6.2.9 Acquisition and analysis of the augmentation index 
With the right wrist in dorsiflexion, the augmentation index was measured at the right 
radial artery. On acquisition of an acceptable waveform, recordings were undertaken for 15 
seconds. For the recording to be accepted, the operator index had to be greater than 80%. 
The operator index is a composite measure of individual quality indices: pulse height 
variation <5%, average pulse height >100 units, diastolic variation<5% and shape variation 
<5%.  The SphygmoCor® Vx system then uses Fourier transformation to convert the radial 
waveform to a central (aortic) waveform. It is from this derived central waveform that the 
arterial pressure waveform is analysed.  The aortic AIx is calculated by dividing the  
augmentation pressure by the pulse pressure. The AIx is automatically corrected to a heart 
rate of 75 beats per minute; the calculated aortic augmentation index (AIx@75). This 
provides a standardized measure for comparison.  
 
Three acceptable recordings were taken for each participant and an average of these was 
taken. Analysis was performed using the average AIx@75. 
 
2.6.2.10 Acquisition and analysis of brachial artery flow mediated dilatation  
Measurements were standardized according to guidelines published by Thijssen et al in 
The American Journal of Physiology: Heart and circulatory physiology (130). Influences 
on FMD include recent ingestion of caffeine and alcohol, dietary intake, smoking and 
recent exercise. Participants avoided these for at least 12 hours prior to a visit.  
 
Acute activation of the sympathetic nervous system and temperature can affect FMD thus 
to minimize these effects, participants lay semi-recumbent for 10 minutes prior to any 
measurements and the room was quiet and darkened with the temperature kept at a 
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consistent 21-23°C. All recordings and analyses were performed by the same experienced 
investigator (the researcher) who was blinded as to which drug (phosphate or lanthanum) 
the participant was taking. Three ECG electrodes were attached to the participant’s chest to 
allow ECG recording to take place throughout the study.  The right arm was extended and 
supported on a level table (Figure 2-8). Using an 8.0MHz linear array transducer (Acuson 
8L5 system, Sequoia 512, Siemens) the brachial artery was identified and scanned 
longitudinally approximately 10 cm proximal to the antecubital fossa. A blood pressure 
cuff was placed on the forearm, just below the antecubital fossa and the ultrasound probe 
was then fixed over the artery using an adjustable steel arm. Baseline measurements of the 
artery diameter were recorded at the end of diastole (images were triggered on the R 
wave). Vessel diameter was assessed with ultrasonic calipers measuring the distance 
between the anterior and posterior interface between the media and adventitia. Within the 
brachial artery, clear vascular boundaries were identified to allow imaging of the double 
lines of Pignoli (353) and this in turn allows a more precise diameter measurement (≤0.05 
mm) to be calculated by automated edge-detection software (Vascular Research Tools 
package version 5, Medical Imaging Applications LLC, USA) (354). Baseline recording 
was for two minutes. The blood pressure cuff on the forearm was then inflated for five 
minutes to 250mmHg. Upon release of the cuff, recording was re-commenced for five 
minutes; to record reactive hyperaemia. After a 10 minute rest, a 2
nd
 baseline reading was 
recorded for two minutes. Two puffs of GTN spray were then administered and 60 seconds 
later a final recording was commenced for five minutes. 
 
Each study was recorded and analysed with automated edge detection software from 
Medical Imaging Applications LLC. This type of software is known to reduce intra-
observer variability, improve reproducibility and the validity of FMD measures (354). 
FMD was expressed as the percentage change in the arterial diameter pre and post cuff 
occlusion, relative to the baseline diameter. For endothelium independent measures 
following GTN, the change in arterial diameter was expressed as the percentage change in 
the arterial diameter pre and post GTN spray, relative to the 2
nd
 recorded baseline diameter. 
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Figure 2-8: FMD set-up with an example recording of the brachial artery (bottom). 
The yellow arrow indicates the ultrasound probe and the orange the blood pressure cuff. The 
brachial artery recording shows the different layers of the vessel wall. The intimal layer is used to 
calculate the brachial artery diameter. 
 
Chapter 2 XXX 131 
2.6.2.11 Blood and urine analysis - routine biochemistry and haematology 
Samples were sent to biochemistry for analysis of urea and electrolytes, bicarbonate, bone 
profile, liver function tests, CRP, urate, lipids and PTH (Diasorin Liason). Full blood count 
was measured by haematology. Immediately prior to each visit, a 24 hour urine collection 
was collected in a bottle without preservative. Urine was analysed in the routine laboratory 
for electrolytes using flame photometry. 
 
2.6.2.12 Vitamin D analysis 
This was undertaken at Glasgow Royal infirmary by Dr Susan Knox. 25-hydroxyvitamin 
D2 and D3 concentrations were measured by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) using a Waters UPLC with the ACQUITY TQD. The current 
assay Coefficient of variation is D3 mean 14nM CV 8.9%, mean 52.7nM CV 7.4%; D2 
mean 14nM CV 9.8%, mean 47.7nM CV 8.8%. 
2.6.2.13 FGF-23 analysis 
After a single thaw, FGF-23 was measured on EDTA plasma samples by ELISA 
(Immunotopics, Inc. San Clemente, CA). The ELISA was performed in accordance with 
the manufacturer’s instructions. The plate was read on a Wallac Victor2 1420 multilabel 
counter. A standard curve was generated by plotting absorbance versus FGF-23 
concentration for each standard. The concentration of FGF-23 in each sample was 
subsequently read from this curve. Urinary FGF-23 was measured with the same ELISA 
kit. 10mls of urine from the 24 hour collections was used and the urine was concentrated 
using Amicon® ultra centrifugal filters (Merck Millipore, Abingdon, UK). The final 
quantity of FGF-23 in the urine was adjusted for the 24 hour urine volume and creatinine. 
  
2.6.2.14 Cyclic GMP 
Urinary cGMP was measured by ELISA (R&D systems Europe Ltd. Abingdon, UK) on 
samples from a 24 hour urine collections. Samples were diluted 10 fold using the calibrator 
dilutant (RD5-5) supplied with the kit. Recommended study procedure was followed using 
96 well plates, with results read on the Wallac Victor2 1420 multilabel counter. Sample 
concentrations were calculated from standard curves. Results were expressed as pM/ml.  
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3 Chapter three – FGF-23: a tale of two studies. 
Relationship with left ventricular mass in CKD 
and phosphate, FGF-23 and cell adhesion 
molecule formation in vitro. 
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3.1 Introduction 
In this chapter the association between phosphate, FGF-23, ED and LVH is considered. 
The excess CV risk seen in CKD is secondary to a combination of traditional and ‘non-
traditional’ CV risk factors (2). The abnormalities arising as a result of disordered bone 
mineral metabolism in CKD; hyperphosphataemia, hyperparathyroidism and 
hypovitaminosis D are examples of ‘non-traditional’ CV risk factors and each has been 
linked independently with increased CV mortality (3-5;163). The mechanisms are poorly 
described but there is evidence that all can induce VC and ED (6;163).  
FGF-23 (sections 1.5.2 and 1.5.3) is now recognised as an essential player in serum 
phosphate regulation. FGF-23 potently lowers serum phosphate levels by inducing renal 
phosphate wasting and is a sensitive biomarker of abnormal renal phosphate handling. 
FGF-23 rises earlier, and to a greater extent, than serum phosphate in progressive CKD 
(197). Levels are elevated, often more than 1000 fold, in patients with ESRD and in 
advanced CKD, hyperphosphataemia develops despite increased levels of FGF-23. This 
reduced responsiveness to FGF-23 may reflect the reduction in the number of intact 
nephrons, and the resulting reduced expression of Klotho on DCT cells (355). 
Elevated FGF-23 is predictive of adverse outcome including premature mortality, CKD 
progression, vascular dysfunction and LVH (163;236;267;268). It is unclear whether FGF-
23 exerts directly toxic effects or whether it is simply a biomarker for these disease states. 
The cell adhesion molecules, soluble E-selectin and soluble VCAM are markers of ED 
associated with accelerated CVD in CKD (186;356). CMRI scanning is acknowledged as 
the gold standard for LVM measurement (357). The relationship between FGF-23 and cell 
adhesion molecules and FGF-23 and LVM, measured by CMRI has not been studied 
previously. The aims of this study were, therefore:  
 To assess the relationship between FGF-23 and LVH using CMRI in patients with 
CKD stages 3 and 4.  
 To assess the effects of phosphate, FGF-23 and Klotho on the expression of E-
selectin and VCAM in HUVECs. 
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3.2 Materials and Methods 
For the clinical study, these are discussed fully in section 2.6.1. Two patient groups were 
recruited: those with a diagnosis of either diabetic nephropathy or biopsy-proven IgA 
nephropathy and CKD stages 3–4 and those with essential hypertension in the absence of 
CKD. LVH was defined as LVMI > 84.1 g/m
2
 for men and >76.4 g/m
2
 for women; LV 
systolic dysfunction was defined as LV ejection fraction (LVEF) <55% (351). Cell culture 
and cell based ELISA are described in section 2.4.2. 
 
3.3 Results 
Forty-eight patients with CKD were included in the analysis. 62% (n=36) had a diagnosis 
of diabetic nephropathy, and 18% had IgA nephropathy. 50% (n=24) had LVH. 27 
‘control’ patients with essential hypertension but without CKD were also included in the 
analysis; 56% (n=15) of them had LVH. Comparison between the patients with and 
without CKD is shown in Table 3-1. There was a similar age distribution (60.0±12 vs 
55.5±9.5 years) and a similar proportion of males (75% vs 74%). LVMI was also similar 
between the two groups (81.2 (70.2-97.6) vs 86 (71.6-99.6) g/m
2
). Patients with CKD had 
significantly higher phosphate, PTH and FGF-23 concentration (237.9 (109.6-393.3) vs 
12.5 (1.5-35.9) RU/ml; p<0.001).  
Figure 3-1 shows stratification of patients by median FGF-23 concentration into four 
groups according to the presence or absence of LVH and CKD. Those with both CKD and 
LVH had the highest FGF-23 concentration followed by those with CKD without LVH 
(283.4 (166.4-414.8) vs 118.4 (61.5-295.0) RU/ml; p<0.001). A scatter plot of FGF-23 
concentration and LVMI in patients with CKD is shown in Figure 3-2 demonstrating 
significant positive correlation between the two (r
2
=0.064; p=0.005). Figure 3-3 shows the 
negative correlation with FGF-23 concentration and renal function (r
2
=0.072; p=0.004). 
There was also a positive correlation with phosphate (r
2
=0.073, p=0.006) (data not shown). 
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Table 3-1: Comparison of the baseline characteristics between the patients with CKD and 
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Figure 3-1: Median FGF-23 concentration in the presence and absence of CKD and LVH.  
Patients were stratified according to the presence or absence of CKD and then further stratified 
according to the presence or absence of LVH (defined as LVMI>84.1g/m
2
 for men and 76.4g/m
2
 for 
women), measured by cMRI using a 1.5-Tesla Siemens (Erlangan) scanner. FGF-23 concentration 
was measured on EDTA plasma samples, after a single thaw, by ELISA (Immunotopics, Inc. San 
Clemente, CA). Patients with CKD had higher concentrations of FGF-23 than those without CKD 
and if LVH was also present, these patients had the highest levels of FGF-23. Values represent 
median and IQR. 
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Figure 3-2: Scatter plot showing the relationship between FGF-23 concentration and LVMI in 
patients with CKD. 
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Figure 3-3: Scatter plot showing the relationship between FGF-23 concentration and renal 
function by the MDRD4 equation in all patients. 
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Further comparison between the patients with CKD +/- LVH is shown in Table 3-2. eGFR 
was significantly lower in those with LVH (27.5±11.7 vs 34.3±11.3 mls/min/1.73m
2
; 
p=0.044), systolic blood pressure and UPCR were significantly higher (158.8 ±19.7 vs 
139.2 ±22.2mmHg; p=0.002 and 82.5 (19.8-218) vs 67.4 (12.5-196)mg/ml; p=0.004). 
Multivariate analysis including creatinine, FGF-23, systolic blood pressure and UPCR 
revealed all, except creatinine, to be independent predictors of LVH (Table 3-3). The r
2
 
value was 0.56. Creatinine was used rather than eGFR because LVH takes into account 
body mass. I tried the model with eGFR and this was not a significant determinant of LVH. 
In the second part of our study we looked at the effects of altered phosphate concentration 
in the presence and absence of FGF-23, Klotho and IL1β on the production of E-selectin 
and VCAM. Compared with HUVECs stimulated only with IL1 β, E-selectin production is 
significantly elevated in HUVECs cultured in high phosphate media (3mM) in the presence 
of FGF-23 and IL1β or Klotho and IL1 β (p=0.005 and 0.04 respectively). This effect is 
attenuated in HUVECs exposed to both FGF-23 and Klotho with IL1β (Figure 3-4). 
Production of VCAM was also increased in HUVECs cultured in high phosphate medium 
(3mM) in the presence of FGF-23 and IL1β or Klotho and IL1 β (p=0.008 and 0.02). Again 
the effect was attenuated in HUVECs exposed to bith FGF-23 and Klotho with IL1β 
(Figure 3-5).  There was no significant difference seen between HUVECs which were not 
stimulated with IL1β (data not shown). 
 
3.4 Discussion 
In this study, we look at the associations of FGF-23 and vascular structure in CKD, with 
additional in vitro studies on the underlying mechanism. It is the first study to assess the 
relationship between FGF-23 and LVH measured with cardiac MRI. We confirm the 
findings of other studies which have used less sensitive measures of LVH; FGF-23 level is 
an independent predictor of LVH in patients with CKD 3 and 4 secondary to diabetic or 
IgA nephropathy.  
Patients without CKD had much lower levels of FGF-23 regardless of the presence or 
absence of LVH (13.8 (1.5-38) vs 20.7 (1.5-42.2) RU/ml; p=0.43). Left ventricular wall 
thickness increases as the heart adapts to chronic pressure overload with resultant LVH 
(358). LVH is found in up to 25% of essential hypertensives without end  
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Table 3-3: Multivariate analysis showing significant predictors of LVH in CKD. 
R
2
 value for the model was 0.56. 
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Figure 3-4: E-selectin production in HUVECs cultured in standard (0.5mM) and high (3mM) 
phosphate concentration media. 
HUVECs cultured in either 0.5mM or 3mM phosphate concentration media were seeded onto 96 
well plates at a density of 1.8 x10
3
 cells per well and left for 24 hours before being treated with 
FGF-23 (final concentration 3.5x10
-7
M) and Klotho (KL; final concentration 2x10
-10
M) either alone 
or in combination; controls were untreated. After a four hour incubation, some wells were also 
treated with IL1β (IL1), and all plates left for a further six hours.The wells were washed with PBS 
and then the cells were fixed with 4% (w/v) paraformaldehyde. Wells were washed with PBS and 
0.1% (w/v) BSA and then probed for E-selectin, mouse anti-human antibody (1/2000 dilution). After 
a one hour incubation, the wells were washed and HRP coupled rabbit anti-mouse antibody added. 
This was washed off and developer added. The wells were read at 630nm absorbance on a 
microplate reader. The figure shows the results of 3 separate experiments, with each condition 
represented in triplicate in each experiment. Values are mean ± SEM.   
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Figure 3-5: VCAM production in HUVECs cultured in standard (0.5mM) and high (3mM) 
phosphate concentration media. 
HUVECs cultured in either 0.5mM or 3mM phosphate concentration media were seeded onto 96 
well plates at a density of 1.8 x10
3
 cells per well and left for 24 hours before being treated with 
FGF-23 (final concentration 3.5x10
-7
M) and Klotho (KL; final concentration 2x10
-10
M) either alone 
or in combination; controls were untreated. After a four hour incubation, some wells were also 
treated with IL1β (IL1), and all plates left for a further six hours.The wells were washed with PBS 
and then the cells were fixed with 4% (w/v) paraformaldehyde. Wells were washed with PBS and 
0.1% (w/v) BSA and then probed for VCAM, sheep anti-human antibody (1/2000 dilution). After a 
one hour incubation, the wells were washed and HRP coupled rabbit anti-goat antibody added. 
This was washed off and developer added. The wells were read at 630nm absorbance on a 
microplate reader. The figure shows the results of 3 separate experiments, with each condition 
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organ damage elsewhere, and up to 60% in those with end-organ damage in other 
territories (359). The low levels of FGF-23 seen in our essential hypertension group with 
LVH suggest that FGF-23 is neither a biomarker for LVH nor does it contribute 
significantly to the development of LVH in patients without CKD.  
LVH is present in up to 75% of patients starting dialysis. Bregman et al studied factors 
affecting LVH in patients with CKD 3 and 4. They demonstrated that it affects 
approximately 50% of patients with this level of CKD and is more common with more 
advanced CKD (360). Both systolic and diastolic blood pressure are described in the 
literature as independent predictors of LVH in patients with and without CKD (361;362). 
There is an increased prevalence of LVH in patients with CKD and it may develop after 
shorter exposure to hypertension and possibly at lower values. In animal models, LVH 
develops in CKD even without significant hypertension (363). This supports the argument 
that additional factors contribute to the development of LVH. There are many other factors 
that may be associated with LVH in CKD including age, anaemia, proteinuria and FGF-23 
level (163;349;359;364).  In our studies of patients with stage 5 CKD, blood pressure is the 
major determinant of LV mass. However calcium-phosphate product is an additional 
contributor to LVH in keeping with the hypothesis that CKD mineral bone disease 
dysregulation is implicated in the pathogenesis of LVH in CKD (350). LVH is a major 
predictor of cardiovascular mortality in advanced CKD and potentially a risk factor for 
progression to dialysis  (365). Regression of LVH therefore represents a possible strategy 
for improving cardiovascular outcomes in CKD patients.  
In the current study, I show that FGF-23 level is an independent predictor of LVH in CKD 
and show the levels to be significantly higher than in those with CKD who do not have 
LVH. Since patients with CKD develop LVH at lower blood pressure levels than patients 
without CKD, some other factor present in CKD is likely to be involved. My data support 
the notion that FGF-23 may be responsible. 
To support a pathophysiological role for FGF-23, it is necessary to show that FGF-23 
either has direct effects on the growth or matrix production of cardiac myocytes (or other 
vascular cells) or that it has the potential to increase blood pressure. I examined the effect 
of FGF-23 on endothelial cells and show that in the hyperphosphataemic environment, 
FGF-23 stimulates the production of the cell adhesion molecules, E-selectin and VCAM. 
Higher levels of E-selectin and VCAM, indicate activation of the vascular endothelium and 
are present in patients with essential hypertension, who have ED (186). In the presence of 
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Klotho, this effect is attenuated consistent with the established role of Klotho as an anti-
ageing protein (366). Thus, FGF-23 may cause activation and dysfunction of the vascular 
endothelium, and contribute to hypertension and LVH in patients with CKD. This is a 
small pilot study and my cell based ELISA findings require confirmation with Western 
blot. Additionally, gene expression of E-selectin and VCAM requires evaluation in cells 
treated with phosphate, FGF-23 and Klotho. 
It remains to be shown whether there are similar direct effects on cardiac myocytes, but our 
findings support the hypothesis that FGF-23 is more than a biomarker of abnormal renal 
phosphate handling and may be a therapeutic target as phosphate binding medication 
reduces FGF-23 as well as phosphate levels (367). 
 
3.5 Conclusion 
In this chapter, the results of a small, single-centre, pilot study are presented showing that 
FGF-23 is associated with the development of LVH in CKD, as measured by the ‘gold 
standard’ method of CMRI. Preliminary evidence of a direct effect of FGF-23, in a high 
phosphate environment, in vitro is also provided: this may contribute to observed ED and 
LVH in CKD. I do not prove causality with elevated FGF-23 and LVH. FGF-23 might be a 
realistic therapeutic target and lowering levels of FGF-23 might offer benefit in terms of 
improved clinical outcomes but until we understand the mechanism of disordered bone 
mineral metabolism and ED and LVH we cannot progress. Further work is necessary to 
ascertain the specific mechanisms of ED in the high phosphate environment and in 
chapters four, five and six, I explore this in vitro with cell lines and resistance vessels. 
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4 Chapter Four – Effects of phosphate on the 
function of rat resistance vessels and on rat 
vascular smooth muscle cells 
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4.1 Introduction 
In work leading up to this thesis, I demonstrated an association between mortality and 
phosphate in renal transplant recipients (section 1.10); a similar association has been 
shown in other populations. In chapter three, I demonstrated an association between FGF-
23 and LVH (a marker of increased CV risk) and showed that in HUVECs, stimulated with 
FGF-23, cultured in a high phosphate environment, production of the cell adhesion 
molecules, E-selectin and VCAM is significantly increased. These cell adhesion molecules 
are markers of ED and suggest that in combination with a hyperphosphataemic 
environment, FGF-23 has a definite role to play in the development of ED, and thus CV 
risk and CVD.  
ED occurs in CKD although independent effects on its relationship to the pathogenesis of 
renal disease are unclear and the mechanism is poorly understood. However, evidence 
suggests a role for the NO pathway, both in laboratory and clinical studies of CKD 
(6;123;124). Phosphate also has a detrimental effect on endothelial function both in vitro 
and in vivo in CKD (6;249;250;368). The effects of phosphate are not limited to CKD but 
also occur in the healthy population, supporting the concept that phosphate may have 
detrimental effects on CV risk even in the face of a normal serum phosphate level (6).  
ED and elevated serum phosphate level are both risk factors for CVD in CKD and in the 
general population but their relationship to each other has not been explored in detail. It is 
likely that CKD causes an environment which initiates endothelial damage and 
dysfunction, leading to a self-perpetuating cycle, oxidative stress, an imbalance in redox 
and sustained ED. Whether the ED seen in CKD is reversible is not known; or whether 
there may be reversible phosphate-dependent effects on ED and the associated CV risk. 
In vivo, resistance vessels regulate blood flow to the tissues: experimental data has shown 
that the function of resistance blood vessels is impaired in CKD with ED and impaired 
relaxation (95). However, no studies in human vessels have separated the effects of 
phosphate exposure and other abnormalities of the uraemic environment (eg hyperkalaemia 
or acidosis). In a rat model of CKD, where impaired vasodilation of aortic rings was seen 
in animals fed a high phosphate diet; this was ameliorated in animals fed a low phosphate 
diet (253). Rat aortic rings incubated in high phosphate for one hour exhibit evidence of 
ED (6). In humans, the effect of phosphate on endothelial function and CV risk is likely to 
relate to long term exposure and thus effects of short term exposure to a high phosphate 
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environment may have limited relevance. However, there is a paucity of studies examining 
either the direct effects of phosphate, separately from the other abnormalities seen in the 
uraemic environment, or the effects of longer exposure to a high phosphate environment in 
humans or experimental animals. 
The aim of the present series of studies was to assess the effects of exposure to high 
phosphate alone on the function of resistance vessels from rats without renal disease by 
examining the: 
 Contractile response to PEP  
 Vasodilator response to carbachol: endothelium dependent vasodilatation 
 Vasodilator response to SNP: endothelium independent vasodilatation 
 Levels of basal NO produced using the NOS inhibitor, L-NAME 
 Contractile response to PEP and vasodilator responses to carbachol and SNP in the 
presence of ascorbic acid, an anti-oxidant. 
 Contractile response to PEP and vasodilatator responses to carbachol and SNP in 
the presence of a PDE5I (zaprinast). 
 Levels of cGMP present in the vessels, incubated in normal and high phosphate 
concentration PSS 
Figure 4-1 illustrates where each of these drugs affects the NO pathway. 
Two further aims addressed using rat VSMCs cultured in normal and high phosphate 
concentration were: 
 To measure expression of eNOS and PKG. 
 To measure NO production by the Griess reaction 
 To measure VEGF production. 
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Figure 4-1: The site of action of the study drugs on the NO pathway. 
Carbachol is an acetylcholine mimetic and thus causes relaxation by direct stimulation of NO 
production. L-NAME is a NOS inhibitor and so blocks production of NO allowing a measure of 
basal NO to made. SNP is a NO donor and so causes endothelium independent vasodilatation by 
blocking the need for an intact endothelium to produce NO. PDE5I is a phosphodiesterase 5 
inhibitor (zaprinast) which prevents break down of cGMP and thus enhances relaxation. PEP acts 
on α1 adrenoceptors on VSMCs to increase calcium and thus stimulate contraction. Adapted from 
Katzung et al (122) . The table illustrates the concentration range for each drug, which the vessels 
were exposed to in the myography chamber. 
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4.2 Materials and Methods 
Rats were sacrificed and vessels were then dissected and incubated for 16 hours in either 
normal (1.18mM) or high phosphate concentration (2.5mM) PSS and then mounted on a 
four chamber wire myograph as described in section 2.3. Following normalisation, the 
vessels were subjected to one of four protocols: 
 Contraction with PEP followed by vasodilatation with increasing concentrations of 
carbachol; pre and post incubation with L-NAME for 30 minutes. 
 Contraction with PEP followed by vasodilatation relaxation with increasing 
concentrations of SNP. 
 Contraction with PEP followed by vasodilatation with carbachol, followed by a 30 
minute wash out period to allow the re-establishment of a baseline and then repeat 
contraction with PEP followed by vasodilatation with SNP in the presence of 
PDE5I (incubation for one hour) 
 Contraction with PEP followed by vasodilatation with carbachol followed by a 30 
minute wash out period to allow the re-establishment of a baseline and repeat 
contraction followed by vasodilatation with SNP in the presence of ascorbic acid 
(incubation for one hour). 
Increasing concentrations of PEP, carbachol and SNP were added in a step wise fashion to 
induce contraction or vasodilatation and to allow construction of cumulative concentration-
response curves. A fixed concentration of L-NAME, ascorbic acid or PDE5I was added. 
PEP was used to elicit contraction in all protocols. Vessels were exposed to each 
concentration of PEP for three minutes or until a peak response at that concentration was 
reached. For vasodilatation with carbachol and SNP, vessels were exposed to each 
concentration for two minutes or until a plateau had been reached. If a complete 
concentration-response curve was not possible, the vessel was discarded. The 
concentration range used for each drug is illustrated in the table incorporated into Figure 4-
1. Blood samples were also taken from rats at the time of sacrifice and stored at -80
o
C. 
Renal function, calcium and phosphate level was measured in the routine biochemistry 
laboratory. 
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4.2.1 Cyclic GMP measurement, VEGF ELISA and Griess Reaction 
Some vessels were snap frozen after 24 hours of incubation and then defrosted for cGMP 
using an ELISA kit as described in sections 2.3.8 and 2.3.9. VEGF ELISA is described in 
section 2.4.9 and the Griess reaction in section 2.4.5.  
4.2.2 Immunoblotting; eNOS and PKG 
Rat VSMCs were cultured from the outset in either standard (0.5mM) or high (3mM) 
phosphate concentration as described in section 2.4. This was intended to mimic chronic 
exposure to a high phosphate environment. Immunoblotting was performed as described in 
section 2.4.8 using antibodies for total and phospho eNOS (Ser 1177) and PKG. GAPDH 
was used as the housekeeping protein. Additionally, cells cultured in normal phosphate 
medium were exposed to high phosphate medium for 48 hours and cells cultured in high 
phosphate medium were exposed to normal phosphate medium. This was designed to test 
whether effects of high phosphate exposure might be reversible. The experiments were 
repeated a minimum of three times.  
 
4.3 Results 
4.3.1 Sample size and baseline demographics 
The number of vessels studied for each drug and the corresponding size of the vessels 
(L100) is detailed in Table 4-1. Blood samples from six rats were analysed in the 
biochemistry laboratory for creatinine, phosphate and calcium. Phosphate and calcium 
values were at the high end of the normal range for human samples (1.39±0.22mM and 
2.56±0.12mM) and creatinine measures were low as would be expected in a small animal 
with normal renal function; 41.8±1.5µM. 
 
4.3.2 Contraction with PEP in the presence and absence of 
LNAME 
Contraction was not significantly different between the vessels incubated in normal or high 
phosphate concentration PSS (Figure 4-2). 
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Table 4-1: Comparison of numbers of vessels studied for each drug and the corresponding 
size of the vessels. 
Number is the number of vessels for which a complete concentration response curve was obtained. 
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 The potency of PEP was similar in both groups with no significant difference in the EC50 
between vessels in incubated in normal compared with high phosphate concentration PSS 
(3.6±1.9  x10
-6
 M and 5.3±2.8 x10
-6 
M).  With the addition of L-NAME, in the vessels 
incubated in normal phosphate PSS, the PEP concentration-response curve shifted to the 
left with a significant difference in the AUC. This difference was not seen in the vessels 
incubated in high phosphate PSS; L-NAME produced no discernible difference in 
contraction to PEP in these vessels. These results are illustrated in Figures 4-3 and 4-4. 
 
4.3.3 Endothelium dependent vasodilatation – carbachol 
The results for the endothelium dependent vasodilator, carbachol are shown in Figure 4-5. 
Following constriction with PEP, the vessels incubated in high phosphate PSS vasodilated 
significantly less well to carbachol than those incubated in normal phosphate PSS. 
Maximum vasodilatation obtained in the vessels incubated in high phosphate was 64% 
±9% compared with 95% ±1% (p<0.001) in the vessels incubated in normal phosphate. 
 
4.3.4 Endothelium independent vasodilatation – SNP 
The results for the NO donor and endothelium independent vasodilator, SNP are shown in 
Figure 4-6. Following constriction with PEP, the vessels incubated in high phosphate PSS 
vasodilated significantly less well to SNP than those incubated in normal phosphate PSS. 
Maximum vasodilatation obtained in the vessels incubated in high phosphate was 45 ±22% 
compared with 73% ±26 (p=0.02) in the vessels incubated in normal phosphate PSS. 
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Figure 4-2: Contraction to PEP in vessels incubated for 16 hours in normal or high 
phosphate PSS. 
Mesenteric resistance vessels from 12 week old WKY rats were incubated in normal (1.18mM) or 
high (2.5mM) phosphate concentration PSS for 16 hours. Vessels (normal phosphate, n=12; high 
phosphate, n=10) were then mounted on a wire myograph and following normalisation, PEP was 




M) to induce contraction 
and to allow construction of cumulative concentration-response curves. Vessels were exposed to 
each concentration of PEP for three minutes or until a peak response at that concentration was 
reached. Response expressed as mean ± SEM and comparison made between AUC and the EC50 
of both groups using the Student’s T test. 
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Figure 4-3: Contraction to PEP in the presence and absence of L-NAME in vessels incubated 
for 16 hours in normal phosphate PSS. 
Mesenteric resistance vessels from 12 week old WKY rats were incubated in normal (1.18mM) 
phosphate concentration PSS for 16 hours. Vessels (n=12) were then mounted on a wire 





M) to induce contraction and to allow construction of cumulative 
concentration-response curves. Vessels were exposed to each concentration of PEP for three 
minutes or until a peak response at that concentration was reached. Following a wash out, the 
vessels were left for 30 minutes before L-NAME was added (1x10
-4
M) and the vessels were then 
left for a further 30 minutes before repeating the addition of PEP at increasing concentrations. L-
NAME is a NOS inhibitor and thus the concentration-response curve for PEP should shift 
significantly to the left because basal NO production is reduced in the presence of L-NAME. 
Response expressed as mean ± SEM and comparison made between AUC of both groups with the 
Student’s T test. 
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Figure 4-4: Contraction to PEP in the presence and absence of L-NAME in vessels incubated 
for 16 hours in high phosphate PSS. 
Mesenteric resistance vessels from 12 week old WKY rats were incubated in high (2.5mM) 
phosphate concentration PSS for 16 hours. Vessels (n=10) were then mounted on a wire 





M) to induce contraction and to allow construction of cumulative 
concentration-response curves. Vessels were exposed to each concentration of PEP for three 
minutes or until a peak response at that concentration was reached. Following a wash out, the 
vessels were left for 30 minutes before L-NAME was added (1x10
-4
M) and the vessels were then 
left for a further 30 minutes before repeating the addition of PEP at increasing concentrations. L-
NAME is a NOS inhibitor and thus the concentration-response curve for PEP should shift 
significantly to the left because basal NO production is reduced in the presence of L-NAME. The 
concentration-response curve for PEP does not shift significantly to the left suggesting lower basal 
NO production. Response expressed as mean ± SEM and comparison made between AUC of both 
groups with the Student’s T test. 
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Figure 4-5: Vasodilatation to increasing concentrations of carbachol expressed as a % of 
maximal contraction (100%) with PEP 1x10
-5
M. 
Mesenteric resistance vessels from 12 week old WKY rats were incubated in normal (1.18mM) or 
high (2.5mM) phosphate concentration PSS for 16 hours. Vessels (normal phosphate, n=12; high 
phosphate, n=10) were then mounted on a wire myograph and following normalisation, PEP was 




M) to induce contraction. 




M) to induce relaxation. 
Vessels were exposed to each concentration of PEP and carbachol for three minutes or until a 
peak response at that concentration was reached. Cumulative concentration-response curves were 
constructed. Response expressed as mean ± SEM and comparison made between AUC of the two 
groups using the Student’s T test. 
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Figure 4-6: Vasodilatation to increasing concentrations of SNP expressed as a % of maximal 
contraction (100%) with PEP 1x10
-5
M. 
Mesenteric resistance vessels from 12 week old WKY rats were incubated in normal (1.18mM) or 
high (2.5mM) phosphate concentration PSS for 16 hours. Vessels (normal phosphate, n=11; high 
phosphate, n=9) were then mounted on a wire myograph and following normalisation, PEP was 




M) to induce contraction. 




M) to induce relaxation. 
Vessels were exposed to each concentration of PEP and SNP for three minutes or until a peak 
response at that concentration was reached. Cumulative concentration-response curves were 
constructed. Response expressed as mean ± SEM and comparison made between AUC of the two 
groups by the Student’s T test. 
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4.3.5 Effect of incubation with ascorbic acid. 
The results of incubation with the anti-oxidant, ascorbic acid for one hour prior to 
contraction with PEP and then vasodilatation with carbachol and SNP are shown in Figures 
4-7 to 4-9. Contraction with PEP remained similar between the vessel groups (Figure 4-7). 
Endothelium dependent vasodilatation with carbachol, in the presence of ascorbic acid, is 
illustrated in Figure 4-8. In the vessels incubated in high phosphate PSS, vasodilatation 
with carbachol initially appeared to improve with the addition of ascorbic acid but this 
improvement was not sustained across the dose range and the maximum vasodilatation was 
70±3% compared with 97±5% in the vessels incubated in normal phosphate PSS 
(p=0.007). 
 There was no significant difference in vasodilatation to carbachol between the normal 
phosphate concentration vessels incubated with and without ascorbic acid (maximum 
vasodilatation 97±5% vs 96±4%). The same was true of the vessels incubated in high 
phosphate PSS with and without ascorbic acid (maximum vasodilatation 70±3% vs 
74±8%) (Figure 4-9). 
The addition of ascorbic acid, to the vessels incubated in high phosphate PSS, improved 
endothelium independent maximum vasodilatation with SNP; maximum vasodilatation 
was 63.1±5.9% in the presence of ascorbic acid compared with 56.1±12.2% when no 
ascorbic acid was present (p=0.011). There was no significant difference in AUC 
comparing the vessels incubated in high phosphate PSS in the presence and absence of 
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Figure 4-7: Contraction to PEP in the presence of ascorbic acid (AA) in vessels incubated 
for 16 hours in normal or high phosphate PSS. 
Mesenteric resistance vessels from 12 week old WKY rats were incubated in normal (1.18mM) or 
high (2.5mM) phosphate concentration PSS for 16 hours. Vessels (normal phosphate, n=10; high 
phosphate, n=8) were then mounted on a wire myograph and following normalisation, the vessels 
were incubated with ascorbic acid (1x10
-5
M) for one hour. PEP was then added in increasing 




M) to induce contraction and to allow the 
construction of cumulative concentration-response curves.  Vessels were exposed to each 
concentration of PEP for three minutes or until a peak response at that concentration was reached. 
Response is expressed as mean ± SEM and comparison made between AUC of the two groups by 
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Figure 4-8: Vasodilatation to increasing concentrations of carbachol, in the presence of 
ascorbic acid (AA), expressed as a % of maximal contraction (100%) with PEP 1x10
-5
M.  
Mesenteric resistance vessels from 12 week old WKY rats were incubated in normal (1.18mM) or 
high (2.5mM) phosphate concentration PSS for 16 hours. Vessels (normal phosphate, n=10; high 
phosphate, n=8) were then mounted on a wire myograph and following normalisation, the vessels 
were incubated with ascorbic acid (1x10
-5
M) for one hour. PEP was added in increasing 




M) to induce contraction. Carbachol was then 




M) to induce relaxation. Vessels were 
exposed to each concentration of PEP and carbachol for three minutes or until a peak response at 
that concentration was reached. Cumulative concentration-response curves were constructed. 
Response is expressed as mean ± SEM and comparison made between AUC of the two groups by 
the Student’s T test. 
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Figure 4-9: Vasodilatation to carbachol in the presence and absence of ascorbic acid (AA) in 




Mesenteric resistance vessels from 12 week old WKY rats were incubated in high (2.5mM) 
phosphate concentration PSS for 16 hours. Vessels (n=10) were then mounted on a wire 










M) to induce relaxation. Vessels were exposed to each 
concentration of PEP and carbachol for three minutes or until a peak response at that 
concentration was reached. Cumulative concentration-response curves were constructed. This was 
repeated in a second group of vessels (n=8) in the presence of ascorbic acid with which the 
vessels were incubated for one hour following normalisation at a concentration of 1x10
-5
M. 
Response is expressed as mean ± SEM and comparison made between AUC of the two groups by 
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4.3.6 Effect of incubation with zaprinast (PDE5I) 
Incubation with PDE5I had no significant effect on contraction to PEP in vessels incubated 
in normal compared with high phosphate PSS. However, incubation with PDE5I 
ameliorated the impaired vasodilatation seen in vessels incubated in high phosphate PSS to 
both the endothelium dependent vasodilator, carbachol and the endothelium independent 
vasodilator, SNP (Figures 4-10 and 4-11). In the presence of zaprinast, the maximum 
vasodilatation in the vessels incubated in normal phosphate PSS to carbachol was 86±6% 
and 93±6% in the vessels incubated in high phosphate (p=NS). With SNP, the maximum 
vasodilatation seen in the vessels incubated in normal phosphate PSS was 70±7% 
compared with 73±7% in the vessels incubated in high phosphate PSS (p=NS).  
Chapter 4 XXX 163 
 
 
Figure 4-10: Vasodilatation to increasing concentrations of carbachol, in the presence of 
PDE5I expressed as a % of maximal contraction (100%) with PEP 1x10
-5
M.  
Mesenteric resistance vessels from 12 week old WKY rats were incubated in normal (1.18mM) or 
high (2.5mM) phosphate concentration PSS for 16 hours. Vessels (normal phosphate, n=10; high 
phosphate, n=13) were mounted on a wire myograph and following normalisation, the vessels were 
incubated with PDE5I (1x10
-6
M) for one hour. PEP was added in increasing concentrations (1x10
-8
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to 1x10
-5





induce relaxation. Vessels were exposed to each concentration of PEP and carbachol for three 
minutes or until a peak response at that concentration was reached. Cumulative concentration-
response curves were constructed. The bottom figure shows a comparison between vessels 
incubated in high phosphate with (n=13) and without (n=10) exposure to PDE5I.  Response is 
expressed as mean ± SEM and comparison made using AUC and the Student’s T test. 
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Figure 4-11: Vasodilatation to increasing concentrations of SNP, in the presence of the 
PDE5I, zaprinast, expressed as a % of maximal contraction (100%) with PEP 1x10
-5
M.  
Mesenteric resistance vessels from 12 week old WKY rats were incubated in normal (1.18mM) or 
high (2.5mM) phosphate concentration PSS for 16 hours. Vessels (normal phosphate, n=10; high 
phosphate, n=13) were mounted on a wire myograph and following normalisation, the vessels were 
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incubated with PDE5I (1x10
-6









M) to induce 
relaxation. Vessels were exposed to each concentration of PEP and SNP for three minutes or until 
a peak response at that concentration was reached. Cumulative concentration-response curves 
were constructed. The bottom figure shows a comparison between vessels incubated in high 
phosphate with (n=13) and without (n=9) exposure to PDE5I.  Response is expressed as mean ± 
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4.3.7 cGMP Measurements 
cGMP concentration was measured in vessels from 11 rats. There were 11 vessels 
incubated in each of normal and high phosphate concentration PSS. Figure 4-12 shows that 
there was significantly more cGMP/µg protein in the vessels incubated in normal 
phosphate concentration PSS compared with the vessels incubated in high phosphate PSS 
(715.6 (418-1541) vs 330.6 (284.1-500.1)pM/µg; p=0.0026). 
 
4.3.8 Immunoblotting for eNOS and PKG 
Phospho and total eNOS expression was measured in cell lysates from rat VSMCs cultured 
in normal and high phosphate concentration medium. There was no discernible difference 
in either phospho or total eNOS expression (normalised to GAPDH) between cells cultured 
in normal or high phosphate (Figure 4-13). 
When cells cultured in normal phosphate were exposed to high phosphate conditions for 48 
hours, eNOS expression increased significantly and in cells cultured in high phosphate 
conditions, exposed to normal phosphate, eNOS expression reduced significantly (Figure 
4-14). 
In cells cultured in 3mM phosphate, PKG expression was significantly reduced compared 
with cells cultured in 0.5mM phosphate (Figure 4-15). When cells cultured in 3mM 
phosphate were exposed to 0.5mM phosphate for 48 hours, expression of PKG increased 
(Figure 4-16). 
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Figure 4-12: Comparison of cGMP concentration (pM/µg protein) in vessels incubated for 24 
hours in normal or high phosphate concentration PSS. 
Rat mesenteric resistance vessels were incubated in 1.18mM (n=11) or 2.5mM (n=11) PSS for 24 
hours and then snap frozen using a combination of dry ice and methanol and stored at -80°C until 
use. The vessels were thawed at 4°C, sonicated and the protein concentration per µl quantified 
using the Bradford’s assay. The solution (180µl) was washed with a 10% (v/v) excess of 1:1 tri-n-
octylamine and 1,2,2-tri chlorofluoroethane (198µl) vortex mixed and centrifuged (14,000rpm at 
4°C for three minutes). The top layer (150µl) was removed and washed a second time as above. 
The top layer was removed (120µl) and stored at -80°C until use.  This was measured according to 
the manufacturer’s instructions using an ELISA kit (Cell Signaling technology, distributed by New 
England Biolabs Ltd, Hertfordshire, UK). A standard curve was plotted using the samples provided 
and plotted in Microsoft Excel on a logarithmic scale with a logarithmic trendline and the 
appropriate equation (y=a*ln(x) + b). Each measure was made in duplicate and an average 
absorbance taken, the average background absorbance was subtracted from this to allow cGMP 
calculation (nM). Results were then expressed as cGMP pM/µg protein. Analysis was by Mann 
Whitney U test. 
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Figure 4-13: Phospho eNOS expression in rat VSMCs (in triplicate). 
VSMCs were cultured on six well plates at a cell density of 1x10
4
 cells/well in 0.5mM and 3mM 
phosphate concentration medium. The cells were cultured until 90% confluence and then cells 
were placed on ice, washed with PBS and lysed using a RIPA buffer, made in house. The Bradford 
assay was used to quantify protein concentration. Proteins were resolved using the NuPAGE 4-
12% Bis-Tris pre-cast gel system. Minimum sample protein content was 10ug per well. Protein 
samples were denatured in NuPAGE LDS sample buffer heating to 70°C for 10 minutes. In order to 
reduce proteins, 50mM DTT was added immediately prior to sample denaturing. Proteins resolved 
by polyacrylamide gel electrophoresis were transferred to Protran nitrocellulose membranes using 
the NuPAGE XCell II blotting apparatus and the manufacturer’s transfer buffer which was 
supplemented with 20% (v/v) methanol. Transfer was performed at 40V for 60mins. Transfer 
efficiency was assessed by staining membranes with Ponceau S solution followed by washing with 
TBS containing 0.1% (v/v) Tween 20. The nitrocellulose membranes were then blocked in 5% (w/v) 
BSA for 1 hour at room temperature. Blots were incubated with a phospho eNOS, primary antibody 
at a 1/1000 concentration in 5% BSA (w/v) overnight at 4°C. Five washes of five minutes with 
TBST were then carried out prior to incubation with anti-rabbit HRP conjugated secondary antibody 
(1/2000) for two hours in 5% (w/v) BSA at room temperature. Blots were washed with TBST for five 
minutes five times. Proteins were visualised by enhanced chemiluminescence (Amersham, GE 
Healthcare, UK) and autoradiography. The blots were also probed for GAPDH (1/2000) as a 
primary antibody with anti-mouse HRP (1/2000) conjugated secondary antibody. The top left panel 
shows the cells cultured in 0.5mM phosphate concentration medium and the top right, those 
cultured in 3mM phosphate medium. The bottom panels show GAPDH. The panels were all taken 
from a single gel and each band represents one well from three separate six well plates.  
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Figure 4-14: Phospho eNOS expression in rat VSMCs (in duplicate). 
VSMCs were cultured on six well plates at a cell density of 1x10
4
 cells/well in 0.5mM and 3mM 
phosphate concentration medium. The cells utilised had been cultured in the appropriate medium 
for two weeks in total before being plated on the six well plates. After 48 hours, the media was 
changed such that cells cultured in 0.5mM media were exposed to 3mM media and cells cultured in 
3mM media were exposed to 0.5mM media. After 48 hours, the cells reached 90% confluence and 
were then placed on ice, washed with PBS and lysed using a RIPA buffer, made in house. The 
Bradford assay was used to quantify protein concentration. Proteins were resolved using the 
NuPAGE 4-12% Bis-Tris pre-cast gel system. Minimum sample protein content was 10ug per well. 
Protein samples were denatured in NuPAGE LDS sample buffer heating to 70°C for 10 minutes. In 
order to reduce proteins, 50mM DTT was added immediately prior to sample denaturing. Proteins 
resolved by polyacrylamide gel electrophoresis were transferred to Protran nitrocellulose 
membranes using the NuPAGE XCell II blotting apparatus and the manufacturer’s transfer buffer 
which was supplemented with 20% (v/v) methanol. Transfer was performed at 40V for 60mins. 
Transfer efficiency was assessed by staining membranes with Ponceau S solution followed by 
washing with TBS containing 0.1% (v/v) Tween 20. The nitrocellulose membranes were then 
blocked in 5% (w/v) BSA for 1 hour at room temperature. Blots were incubated with a phospho 
eNOS, primary antibody at a 1/1000 concentration in 5% BSA (w/v) overnight at 4°C. Five washes 
of five minutes with TBST were then carried out prior to incubation with anti-rabbit HRP conjugated 
secondary antibody (1/2000) for two hours in 5% (w/v) BSA at room temperature. Blots were 
washed with TBST for five minutes five times. Proteins were visualised by enhanced 
chemiluminescence (Amersham, GE Healthcare, UK) and autoradiography. The blots were also 
probed for GAPDH (1/2000) as a primary antibody with anti-mouse HRP (1/2000) conjugated 
secondary antibody. The top left panel shows the cells cultured in 0.5mM phosphate concentration 
medium initially and then exposed to 3mM medium and the top right, those cultured in 3mM 
phosphate medium initially and then exposed to 0.5mM medium. The bottom panels show GAPDH. 
The panels were all taken from a single gel and each band represents one well from two separate 
six well plates.  
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Figure 4-15: PKG expression in rat VSMCs (in triplicate). 
VSMCs were cultured on six well plates at a cell density of 1x10
4
 cells/well in 0.5mM and 3mM 
phosphate concentration medium. The cells were cultured until 90% confluence and then cells 
were placed on ice, washed with PBS and lysed using a RIPA buffer, made in house. The Bradford 
assay was used to quantify protein concentration. Proteins were resolved using the NuPAGE 4-
12% Bis-Tris pre-cast gel system. Minimum sample protein content was 10ug per well. Protein 
samples were denatured in NuPAGE LDS sample buffer heating to 70°C for 10 minutes. In order to 
reduce proteins, 50mM DTT was added immediately prior to sample denaturing. Proteins resolved 
by polyacrylamide gel electrophoresis were transferred to Protran nitrocellulose membranes using 
the NuPAGE XCell II blotting apparatus and the manufacturer’s transfer buffer which was 
supplemented with 20% (v/v) methanol. Transfer was performed at 40V for 60mins. Transfer 
efficiency was assessed by staining membranes with Ponceau S solution followed by washing with 
TBS containing 0.1% (v/v) Tween 20. The nitrocellulose membranes were then blocked in 5% (w/v) 
BSA for 1 hour at room temperature. Blots were incubated with a PKG, primary antibody at a 
1/1000 concentration in 5% BSA (w/v) overnight at 4°C. Five washes of five minutes with TBST 
were then carried out prior to incubation with anti-rabbit HRP conjugated secondary antibody 
(1/2000) for two hours in 5% (w/v) BSA at room temperature. Blots were washed with TBST for five 
minutes five times. Proteins were visualised by enhanced chemiluminescence (Amersham, GE 
Healthcare, UK) and autoradiography. The blots were also probed for GAPDH (1/2000) as a 
primary antibody with anti-mouse HRP (1/2000) conjugated secondary antibody. The top left panel 
shows the cells cultured in 0.5mM phosphate concentration medium and the top right, those 
cultured in 3mM phosphate medium. The bottom panels show GAPDH. The panels were all taken 
from a single gel and each band represents one well from three separate six well plates.  
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Figure 4-16: Expression of PKG in rat VSMCs (in triplicate). 
VSMCs were cultured on six well plates at a cell density of 1x10
4
 cells/well in 3mM phosphate 
concentration medium. After 48 hours, the media was changed and the cells were exposed to 
0.5mM media. After 48 hours, the cells reached 90% confluence and were then placed on ice, 
washed with PBS and lysed using a RIPA buffer, made in house. The Bradford assay was used to 
quantify protein concentration. Proteins were resolved using the NuPAGE 4-12% Bis-Tris pre-cast 
gel system. Minimum sample protein content was 10ug per well. Protein samples were denatured 
in NuPAGE LDS sample buffer heating to 70°C for 10 minutes. In order to reduce proteins, 50mM 
DTT was added immediately prior to sample denaturing. Proteins resolved by polyacrylamide gel 
electrophoresis were transferred to Protran nitrocellulose membranes using the NuPAGE XCell II 
blotting apparatus and the manufacturer’s transfer buffer which was supplemented with 20% (v/v) 
methanol. Transfer was performed at 40V for 60mins. Transfer efficiency was assessed by staining 
membranes with Ponceau S solution followed by washing with TBS containing 0.1% (v/v) Tween 
20. The nitrocellulose membranes were then blocked in 5% (w/v) BSA for 1 hour at room 
temperature. Blots were incubated with a PKG, primary antibody at a 1/1000 concentration in 5% 
BSA (w/v) overnight at 4°C. Five washes of five minutes with TBST were then carried out prior to 
incubation with anti-rabbit HRP conjugated secondary antibody (1/2000) for two hours in 5% (w/v) 
BSA at room temperature. Blots were washed with TBST for five minutes five times. Proteins were 
visualised by enhanced chemiluminescence (Amersham, GE Healthcare, UK) and 
autoradiography. The blots were also probed for GAPDH (1/2000) as a primary antibody with anti-
mouse HRP (1/2000) conjugated secondary antibody. The top panel shows the bands for PKG and 
the bottom panel shows GAPDH. The panels were all taken from a single gel and each band 
represents one well from two separate six well plates.  
. 
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4.3.9 VEGF ELISA 
There was no difference in VEGF production in cells cultured in high phosphate medium. 
In cells stressed by exposure to hypoxic conditions for 24 hours, VEGF production 
increased significantly in cells cultured in standard phosphate concentration medium 
(0.5mM) and decreased significantly in cells cultured in high phosphate medium (3mM) 
when compared with cells cultured in 0.5mM medium in standard conditions (Figure 4-
17). 
 
4.3.10  NO production:  Griess reaction 
There was a clear albeit non significant trend to a reduction in NO in the cells cultured in 
high phosphate. Treatment with L-NAME significantly reduced the quantity of NO further 
and with L-arginine there was a non-significant trend towards an increase in NO 
production. In the cells cultured in normal phosphate concentration medium, there was a 
reduction in NO production with the addition of L-NAME. Culturing with L-arginine did 
not alter the level of NO (Figure 4-18). 
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Figure 4-17: VEGF concentration in supernatant of cells cultured in 0.5mM and 3mM 
phosphate in standard and hypoxic (-O2) conditions. 
VEGF was measured on VSMC supernatants. The cells were cultured in six well plates at a density 
of 1x10
4
 cells /well. The supernatant from each well of one six well plate was combined and then 
concentrated and used to represent one replicate for each phosphate concentration. Three 
replicates were used for each condition and stored at -80°C. After a single thaw, the supernatant 
was concentrated using appropriately sized Amicon® ultra centrifugal filters. A solid phase ELISA 
kit purchased from R&D systems was used and the ELISA was performed and analysed in 
accordance with the manufacturer’s instructions. VEGF is known to be induced when cells are 
exposed to hypoxic condition. Cells exposed to hypoxic conditions were therefore used as a 
positive control. Cells were put into an air tight chamber for 24 hours to induce hypoxia. The 
reliable air tight seal and the fast gas exchange properties of the chamber, allow for the rapid and 
economical creation of a non-fluctuating hypoxic environment. Once sealed, this is a closed air 
tight system. The gas is a mixture of 5% CO2 and 95% N2. The cells are placed into the chamber in 
six well plates in the hood. The gas is bubbled through for four minutes then the chamber is sealed 
and put into the incubator. The lids are left off the plates (there is O2 in media). After 12 hours, 
fresh gas was bubbled through to ensure hypoxia was maintained. After 24 hours, the cells were 
removed and the supernatant obtained, combined (as above) and stored. Values are mean±SEM.  
 
 




Figure 4-18: Relative NO production in rat VSMCs cultured in high (3mM) and standard 
(0.5mM) phosphate concentration medium +/- L-NAME (LN) and L-arginine (LA). 
On day one, VSMCs were plated onto a 96 well plate at a cell density of 1x810
3 
cells/well. After 24 
hours fresh media was added to each well. Simultaneously cells were treated with L-NAME (1x10
-
4
M) or L-Arginine (1x10
-5
M); controls were left untreated. L-NAME was used as a NOS inhibitor and 
thus a reduction in NO would be expected. L-arginine was added to increase the available 
substrate for eNOS with an anticipated subsequent increase in NO production. The media was 
replaced daily with fresh L-NAME or L-arginine as appropriate until day four when a Griess reaction 
was performed. Sodium nitrite was used to generate a standard curve in each plate at a 
concentration of 0-100µM. 50µl of Griess was added to each well, the plate was then wrapped in 
tinfoil and replaced in the incubator for 30 minutes before being read at an absorbance of 540nm 
on a microplate reader. This was performed in duplicate and a minimum of six replicates were used 
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4.3.11 Summary of results 
In rat resistance vessels incubated in high phosphate concentration PSS (2.5mM) for 16 
hours, using wire myography to assess vessel function there is evidence of: 
 Reduced basal NO production 
 Impaired endothelium dependent vasodilatation to carbachol 
 Impaired endothelium independent vasodilatation to SNP 
 Improved initial but not overall endothelium dependent vasodilatation in the 
presence of the anti-oxidant, ascorbic acid. 
 Significant improvement in maximum endothelium independent vasodilatation in 
the presence of ascorbic acid 
 Significant improvement in both endothelial dependent and independent 
vasodilatation in the presence of the PDE5I, zaprinast. 
 Significantly lower concentration of cGMP.  
In rat VSMCs cultured in standard phosphate medium (0.5mM) and high phosphate 
medium (3mM):  
 There is no difference in expression of total or phospho eNOS (Ser 1177) in the 
chronic high phosphate environment but acute exposure (48 hours) to 3mM 
phosphate results in significantly increased expression of total and phospho eNOS 
in cells cultured in normal phosphate concentration medium. 
 Acute exposure (48 hours) to 0.5mM phosphate results in significantly reduced 
expression of total and phospho eNOS in cells cultured in high phosphate 
concentration medium. 
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 There is reduced expression of PKG in cells cultured in high phosphate medium 
and PKG expression increases in cells cultured in 3mM phosphate medium upon 
exposure to normal phosphate medium (0.5mM) for 48 hours. 
 VEGF concentration is comparable in cells cultured in normal and high phosphate 
concentration medium but upon exposure to stress (hypoxia), cells cultured in 
normal phosphate produce significantly higher quantities of VEGF and cells 
cultured in high phosphate produce significantly less VEGF.  
 A non-significant trend towards reduced NO production estimated by the Griess 
reaction in cells cultured in high phosphate compared with normal phosphate. 
 
4.4 Discussion 
These ex vivo studies have demonstrated for the first time that exposing resistance vessels, 
from healthy rats, to elevated phosphate for a sustained period of time, causes impaired 
endothelium dependent and independent vasodilatation. This suggests a direct effect of 
phosphate on the endothelium and on the VSMC and separates an effect of phosphate from 
other effects of uraemia. Thus, the endothelium in the high phosphate environment is less 
able to produce NO, upon stimulation. Similarly, the VSMC is less able to respond to NO 
possibly as a consequence of altered cGMP levels or guanylate cyclase expression or 
activity. The contractile response was preserved in the high phosphate environment in our 
study. However, in the presence of L-NAME, there was a significant increase in 
contraction in vessels incubated in normal phosphate concentration PSS which was not 
seen in the vessels incubated in high concentration PSS. This suggests that the vessels 
exposed to high phosphate produce less basal NO.  
My aim was to separate the effects of phosphate exposure from other effects of uraemia 
and this is the first study to do this in resistance vessels. My findings are in keeping with 
those of the only other study which has looked at the direct effect of phosphate on 
vasodilatation (6). This demonstrated impaired endothelium dependent relaxation in rat 
aortic rings, not resistance vessels, exposed to a high phosphate environment for a much 
shorter time period (one hour). They did not study endothelium independent vasodilatation. 
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In models of CKD, Wang et al performed studies using resistance vessels from rats with 
mild CKD and also found evidence that there was reduced basal NO production when 
compared with control animals (369). Our results suggest this observation may be directly 
related to phosphate rather than other aspects of the uraemic milieu. Interestingly our 
results conflict with those of Thuraisingham et al who demonstrated no difference in either 
endothelium dependent or independent relaxation in resistance vessels from uraemic rats 
compared with control animals and the spontaneously hypertensive rat (370). However, 
this study had a number of limitations including using a smaller number of vessels and 
sacrificing the animals under anaesthesia which itself may affect the ability of the vessels 
to vasodilate and may have clouded the observed findings. Furthermore they added a single 
and not an increasing concentration of SNP and all experiments were performed in the 
presence of the cyclo-oxygenase inhibitor, indomethacin which attenuates the production 
of prostaglandins. It may be that some of my findings, particularly in relation to the 
observed impaired endothelial independent vasodilatation, could be explained by 
alterations in the productions of prostaglandins. I did not, however, perform studies with 
indomethacin. 
Morris et al demonstrated impaired endothelial vasodilatation in human resistance vessels 
from patients with and without CKD and although endothelium independent vasodilatation 
was not significantly different in this study there was a trend towards impaired relaxation 
with SNP in uraemic vessels (95). Interestingly, they do not provide information about 
serum phosphate level in the uraemic patients compared with controls although it is likely 
to have been significantly higher. The observed effects may be the result of exposure to 
higher phosphate and further studies in human vessels from patients with and without CKD 
exposed to different phosphate concentrations would address this. 
There are a number of possible mechanistic explanations for our results; it may be that 
exposure to elevated phosphate leads to one or a combination of: 
 Down-regulation of eNOS, production of ROS and less bioavailable NO 
 Altered expression or activity of gunaylate cyclase 
 Altered production of cGMP 
 Alterations in intra-cellular calcium 
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 Alterations in cell growth as a consequence of reduced levels of NO and cGMP 
leading to hypertrophy and dysfunction of both ECs and VSMCs. 
To explore the mechanistic explanation for my observed effects, I went on to look at the 
response of the vessels in the presence of an antioxidant, ascorbic acid which may redress 
an imbalance in redox and in the presence of a PDE5I which should improve relaxation by 
reducing cGMP breakdown.  
I found that ascorbic acid was able to significantly improve maximal endothelial 
independent relaxation in the vessels incubated in high phosphate. Endothelial dependent 
vasodilatation was improved at low but not high dose carbachol. This suggests that 
oxidative stress might contribute to the mechanism by which phosphate results in impaired 
endothelial dependent and independent vasodilatation. Ascorbic acid is an electron donor 
and it can interact with free radicals to form a less reactive ascorbyl radical (371). 
Phosphate might trigger the production of ROS which results in EC and VSMC damage. In 
clinical studies, ascorbic acid appears to increase NO synthesis and can improve the 
impaired endothelial function seen in the setting of hyperglycaemia (372;373). Although I 
did not see a significant improvement in endothelium dependent vasodilatation, this might 
be explained by too short an incubation time or too low a dose of ascorbic acid. Another 
possibility is that NO levels are so reduced (as a result of reduced bioavailability or 
reduced expression on eNOS or both) that an antioxidant alone is not enough to reverse the 
effects. 
The addition of PDE5I ameliorated the impaired endothelium dependent and independent 
vasodilatation seen in the vessels incubated in high phosphate PSS. Zaprinast, the PDE5I 
utilised in our studies has been shown to increase NO levels and cGMP levels and to have 
anti-proliferative effects (374). It has not previously been studied in the context of CKD 
but in other disease processes, for example pulmonary hypertension, where ED is 
prominent studies have shown beneficial effects mediated by improvements in NO and 
cGMP levels (375). Long term phosphate might trigger structural changes in the vessel 
wall in addition to shorter term effects on cGMP and NO level. To explore this further, I 
measured cGMP levels in the vessels and found that those incubated in high phosphate 
concentration PSS had significantly lower concentrations of cGMP. 
I studied expression of eNOS in rat VSMCs and found there to be no difference in 
expression in cells cultured in high compared with normal phosphate concentration 
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medium. This is not unexpected because the majority of eNOS is expressed in the EC 
rather than the VSMC. eNOS expression must therefore be further studied in the EC. 
The increase in eNOS expression seen in cells cultured in 0.5mM phosphate and exposed 
acutely for 48 hours to 3mM phosphate does however suggest that there is an effect of 
phosphate acutely and perhaps a degree of adaption in the VSMC chronically exposed to 
the high phosphate environment. Perhaps acute exposure to high phosphate conditions 
triggers oxidative stress resulting in increased eNOS expression and thus NO production to 
counter balance the detrimental effects of phosphate. There may be alterations in signalling 
pathways including phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B 
(p13/Akt) or MAPK. Chronic exposure to high phosphate does not influence eNOS 
expression and thus perhaps longer term VSMCs have the capacity to adapt to the higher 
phosphate environment. Interestingly, exposing cells cultured in 3mM phosphate to 0.5mM 
phosphate for 48 hours results in significantly reduced eNOS expression. The explanation 
for this is unclear but might relate at least in part to the cells adapting to the high phosphate 
environment such that introduction of normal phosphate concentration medium results in 
stress to the cells and thus increased free radical production but an inability to react 
appropriately and thus reduced NO production. It does suggest that any changes induced 
by high phosphate can be modified although these modifications may not be positive. 
Similarly VEGF production is unaltered in cells cultured in 3mM compared with 0.5mM 
medium. However, exposing the cells to hypoxia should result in an increase in VEGF. 
This does not occur in cells cultured in 3mmol/L phosphate which suggests that the high 
phosphate environment results in an abnormal ‘stress’ response in these cells. This is likely 
to have atypical and abnormal effects on many signal transduction pathways leading to 
abnormal activation and inhibition of many factors including possibly eNOS, cGMP, 
gunaylate cyclase activity and expression and PKG. 
I examined NO production in the VSMCs using the Griess reaction; there was a non-
significant trend towards lower NO in the cells cultured in high phosphate. However, the 
Griess reaction cannot accurately detect small changes and NO is very difficult to measure 
directly. Moreover, these experiments require to be repeated in the EC which is the major 
source of NO. The trend towards reduced NO even in the VSMC does lend some weight to 
my hypothesis that elevated phosphate causes disruption to the NO pathway thus leading to 
ED. In reality it is likely that phosphate interrupts multiple pathways, mediators and factors 
which leads to impaired vasodilatation and ED. 
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4.5 Conclusion 
Exposure to elevated phosphate concentration PSS results in impaired endothelium 
dependent and independent relaxation in isolated rat vessels. These deleterious effects can 
be improved following incubation with an antioxidant and particularly with a PDE5I. This 
suggests a degree of reversibility at least in the early stages of phosphate exposure. 
I have attempted to study the effects of longer term exposure to elevated phosphate than in 
previous studies. In the context of myography experiments, incubation for longer than 16 
hours is not possible because the vessels do not survive for more than 24 hours ex vivo.  
To further tease out the underlying mechanism of action of phosphate as a cardiovascular 
risk factor, in chapter five I describe studies in human resistance vessels and ECs. These 
studies were designed to assess the effects of the high phosphate environment in vessels 
from patients with and without CKD, the rate of superoxide production in whole blood 
from patients with and without CKD and to study eNOS and nitrotyrosine expression in 
HUVECs. Additionally, I compare intracellular calcium levels in cells cultured in normal 
and high phosphate concentration medium.  
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5 Chapter Five – Phosphate; effects on the 
function of human resistance vessels and on the 
nitric oxide pathway in human cell lines 
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5.1 Introduction 
In chapter four of this thesis, a series of studies were presented to assess the effects of 
exposure to high phosphate on the function of resistance vessels from healthy rats and on 
rat VSMCs. The major finding was that exposure to elevated phosphate concentration 
leads to impaired endothelium dependent and independent relaxation of the vessels, 
mediated, in part, by the NO pathway. The cell studies confirmed differences in aspects of 
the NO pathway between VSMCs cultured in high and normal phosphate. There was not, 
however, a significant difference in eNOS expression or in NO production in VSMCs 
cultured in high phosphate, which might relate to the relatively low eNOS expression in 
this cell line compared with ECs. Whilst these studies add to the existing literature and 
offer insight into the possible mechanism of phosphate as a CV risk factor, there remain 
unanswered questions regarding exactly how phosphate might increase CV risk. 
The results presented in chapter four cannot necessarily be extrapolated to humans. Thus it 
is necessary to study human resistance vessels to ascertain if phosphate has similar effects. 
In vivo, the resistance vessels play a key role in regulating blood flow to tissues; 
dysfunction is associated with increased CV risk. The effect of phosphate in vessels from 
healthy patients has not been examined and whilst Morris et al studied resistance vessels 
from patients with CKD and demonstrated impaired relaxation, they did not look 
separately at the effects of phosphate (95).  Teasing out the mechanism of action of 
phosphate requires that phosphate exposure be considered separately from other 
abnormalities of the uraemic environment. In 5/6 nephrectomised rats, fed a high calcium, 
high phosphate or standard diet, Koobi et al showed that resistance vessels from uraemic 
animals demonstrated impaired endothelium dependent relaxation. When fed a high 
phosphate diet the impaired relaxation was worsened further compared to controls; the 
group did not look at the effect on vasodilatation of a high phosphate diet alone (251). 
Interestingly, they observed an improvement in vasodilatation with the uraemic animals 
fed a high calcium diet.   
The impaired endothelium dependent and independent relaxation observed in the rat 
vessels is consistent with disruption of the NO pathway and reduction in available NO. 
Reduced eNOS expression has previously been demonstrated in bovine ECs and in two 
human EC lines (EAhy926 cells and GM-7373), exposed to high phosphate, phosphate 
also induces ROS production (6;250). In the context of hyperphosphataemia the NO 
pathway has not been extensively studied; beyond the observation of altered eNOS 
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expression. Thus, disruption of the NO pathway seen upon exposure to elevated phosphate 
concentration needs to be explored in human vessels and human EC lines. The possibility 
remains that any observed effects of phosphate on endothelium dependent and independent 
relaxation relate to changes in intracellular calcium concentration and the impact of 
phosphate on calcium levels requires further investigation.   
The aims of the studies presented in this chapter, therefore, were to study resistance vessels 
from patients without CKD and from patients with advanced CKD (stage 5); to assess the 
effects of exposure to elevated phosphate on human cell lines specifically looking at the 
NO pathway. Additionally I quantified intracellular calcium content in both rat and human 
cell lines exposed to altered concentrations of phosphate. The specific experiments 
involved were: 
 Contractile response of vessels to PEP 
 Vasodilatation response to both carbachol and SNP 
 Measurement  of O2
-
 in whole blood from patients with and without CKD 
 Expression of eNOS and nitrotyrosine in HUVECs cultured in standard (0.5mM) 
and high (3mM) phosphate concentration 
 Measurement of NO in HUVECs 
 Intracellular calcium content of human and rat ECs and rat VSMCs cultured in 
normal and high phosphate media.  
 
5.2  Materials and Methods 
5.2.1  Vessel studies 
Patients with and without CKD, undergoing nephrectomy for living kidney donation and 
patients with CKD 5 undergoing live donor renal transplant were recruited (section 2.3.2). 
The wire myography technique is described in section 2.3. Vessels were dissected and 
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stored for 16 hours in either normal (1.18mM) or high phosphate (2.5mM) concentration 
PSS. The composition of these solutions is presented in Tables 2-1 and 2-2. EDTA was 
also added at a final concentration of 0.023mM. Vessels were contracted with PEP and 
relaxed with increasing concentrations of carbachol. This was repeated with PEP and SNP.  
Vessels were exposed to each concentration of PEP for three minutes or until a peak 
response at that concentration was reached. For vasodilatation with carbachol and SNP, 
vessels were exposed to each concentration for two minutes or until a plateau had been 














Vessels were not available from all recruited subjects due to either absence of adipose 
tissue or suitable vessels. The use of human vessels is more difficult and success was lower 
than in rat vessels which is in keeping with the literature (376). There is also debate as to 
the applicability of normalisation to vessels other than third order rat resistance vessels and 
so I did not use this in the human vessels (343). 
Additionally, I experimented with different drugs working on different receptors. Dr Craig 
Daly (Life Sciences Research Fellow, University of Glasgow) stained the vessels with 
syto62, a nuclear stain; QAPB dye, fluorescent prazosin, a selective α1 antagonist; and 
CGP12177, a β1 and β2 antagaonist and partial agonist and used confocal microscopy to 
determine which receptors were present in human vessels to help guide the final choice of 
drug.  The vessels expressed α1 adrenoceptors on both the smooth muscle and the 
endothelium (Figure 5-1). 
5.2.2 Superoxide, FGF-23 and vitamin D measurement 
O2
-
 was measured by EPR in HUVEC cell supernatant (section 2.4.11) and in whole blood 
(section 2.3.10). Vitamin D and FGF-23 measurements were performed on stored samples 
as described in sections 2.6.2.12 and 2.6.2.13.  
5.2.3 Imunoblotting, Griess reaction and epi-fluorescence   
HUVECs were cultured from the outset in either 0.5mM or 3mM phosphate concentration 
(section 2.4). This was intended to mimic chronic exposure to a high phosphate 
environment. Immunoblotting was performed on cell lysates using antibodies for total and 
phospho-eNOS (Ser 1177) and nitrotyrosine (section 2.4.8).  
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Figure 5-1: Confocal microscopy pictures of human artery stained with QAPB dye (green), 
CGP12177 (red) and syto62 (blue). 
Dr Craig Daly (Life Sciences Research Fellow, University of Glasgow) stained two human 
resistance vessels, from subcutaneous abdominal fat, from three live donors with syto62, a nuclear 
stain; QAPB dye, fluorescent prazosin, a selective α1 antagonist; and CGP12177, a β1 and β2 
antagaonist and partial agonist and used confocal microscopy to determine which receptors were 
present in human vessels.  The vessels expressed α1 adrenoceptors on both the smooth muscle 
and the endothelium. The top two panels are human artery smooth muscle and α1 adrenoceptors 
are clearly present but there are no β adrenoceptors. This is in contrast to the endothelium which is 
seen in the bottom two panels. Here there is highly autofluorescent internal lamina (yellow) and 
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GAPDH was used as the housekeeping protein. A minimum of three experiments were 
performed. Griess reaction to estimate NO was performed as detailed in section 2.4.5, in 
duplicate on five replicates. 
Intracellular calcium was measured by epifluorescence with FURA-2AM (section 2.4.10). 
This was performed in three cell lines; HUVECs, rat aortic ECs and rat VSMCs. For each 
cell line, the intracellular calcium content was measured in a minimum of three cells on 
three separate occasions. The mean intracellular calcium concentration was calculated for 
each concentration of phosphate and values were compared with a Student’s T test. 
 
5.3 Results 
5.3.1 Sample size and baseline demographics 
The baseline demographics of the patients whose vessels were used in the myography 
experiments are detailed in Table 5-1. None of the patients had a history of DM or CVD. 
Comparison is between living kidney donors, without CKD, and patients with CKD. As 
would be expected, patients with CKD had a lower eGFR, higher phosphate and higher 
FGF-23. 89% (n=8) of the patients with CKD were taking a phosphate binder; of them 
33% (n=3) were taking a calcium containing phosphate binder and 67% (n=6) a non-
calcium containing phosphate binder. 89% (n=8) were taking at least one anti-
hypertensive. 
The number of vessels studied for each drug and the corresponding length and diameter of 
the vessels is shown in Table 5-2. There was no significant difference in the size of the 
vessels obtained from patients with or without CKD nor between vessels which were 
incubated in high or normal phosphate concentration PSS. 
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5.3.2 Contraction and relaxation response in vessels from living 
kidney donors 
Contraction with PEP did not differ significantly between the vessels incubated in normal 
or high phosphate concentration PSS (Figure 5-2). The potency of PEP was similar with no 





contraction with PEP at a concentration of 3x10
-5
M was significantly higher in the vessels 
incubated in normal compared with high phosphate PSS (1.76± 0.71g and 1.16g±0.66g; 
p=0.05). 
Relaxation response to the endothelium dependent vasodilator, carbachol is illustrated in 
Figure 5-3. The vessels incubated in high phosphate PSS vasodilated significantly less well 
than those incubated in normal phosphate PSS (AUC, p=0.009). Maximum vasodilatation 
obtained in the vessels incubated in high phosphate was lower than in the vessels incubated 
in normal phosphate (42.9±12% vs 79.4±8.2%; p=0.003. The results for the endothelium 
independent vasodilator, SNP are shown in Figure 5-4. The vessels incubated in high 
phosphate PSS vasodilated significantly less well than those incubated in normal 
phosphate PSS (AUC p=0.04). Maximum vasodilatation obtained in the vessels incubated 
in high phosphate was lower than in the vessels incubated in normal phosphate 
(59.7±13.8% compared with 99.8±20.2; p=0.02). 
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Table 5-1: Demographics of the study population. 
Demographics for the patients whose vessels were used are shown in columns two to four (LD 
n=14 and CKD n=14) and for the patients whose blood samples were used in the O2
-
 study (n=9) 
are shown in the last three columns. 
 
 
Table 5-2: Comparison of numbers of vessels studied for each patient group.  
The number of vessels in which a complete concentration response curve was obtained for each 
drug and the corresponding size of the vessels is presented. Comparison was made with a one-
way ANOVA. 
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Figure 5-2: Contraction to PEP in vessels from living kidney donors.  
Subcutaneous resistance vessels from abdominal fat from living kidney donors, collected at the 
time of donation, were incubated in normal (1.18mM) or high (2.5mM) phosphate concentration 
PSS for 16 hours. Vessels (normal phosphate, n=13; high phosphate, n=12) were then mounted on 
a wire myograph and set, in stages, to 0.8g of tension. PEP was then added in increasing 




M) to induce contraction and to allow the 
construction of cumulative concentration-response curves.  Vessels were exposed to each 
concentration of PEP for three minutes or until a peak response at that concentration was reached. 
Response is expressed as mean ± SEM and comparison made between AUC of the two groups by 
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Figure 5-3: Vasodilatation to increasing concentrations of carbachol expressed as a % of 
maximal contraction (100%) with PEP 1x10
-5
M (living kidney donors). 
Subcutaneous resistance vessels from abdominal fat from living kidney donors, collected at the 
time of donation, were incubated in normal (1.18mM) or high (2.5mM) phosphate concentration 
PSS for 16 hours. Vessels (normal phosphate, n=13; high phosphate, n=12) were then mounted on 
a wire myograph and set, in stages, to 0.8g of tension. PEP was added in increasing 




M) to induce contraction. Carbachol was then 




M) to induce relaxation. Vessels were 
exposed to each concentration of PEP and carbachol for three minutes or until a peak response at 
that concentration was reached. Cumulative concentration-response curves were constructed. 
Response expressed as mean ± SEM and comparison made between AUC of the two groups by 
the Student’s T test. 
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Figure 5-4: Vasodilatation to increasing concentrations of SNP expressed as a % of maximal 
contraction (100%) with PEP 1x10
-5
M (living kidney donors). 
Subcutaneous resistance vessels from abdominal fat from living kidney donors, collected at the 
time of donation, were incubated in normal (1.18mM) or high (2.5mM) phosphate concentration 
PSS for 16 hours. Vessels (normal phosphate, n=13; high phosphate, n=12) were then mounted on 
a wire myograph and set, in stages, to 0.8g of tension. PEP was added in increasing 




M) to induce contraction. SNP was then 




M) to induce relaxation. Vessels were 
exposed to each concentration of PEP and SNP for three minutes or until a peak response at that 
concentration was reached. Cumulative concentration-response curves were constructed. 
Response expressed as mean ± SEM and comparison made between AUC of the two groups by 
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5.3.3 Contraction and relaxation response in vessels from 
patients with CKD 
Contraction with PEP was not significantly different between the vessels incubated in 
normal or high phosphate concentration PSS (Figure 5-5). The potency of PEP was similar 









M) or in maximal contraction (1.62± 0.69g vs 1.37±0.73g). When 
compared with vessels from live kidney donors, there was no difference in EC50, the 
maximal contraction with PEP or in AUC.  
Relaxation response to carbachol is illustrated in Figure 5-6. The vessels incubated in high 
phosphate PSS vasodilated significantly less well to carbachol than those incubated in 
normal phosphate PSS (AUC, p=0.008). Maximum vasodilatation obtained in the vessels 
incubated in high phosphate was lower than in the vessels incubated in normal phosphate 
(25.3±11.1% vs 75.7±13.6%; p<0.001). When compared with vessels from live kidney 
donors, there was not a significant difference in either AUC or maximal relaxation between 
the two groups of vessels incubated in normal phosphate PSS. Compared with the vessels 
from patients with CKD, the vessels from live donors incubated in high PSS relaxed 
significantly better to carbachol (AUC p=0.03) 
The results for vasodilatation to SNP are shown in Figure 5-7. Following constriction with 
PEP, there was not a significant difference in relaxation to SNP between the vessels 
incubated in high or normal phosphate PSS. Maximum relaxation was not significantly 
different. When compared with the vessels from live kidney donors, the vessels from the 
patients with CKD relax less well to SNP both in term of AUC and maximal relaxation but 
this does not achieve statistical significance. 
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Figure 5-5: Contraction to PEP in vessels from patients with CKD.  
Subcutaneous resistance vessels from abdominal fat from patients with CKD, collected at the time 
of live kidney transplant, were incubated in normal (1.18mM) or high (2.5mM) phosphate 
concentration PSS for 16 hours. Vessels (normal phosphate, n=12; high phosphate, n=9) were 
then mounted on a wire myograph and set, in stages, to 0.8g of tension. PEP was then added in 




M) to induce contraction and to 
allow the construction of cumulative concentration-response curves.  Vessels were exposed to 
each concentration of PEP for three minutes or until a peak response at that concentration was 
reached. Response is expressed as mean ± SEM and comparison made between AUC of the two 
groups by the Student’s T test. 
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Figure 5-6: Vasodilatation to increasing concentrations of carbachol expressed as a % of 
maximal contraction (100%) with PEP 1x10
-5
M (CKD).  
Subcutaneous resistance vessels from abdominal fat from patients with CKD, collected at the time 
of live kidney transplant, were incubated in normal (1.18mM) or high (2.5mM) phosphate 
concentration PSS for 16 hours. Vessels (normal phosphate, n=12; high phosphate, n=9) were 
then mounted on a wire myograph and set, in stages, to 0.8g of tension. PEP was added in 




M) to induce contraction. 




M) to induce relaxation. 
Vessels were exposed to each concentration of PEP and carbachol for three minutes or until a 
peak response at that concentration was reached. Cumulative concentration-response curves were 
constructed. Response expressed as mean ± SEM and comparison made between AUC of the two 
groups by the Student’s T test. 
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Figure 5-7: Vasodilatation to increasing concentrations of SNP expressed as a % of maximal 





Subcutaneous resistance vessels from abdominal fat from patients with CKD, collected at the time 
of live kidney transplant, were incubated in normal (1.18mM) or high (2.5mM) phosphate 
concentration PSS for 16 hours. Vessels (normal phosphate, n=12; high phosphate, n=9)) were 
then mounted on a wire myograph and set, in stages, to 0.8g of tension. PEP was added in 




M) to induce contraction. SNP was 




M) to induce relaxation. Vessels were 
exposed to each concentration of PEP and SNP for three minutes or until a peak response at that 
concentration was reached. Cumulative concentration-response curves were constructed. 
Response expressed as mean ± SEM and comparison made between AUC of the two groups by 





Chapter 5 XXX 197 
 
 
5.3.4 Superoxide measurement  
O2
-
 measurements were made in whole blood samples from living kidney donors and CKD 
patients. The demographics of these patients are shown in Table 5-1. The rate of 
superoxide production (expressed as pmol superoxide/ng of protein/minute) was slightly 





. This did not reach statistical significance (Figure 5-8). The patients were of 
a similar age and those with CKD had a higher phosphate and FGF-23 as would be 
expected with a lower eGFR. There were more males in the CKD group. 
HUVECs cultured in 0.5mM phosphate concentration medium appear to produce less O2
-
 
(corrected for protein content) than cells cultured in 3mM phosphate medium but this does 
not reach statistical significance (Figure 5-9). Similar results were obtained from rat ECs 
(data not shown). 
5.3.5 Immunoblotting for eNOS and nitrotyrosine 
There was significantly less phospho and total eNOS (normalised to GAPDH) present in 
the HUVECs cultured in high phosphate medium (Figure 5-11 shows total eNOS 
expression and Figure 5-12, phospho eNOS expression). Figure 5-13 shows nitrotyrosine 
expression; cells cultured in high phosphate expressed higher quantities of nitrotyrosine 
(normalised to GAPDH) than cells cultured in normal phosphate concentration medium. 
5.3.6 Griess reaction in HUVECs 
As illustrated in Figure 5-13, there were significantly lower levels of NO in the cells 
cultured in high phosphate (16.9±1.6 µM vs 21.7±1.3 µM; p=0.03). 
5.3.7 Intra-cellular calcium measurements 
In HUVECs, the intra-cellular calcium measurements were not significantly different 
between cells cultured in high compared with normal phosphate concentration medium 
(749.5±13.9nM vs 752±54.2nM). In rat ECs and VSMCs, there was also no difference in 
the intra-cellular calcium content of cells cultured in normal compared with high phosphate 
concentration medium (Figure 5-14 illustrates the HUVEC and the rat VSMC data). 
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Figure 5-8: The rate of superoxide production (expressed as superoxide production/ng of 
protein/minute) in patients with and without CKD. 
This was undertaken by Ms Elaine Friel (Technician, Institute of Cardiovascular and Medical 
Sciences). Whole blood samples were collected from patients with and without CKD (n=9 in each 
group). The samples were placed on ice immediately after collection. The Bruker e-scan EPR 
machine was calibrated using a reduced form of the spin probe, CP (3-carboxyl-proxyl radical) at 
concentrations of 1µM, 5µM and 10µM. Each was read ten times and the mean, standard deviation 
(SD) and coefficient of variation were calculated from these results. A HEPES buffer containing 
100mM DTT and 20% (v/v) Tween-20 was used to keep the pH of the solutions constant at 7.4. DF 
and DTEC) were used as chelators at final concentrations of 25µM and 5µM respectively. CPH (1-
hydroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine) was then used as a spin probe, labelling the 
superoxide present in the sample (final concentration 1mM). Everything was kept on ice 
throughout. Blood was added to HEPES buffer and chelators and finally CPH was added 
immediately before processing. The solution was drawn up by a 15µl capillary tube and sealed with 
‘cristoseal’ sealant. After ten minutes on the EPR machine, the sample was removed and disposed 
of. Each blood sample was processed three times. Results were analysed in Microsoft excel using 
a linear equation and plotted in GraphPad Prism. Values are mean ± SEM  
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Figure 5-9: Superoxide production from HUVECs. 
HUVECs were cultured and plated onto six well plates at a cell density of 1x10
4
 cells/well. Upon 
reaching 90% confluence, the cells were washed twice with PBS and then incubated with a Krebs-
HEPES buffer and the CPH spin probe for one hour at 37°C. The CPH spin probe and Krebs-
HEPES buffer were also incubated in a well without cells for the same time period. The supernatant 
was then removed and immediately put onto ice before the solution was drawn up by a 15µl 
capillary tube and sealed with ‘cristoseal’ sealant and then run through the EPR machine in 
triplicate. The CPH without exposure to cells was used to assess the natural oxidation of the spin 
probe. The protein content of each well was quantified using the Bradford’s assay. The figures 
obtained from the spin probe alone were subtracted from those attained with cells present and then 
normalised to the protein content of each well. Thus the final value is pmol superoxide/ng of 
protein/minute. Values are mean ± SEM and represent replicates from four separate experiments. 
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Figure 5-10: Total eNOS expression in HUVECs. 
HUVECs were cultured on six well plates at a cell density of 1x10
4
 cells/well in 0.5mM and 3mM 
phosphate concentration medium. The cells were cultured until 90% confluence and then cells 
were placed on ice, washed with PBS and lysed using a RIPA buffer, made in house. The Bradford 
assay was used to quantify protein concentration. Proteins were resolved using the NuPAGE 4-
12% Bis-Tris pre-cast gel system. Minimum sample protein content was 10ug per well. Protein 
samples were denatured in NuPAGE LDS sample buffer heating to 70°C for 10 minutes. In order to 
reduce proteins, 50mM DTT was added immediately prior to sample denaturing. Proteins resolved 
by polyacrylamide gel electrophoresis were transferred to Protran nitrocellulose membranes using 
the NuPAGE XCell II blotting apparatus and the manufacturer’s transfer buffer which was 
supplemented with 20% (v/v) methanol. Transfer was performed at 40V for 60mins. Transfer 
efficiency was assessed by staining membranes with Ponceau S solution followed by washing with 
TBS containing 0.1% (v/v) Tween 20. The nitrocellulose membranes were then blocked in 5% (w/v) 
BSA for 1 hour at room temperature. Blots were incubated with a total eNOS, primary antibody at a 
1/1000 concentration in 5% BSA (w/v) overnight at 4°C. Five washes of five minutes with TBST 
were then carried out prior to incubation with anti-rabbit HRP conjugated secondary antibody 
(1/2000) for two hours in 5% (w/v) BSA at room temperature. Blots were washed with TBST for five 
minutes five times. Proteins were visualised by enhanced chemiluminescence (Amersham, GE 
Healthcare, UK) and autoradiography. The blots were also probed for GAPDH (1/2000) as a 
primary antibody with anti-mouse HRP (1/2000) conjugated secondary antibody. The top panel 
shows the cells cultured in 3mM phosphate concentration medium, in triplicate, followed by the 
cells cultured in 0.5mM phosphate concentration medium, in triplicate. The bottom panel shows 
GAPDH. The panels were all taken from a single gel and each band represents one well from three 
separate six well plates.  
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Figure 5-11: Phospho eNOS expression in HUVECs. 
HUVECs were cultured on six well plates at a cell density of 1x10
4
 cells/well in 0.5mM and 3mM 
phosphate concentration medium. The cells were cultured until 90% confluence and then cells 
were placed on ice, washed with PBS and lysed using a RIPA buffer, made in house. The Bradford 
assay was used to quantify protein concentration. Proteins were resolved using the NuPAGE 4-
12% Bis-Tris pre-cast gel system. Minimum sample protein content was 10ug per well. Protein 
samples were denatured in NuPAGE LDS sample buffer heating to 70°C for 10 minutes. In order to 
reduce proteins, 50mM DTT was added immediately prior to sample denaturing. Proteins resolved 
by polyacrylamide gel electrophoresis were transferred to Protran nitrocellulose membranes using 
the NuPAGE XCell II blotting apparatus and the manufacturer’s transfer buffer which was 
supplemented with 20% (v/v) methanol. Transfer was performed at 40V for 60mins. Transfer 
efficiency was assessed by staining membranes with Ponceau S solution followed by washing with 
TBS containing 0.1% (v/v) Tween 20. The nitrocellulose membranes were then blocked in 5% (w/v) 
BSA for 1 hour at room temperature. Blots were incubated with a phospho eNOS, primary antibody 
at a 1/1000 concentration in 5% BSA (w/v) overnight at 4°C. Five washes of five minutes with 
TBST were then carried out prior to incubation with anti-rabbit HRP conjugated secondary antibody 
(1/2000) for two hours in 5% (w/v) BSA at room temperature. Blots were washed with TBST for five 
minutes five times. Proteins were visualised by enhanced chemiluminescence (Amersham, GE 
Healthcare, UK) and autoradiography. The blots were also probed for GAPDH (1/2000) as a 
primary antibody with anti-mouse HRP (1/2000) conjugated secondary antibody. The top panel 
shows the cells cultured in 3mM phosphate concentration medium, in duplicate, followed by the 
cells cultured in 0.5mM phosphate concentration medium, in duplicate. The bottom panel shows 
GAPDH. The panels were all taken from a single gel and each band represents one well from three 
separate six well plates.  
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Figure 5-12: Nitrotyrosine expression in HUVECs. The antibody detects nitrotyrosine 
adducts on proteins. 
HUVECs were cultured on six well plates at a cell density of 1x10
4
 cells/well in 0.5mM and 3mM 
phosphate concentration medium. The cells were cultured until 90% confluence and then cells 
were placed on ice, washed with PBS and lysed using a RIPA buffer, made in house. The Bradford 
assay was used to quantify protein concentration. Proteins were resolved using the NuPAGE 4-
12% Bis-Tris pre-cast gel system. Minimum sample protein content was 10ug per well. Protein 
samples were denatured in NuPAGE LDS sample buffer heating to 70°C for 10 minutes. In order to 
reduce proteins, 50mM DTT was added immediately prior to sample denaturing. Proteins resolved 
by polyacrylamide gel electrophoresis were transferred to Protran nitrocellulose membranes using 
the NuPAGE XCell II blotting apparatus and the manufacturer’s transfer buffer which was 
supplemented with 20% (v/v) methanol. Transfer was performed at 40V for 60mins. Transfer 
efficiency was assessed by staining membranes with Ponceau S solution followed by washing with 
TBS containing 0.1% (v/v) Tween 20. The nitrocellulose membranes were then blocked in 5% (w/v) 
BSA for 1 hour at room temperature. Blots were incubated with a nitrotyrosine, primary antibody at 
a 1/1000 concentration in 5% BSA (w/v) overnight at 4°C. Five washes of five minutes with TBST 
were then carried out prior to incubation with anti-rabbit HRP conjugated secondary antibody 
(1/2000) for two hours in 5% (w/v) BSA at room temperature. Blots were washed with TBST for five 
minutes five times. Proteins were visualised by enhanced chemiluminescence (Amersham, GE 
Healthcare, UK) and autoradiography. The blots were also probed for GAPDH (1/2000) as a 
primary antibody with anti-mouse HRP (1/2000) conjugated secondary antibody. The top panel 
shows nitrotyrosine, with high phosphate and normal phosphate cells alternating, in duplicate, and 
the bottom panel shows GAPDH. The panels were all taken from a single gel and each band 
represents one well from three separate six well plates.  
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Figure 5-13: Relative NO concentration in HUVECs. 
On day one, HUVECs were plated onto 12 well plates at a cell density of 1x105
 
cells/well. After 24 
hours fresh media was added to each well. The media was replaced daily until day four when a 
Griess reaction was performed. Sodium nitrite was used to generate a standard curve in each plate 
at a concentration of 0-100µM. 50µl of Griess was added to each well, the plate was then wrapped 
in tinfoil and replaced in the incubator for 30 minutes before being read at an absorbance of 540nm 
on a microplate reader. This was performed in duplicate, an average taken and 10 replicates were 
used for each condition. Values are mean ± SEM  
 




Figure 5-14: Intracellular calcium content of HUVECs (top) and rat VSMCs (bottom) cultured 
in normal (0.5mM) and high (3mM) phosphate concentration medium. 
Cells were plated in glass bottomed plates and allowed to adhere overnight. The following day, 
cytosolic loading of FURA-2-AM was achieved by incubating the cells with FURA-2-AM (10µM 
endothelial cells and 5µM SMCs) at 37
o
C for 40 minutes (ECs) or 15 minutes (VSMCs). The cells 
were then washed with 1ml of media and incubated at 37
o
C for a further 15 minutes. Plates were 
mounted on an inverted microscope and isolated cells were imaged. Using an oscilloscope and the 
Clampex data acquisition software, baseline fluorescence was recorded. 2µM calcium ionophore 
was added to prove that a calcium sensitive signal could be generated. On addition of calcium 
ionophore, the 340/380 fluorescence ratio rises and plateaus. Following this the cell lyser, saponin 
was added (10µM) to trigger cell lysis. A recording was made until the 380 nm wavelength began 
to fall. The Clampfit programme (Molecular Devices LLC, USA) was used to analyse the data and 
to determine the baseline fluorescence and the Rmax values. Values are mean ± SEM and are from 
at least 3 experiments with the number of cells included indicated by (n). 
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5.3.8 Summary of results 
In human resistance vessels, from live donors without CKD, incubated in high phosphate 
concentration PSS (2.5mmol/L) for 16 hours, using wire myography to assess vessel 
function there is evidence of: 
 Impaired maximal contraction to PEP. 
 Impaired endothelium dependent vasodilatation to carbachol. 
 Impaired endothelium independent vasodilatation to SNP.  
In vessels from patients with CKD, there is evidence of: 
 Impaired endothelium dependent vasodilatation to carbachol. 
 Improved endothelium dependent vasodilatation (similar to that of live donor 
vessels) to carbachol in the presence of a normal phosphate concentration PSS. 
 Intact endothelium independent vasodilatation to SNP.   
In whole blood samples from patients with CKD compared to those without CKD, there is 
a non-significant trend towards increased O2
-
 production. 
In HUVECs cultured in high phosphate medium (3mM) compared with standard phosphate 
medium (0.5mM):  
 There is a non-significant trend towards increased O2
-
  production. 
 There is reduced expression of total and phospho eNOS (Ser 1177). 
 There is significantly reduced NO production by the Griess reaction in cells 
cultured in high phosphate compared with normal phosphate. 
Intracellular calcium is unchanged in cells (HUVECs, rat endothelial cells and rat SMCs) 
cultured in normal compared with high concentration phosphate medium. 
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5.4 Discussion 
The in vitro study in human resistance vessels presented here demonstrates, for the first 
time, that exposing resistance vessels to elevated phosphate for a sustained period of time 
causes impaired endothelium dependent vasodilatation both in patients with and without 
CKD. This suggests a direct effect of phosphate on the endothelium and on the vascular 
smooth muscle cell and separates an effect of phosphate from other effects of uraemia. 
These findings are in keeping with the results of the in vitro study presented in chapter 
four. Thus, the endothelium in the high phosphate environment is less able to produce NO, 
upon stimulation. I confirm this in a human endothelial cell line by demonstrating reduced 
expression of eNOS and reduced levels of NO in cells which have been cultured, long 
term, in a high phosphate medium. 
Morris et al described impaired endothelium dependent relaxation in human uraemic 
resistance vessels and therefore we expected to see impaired endothelium dependent 
relaxation in the vessels from our patients with CKD, incubated in normal phosphate 
concentration PSS, when compared with the live donor vessels also incubated in normal 
phosphate concentration PSS (95). The CKD vessels in our study relaxed as well as the 
live donor vessels when exposed to a normal phosphate environment. This suggests two 
things: 
 There may be a circulating factor which is ‘washed out’ and removed when the 
CKD vessels are exposed, overnight, to a normal phosphate environment. 
Possibilities include asymmetric dimethylarginine (ADMA), ROS (including O2
-
 
and nitrotyrosine), advanced glycation end products, indoxyl sulphate and p-cresyl 
sulphate (377;378). 
 The endothelium dependent dysfunction seen on exposure to a high phosphate 
environment is potentially reversible. This agrees with our findings in rat SMCs in 
chapter 5 and also strengthens the need to identify clearly how phosphate results in 
its adverse effects. 
The possible circulating factors, mentioned above, are known to disrupt the NO pathway at 
different points and thus could also help to explain the findings of reduced eNOS 
expression and NO production in the HUVECs cultured in high phosphate medium. 
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Phosphate might increase ROS which may serve as a circulating factor and I show 
increased nitrotyrosine expression in HUVECs cultured in high phosphate medium. 
There was a non-significant trend towards increased rate of production of the ROS, O2
-
 in 
whole blood from the patients with CKD. The lack of a discernible difference is unclear 
but may simply rate to the small numbers of patients included. Similarly in HUVECs 
cultured in high phosphate medium, I also saw a non-significant trend towards an increase 
in O2
-
 production. Possible explanations for this include too few replicates and difficulties 
with the natural degradation of the spin probe with the EPR technique. O2
-
 has a short half 
life and a high reactivity which makes it difficult to measure. Additionally, I measured O2
-
 
in the cell supernatant and not intracellularly. 
The aim was to separate the effects of phosphate from other effects of the uraemic 
environment. The significantly worse endothelium dependent vasorelaxation observed in 
the CKD vessels exposed to high phosphate concentration PSS when compared with those 
in normal phosphate PSS and the live donor vessels supports a directly detrimental effect 
of phosphate, separate from other uraemic factors including pH and potassium. 
The similar level of relaxation seen in the CKD and live donor vessels incubated in normal 
phosphate PSS conflicts with results from Morris et al. There are several differences in 
method between the two studies which may explain the difference. 
 Morris et al did not include potassium dihydrogen orthophosphate (KH2PO4) in the 
PSS which they used and thus the vessels were exposed to an artificial environment 
which contained no phosphate at all. 
  The drugs utilised were different: noradrenaline and acetylcholine. Noradrenaline 
acts on both α1 and α2 adrenoceptors and acetylcholine was used at a higher dose 
by Morris et al, possibly inducing further relaxation. Additionally, in our study we 
pre-constricted with higher doses of PEP, which may have affected the relaxation 
ability of vessels.  
 Morris et al normalised their vessels using Mulvany’s method; I chose not to do 
this.  
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The vessels from living kidney donors demonstrated impaired endothelium independent 
relaxation to SNP when exposed to high phosphate PSS. This suggests disruption further 
down the NO pathway as a result of phosphate, for example alterations in guanylate 
cyclase expression or cGMP level. In chapter four we support this hypothesis by 
demonstrating reduced cGMP level in vessels incubated in high phosphate PSS and 
reduced PKG expression in cells cultured in a high phosphate medium.  
In the CKD vessels, endothelium independent relaxation was worse in the vessels 
incubated in normal phosphate PSS when compared with the live donor equivalent vessels. 
This suggests a role for altered cGMP handling in the uraemic environment. However 
when comparing CKD vessels in high and normal phosphate PSS, there was not a 
difference in endothelium independent relaxation. This hints at other aspects of the 
uraemic environment, rather than phosphate, as the culpable factors for the observed 
differences between the endothelium independent vasorelaxation in CKD and live donor 
vessels.  
One explanation for these observations is that chronic exposure to an altered phosphate 
environment, as is the case in CKD, allows adaption such that an additional phosphate load 
(as occurs with the high phosphate concentration PSS) does not have an additive 
detrimental effect on the cGMP pathway over uraemia alone.   
Intra-cellular calcium is closely involved in the process of endothelium relaxation and one 
important alternative explanation for the results I demonstrate in rat and human resistance 
vessels is an alteration in the intracellular calcium level in a high phosphate environment. 
Using cell lines rather than vessels, I demonstrate that the intra-cellular calcium content is 
unchanged between cells cultured in normal and high phosphate concentration medium. 
The observed effects of phosphate are, therefore, independent of changes in calcium. To 
observe a difference of approximately 10% in tone, the difference in intracellular calcium 
content would need to be roughly 200nM (379). 
The series of experiments presented in this chapter provide further evidence to support the 
following in the context of a hyperphosphataemic environment: 
 Reduced NO and/or alterations in eNOS expression. 
 Increased levels of ROS. 
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 Changes seen in the hyperphosphataemic environment can be modified. 
 
5.5 Conclusion 
Exposing human resistance vessels, from patients with and without CKD, to high 
phosphate concentration PSS leads to impaired endothelium dependent relaxation. The 
altered expression of eNOS and nitrotyrosine, the reduced production of NO seen in cells 
cultured in high phosphate medium, together with the trend towards higher O2
-
 levels in the 
uraemic environment support the concept that phosphate disrupts the NO pathway and it is 
this which results in ED.  
In CKD vessels, the improved relaxation seen upon exposure to normal phosphate 
concentration PSS suggests that a circulating factor which is ‘washed away’ is part of the 
pathogenesis of the ED seen with hyperphosphataemia. This implies reversibility of the 
effects of hyperphosphataemia which is crucial if we are to be able to reduce CV risk 
attributable to elevated phosphate. 
The findings here support those presented in chapter four where I demonstrated disruption 
to the NO pathway and that similar abnormalities in rat resistance vessels could be at least 
partially reversed with the addition of an antioxidant or PDE5I. To further investigate the 
reversible nature of the impaired endothelium dependent relaxation seen in human 
resistance vessels, these experiments should be repeated in human resistance vessels, in the 
presence of PDE5I, from patients with and without CKD. 
My goal was to study the effects of longer term exposure to elevated phosphate than in 
previous studies and to separate the effects of phosphate from other effects of the uraemic 
environment. Importantly, I show in three cell lines that any observed effects of phosphate 
are not the result of alterations in intra-cellular calcium content. 
In attempting to tease out the underlying mechanism of action of phosphate as a 
cardiovascular risk factor, I provide strong evidence in both chapters four and five of ED 
as a result of disruption to the NO pathway. In chapter six, I describe further cell studies 
designed to investigate the effects of reduced available NO on cells cultured in a high 
phosphate concentration medium. 
210 
6 Chapter Six – Studies of the effect of phosphate 
on the growth and proliferation of cultured cells. 
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6.1 Introduction 
In chapters four and five, I presented a series of studies providing evidence that exposure 
to high phosphate disrupts the NO pathway. Whilst undertaking these studies, simple 
observation suggested that the cells cultured in high phosphate concentration media 
seemed to proliferate more quickly and appeared bigger than the cells cultured in standard 
phosphate concentration medium. This was an interesting observation which I elected to 
explore further to ascertain if there was any measurable difference in the proliferation of 
the cells cultured in the two different phosphate concentrations.   
NO has been studied extensively, particularly in the setting of cancer, and there is 
significant evidence of an inhibitory effect on growth (380-382). This provides a possible 
explanation for the effect of phosphate on growth, given its effects on NO production. 
Increased growth of cells in high phosphate conditions, for example VSMCs, might 
provide a further link between phosphate, NO and CVD. 
In CKD, any effect of NO on growth in the presence of elevated phosphate may be of 
particular relevance to the heart. LVH is an independent risk factor for the development of 
development of cardiac failure, arrhythmias and sudden death and it is highly prevalent in 
patients with CKD. Up to 40% of pre-dialysis patients and 75% of dialysis patients 
(232;383;384) have LVH. Strategies to reduce CV risk in CKD therefore should include 
prevention of, and regression of LVH. The aetiology of LVH is multi-factorial, and 
incompletely understood, contributing to problems in its management (385). Serum 
phosphate and its regulators have been linked, independently of traditional risk factors like 
hypertension, to the development of LVH in CKD (268;385). In the myocardium, high 
phosphate may cause reduced NO production and associated cell proliferation, offering a 
potential pathophysiological link between hyperphosphataemia and CVD in CKD. 
The series of studies presented in this chapter were therefore designed to test the 
hypothesis that elevated phosphate concentration alters NO production and cell 
proliferation in a high phosphate environment. Specifically these studies sought to 
examine: 
 Differences in proliferation in cells cultured in standard and high phosphate 
medium by the MTT proliferation assay (HUVECs, rat ECs, rat VSMCs and 
cardiac myocytes). 
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 Differences in gene expression with particular focus on genes involved in cell cycle 
regulation and cell growth by Microarray and RT-PCR (HUVECs). 
 
6.2  Materials and Methods 
6.2.1 Staining and imaging cells 
This is described in section 2.4.3. 
6.2.2 MTT proliferation assay 
The basic assay is described in section 2.4.4. This was performed in rat VSMCs, rat ECs, 
HUVECs and cardiac myocytes, cultured in normal and high phosphate concentration 
media. In HUVECs, rat VSMCs and cardiac myocytes, the experiments were repeated in 
the presence of L-NAME.  In HUVECs and cardiac myocytes, the experiments were 
repeated in the presence of FGF-23 and Klotho. Lastly, the HUVEC assays were 
performed in the presence of IL1β.  
6.2.3 Microarray and PCR 
These techniques are described fully in sections 2.5.1 to 2.5.4. 
 
6.3 Results 
6.3.1 Cell staining and imaging 
The cells cultured in high phosphate appeared bigger on simple staining and imaging. This 
was true of all four cell lines. Example images of rat VSMCs and human cardiac myocytes 
are shown in Figures 6-1 and 6-2.  
6.3.2 Qualitative PCR 
This confirmed that ECs, cultured in standard phosphate concentration medium, express 
eNOS, the FGFR, Klotho and the type two sodium phosphate co-transporter (Figure 6-3).  
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Figure 6-1: Rat smooth muscle cell cultured in A, normal phosphate (0.5mM) and B, high 
phosphate (3mM) concentration media. 
Cells were plated onto four chamber glass slides at a density of 1.8x10
3
 cells per chamber. The 
following day the cells were washed with PBS and then fixed with paraformaldehyde 4% (w/v). The 
cells were washed in PBS and then stained with haematoxylin (0.1% w/v) and eosin (0.2% w/v). 
The slides were washed in 70% (v/v), 90% (v/v) and then 100% (v/v) ethanol and placed in 
histoclear. A cover slip was placed into the slide and the cells were then image and photpgraphed 
with an Olympus BX40 microscope and a Micropublisher RTV camera using Image Pro Software.  
  
 
Figure 6-2: Human cardiac myocytes, cultured in A, normal phosphate (0.5mM) and B, high 
phosphate (3mM) concentration media. 
Cells were plated onto four chamber glass slides at a density of 1.8x10
3
 cells per chamber. The 
following day the cells were washed with PBS and then fixed with paraformaldehyde 4% (w/v). The 
cells were washed in PBS and then stained with haematoxylin (0.1% w/v) and eosin (0.2% v/v). 
The slides were washed in 70% (v/v), 90% (v/v) and then 100% (v/v) ethanol and placed in 
histoclear. A cover slip was placed into the slide and the cells were then image and photpgraphed 
with an Olympus BX40 microscope and a Micropublisher RTV camera using Image Pro Software.  
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Figure 6-3: Qualitative PCR showing expression of Klotho (KL), eNOS, the FGFR (FGF1) and 
NaPi2b in HUVECs. Control bands run with water and not DNA are also shown (suffix b). 
HUVECs were cultured in standard phosphate concentration medium (0.5mM).on 6 well plates at a 
cell density of 1x10
4
 cells per well. Cells were trypsinised at 90% confluence and cytoplasmis RNA 
was extracted using the Qiagen RNeasy Mini Kit, cDNA was then synthesised using the Invitrogen 
M-MLV reverse transcriptase kit and PCR was performed using a PTC-100 programmable thermal 
controller with the Invitrogen Superscript III™ first strand system for RT PCR. A 1µl of template 
(0.2ng), 0.25µl, 100nM forward and reverse primers, 0.5mls of 10mM dNTPs, 0.25µl Taq 
polymerase (5U/µl), 5µl 10x buffer (200mM Tris-HCl (pH 8.4), 500mM KCl) and PCR-grade water 
were combined to give a 25µl reaction volume. Samples were denatured at 94°C for 30 seconds 
then primers annealed at 55°C for 45 seconds and DNA extended at 68°C for 1 minute. This 
thermal cycling profile was used for 35 cycles.The DNA samples were mixed with blue loading 
buffer and 15µl of sample/loading buffer mix was loaded onto the agarose gel. The DNA samples 
were run at 100V for 1 hour with TAE buffer (0.04M Tris-acetate, 0.001M EDTA). The 2% Agarose 
gels were made using 0.8g agarose for molecular biology, 40ml of TAE buffer and 4µl ethidium 
bromide. An ultraviolet transilluminator was used to visualise bands and images were recorded on 
a BioRad ChemiDoc XRS digital imaging system. 
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6.3.3  MTT proliferation assays 
6.3.3.1 Endothelial cells 
HUVECs cultured in high phosphate proliferated more than those cultured in normal 
phosphate concentration media (p<0.001). When cells cultured in 0.5mM phosphate 
concentration medium were exposed to L-NAME, proliferation increased such that there 
was a significant difference between these cells and cells cultured in 0.5mM media alone 
(p<0.001) and no difference between these cells and cells cultured in high phosphate 
medium (3mM). This is illustrated in Figure 6-4. Adding L-NAME to cells cultured in high 
phosphate medium did not alter proliferation rate (data not shown). When the cultured cells 
were exposed to FGF-23 and Klotho, there was no added effect on proliferation in either 
0.5mM or 3mM phosphate concentration media (Figure 6-4). 
Lastly, the addition of IL1β made no significant difference to the proliferation effect of 
phosphate; there was a trend to increased proliferation in the cells cultured in normal 
phosphate concentration medium. The differences in proliferation between cells cultured in 
normal and high phosphate concentration media alone were maintained (data not shown). 
In rat ECs, cells cultured in high phosphate also proliferated significantly more than those 
in normal phosphate (p<0.05; data not shown). 
6.3.3.2 Human Cardiac Myocytes 
Cells cultured in high phosphate medium proliferated significantly more than those 
cultured in normal phosphate medium (p<0.001). The addition of L-NAME increased 
proliferation, although not significantly, in the cells cultured in 0.5mM phosphate. L-
arginine had no effect (Figure 6-5). In cells cultured in 3mM phosphate, the addition of L-
arginine (data not shown) or L-NAME did not affect proliferation (Figure 6-5). 
6.3.3.3 Rat VSMCs 
Rat VSMCs cultured in high phosphate proliferated significantly more than those cultured 
in normal phosphate (p<0.05). The addition of L-NAME had no effect on proliferation at 
either phosphate concentration (data not shown). 
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Figure 6-4: Cell proliferation in HUVECs +/- L-NAME (top) and +/-FGF-23 and Klotho 
(bottom). 
Cells were cultured, in either normal (0.5mM) or high (3mM) phosphate concentration media, on 12 
well plates at a cell density of 1x10
5
 cells per well. Cells were plated on day one and the media was 





M) and Klotho (2x10
-6
M) were added to selected wells. On day four, MTT was added 
(final concentration 1mg/ml) and the cells were incubated for three and a half hours. The 
media/MTT solution was removed and MTT solvent was added (1:1 ethanol/DMSO mixture).The 
plate was covered and agitated on an orbital shaker before being read on a microplate reader. 
There were control wells in each plate which contained media but no cells. The figures are the 
combined results from six separate experiments. For each experiment, there were two control wells 
per phosphate concentration, two wells containing cells only and two wells containing either 
LNAME or FGF-23 and Klotho. Values are mean ± SEM. 
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Figure 6-5: Cell proliferation in cardiac myocytes+/-L-NAME. 
Cells were cultured, in either normal (0.5mM) or high (3mM) phosphate concentration media, on 12 
well plates at a cell density of 1x10
5
 cells per well. Cells were plated on day one and the media was 
changed daily. On days two and three when the media was changed, L-NAME (1x10
-4
M) was 
added to selected wells. On day four, MTT was added (final concentration 0.5mg/ml) and the cells 
were incubated for one hour. The media/MTT solution was removed and MTT solvent was added 
(1:1 ethanol/DMSO mixture).The plate was covered and agitated on an orbital shaker before being 
read on a microplate reader. There were control wells in each plate which contained media but no 
cells. The figure shows the combined results from four separate experiments. For each experiment, 
there were two control wells per phosphate concentration, two wells containing cells only and two 
wells containing LNAME. Values are mean ± SEM. 
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6.3.4 Gene expression studies 
6.3.4.1 Microarray 
Prior to cDNA synthesis, HUVEC total RNA quality was confirmed by electrophoresis of 
the total RNA samples on the Agilent Bioanalyzer 2100 (Dr Jing Wang, Glasgow 
Polyomics centre, University of Glasgow). Figure 6-6 shows a representative result. There 
is a marker peak evident at 25 nucleotides and defined bands for 28S and 18S rRNA 
species. Below the 18S band, between 25 and 200 nucleotides, there is a very small hump 
which is 5S and transfer RNA . RNA Integrity Numbers (RINs) were consistently above 
9.5. Following IVT to synthesise biotinylated cRNA, cRNA quality was also assessed by 
electrophoresis on the Agilent Bioanalyzer 2100. Results demonstrated approximately 
normal distribution and equal concentrations of cRNA for all samples (Figure 6-7). 
6.3.4.2 Microarray Data Quality Control and Beadstudio analysis 
Direct Hyb Control Plots obtained for samples were consistent with BeadStudio example 
control plots, verifying the validity of microarray gene expression data. Using Illumina® 
BeadStudio software, a total of 131 probes were found to be differentially expressed by a 
minimum of 2 fold between HUVECs cultured in normal or high phosphate concentration 
medium. Expression of 58 probes was up-regulated in HUVECs cultured in high phosphate 
whilst 73 probes were down-regulated. A complete list of differentially expressed probes is 
shown in Table A1 in the Appendix (section 9.2). 
6.3.4.3 MetaCore™ Analysis 
Using MetaCore™ software, analysis of BeadStudio microarray data identified aspects of 
the cell cycle as being significantly affected in cells cultured in high phosphate; seven of 
the ten most significantly affected pathways included the cell cycle (Figure 6-8). 
Significance is based upon the total number of genes with differentially expressed probes 
which map to the particular pathway.  The two most significant pathways were ‘The Role 
of APC in cell cycle regulation’ and ‘Chromosome condensation in prometaphase’ 
(Figures 6-9 and 6-10). From these pathways, I identified candidate genes for further study 
to confirm differential expression: CCNA2, CCNB2 (encoding Cyclin A, CyclinB; generic 
binding proteins), AURKA and AURKB  (encoding Aurora-A and Aurora B; protein 
kinases). Each of these genes was upregulated in high phosphate conditions (Table A1, 
appendix).  
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Figure 6-6: Agilent Bioanalyzer 2100 Assessment of Total RNA Quality.  
The top figure shows electrophoresis of a single representative total RNA sample with defined 
bands for 28S and 18S rRNA. The green bands represent a 200 base pair size marker (to align 
samples and controls). The bottom figure is a representative individual electropherogram with the 
marker peak and defined peaks for 28S and 18S rRNA.  No RNA species smaller than 18S rRNA 
were observed - indicative of intact RNA. This was undertaken by Dr Jing Wang, Glasgow 
Polyomics centre, University of Glasgow. 
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Figure 6-7: Agilent Bioanalyzer 2100 Assessment of cRNA Quality.  
This shows a single representative electropherogram showing approximately normal distribution of 
cRNAs. The 200 bp size marker is shown. This was undertaken by Dr Jing Wang, Glasgow 
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Figure 6-8: MetaCore™ pathway analysis of BeadStudio Microarray data. 
Pathway maps significantly affected by the presence of high phosphate in cell growth medium were 
observed to cross the threshold value (p≤0.05). Significance is based on the number of 
differentially expressed genes in the pathway. The table to the right shows the actual p value and 
the false discovery rate (FDR). The ratio is the number of differentially expressed genes mapping 
to the pathway divided by the total number of genes mapping to the pathway. Differentially 
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Figure 6-9: The Role of APC in cell cycle regulation. 
The products encoded by candidate genes are circled in red and the adjacent small red and white 
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Figure 6-10: Chromosome condensation in prometaphase. 
The products encoded by candidate genes are circled in red and the adjacent small red and white 
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In addition to any influence on the cell cycle and cell growth, I have shown that phosphate 
and its regulators affect the NO pathway and cell adhesion (chapters 3, 4 and 5) and thus I 
also selected to study the following genes: E-selectin, ADORA2A (encodes the adenosine 
2A receptor), NOS 2 (the inducible form of NOS 2), Nitric oxide synthase-interacting 
protein (NOSIP), PiT 1 and PiT2. E-selectin and ADORA-2A play a role in inflammation 
and ED (386). In chapter four of this thesis, FGF-23 in combination with a 
hyperphosphataemic environment was found to stimulate production of cell adhesion 
molecules including E-selectin in HUVECs. NOSIP encodes the enzyme of the same name 
which modulates eNOS activity and plays a role in cell-cycle related actions of eNOS 
(387).  PiT 1 and PiT 2 are type 3 phosphate transporters responsible for transporting 
phosphate into the cell; alterations in expression may affect the quantity of phosphate 
entering an individual cell.  
6.3.4.4 Confirmation of differential expression of candidate genes 
TaqMan® RT-PCR confirmed the differential expression of CCNA2, CCNB2, AURKA and 
AURKB seen in the microarray. Each of the four genes was up-regulated in cells cultured 
in high phosphate medium. This is illustrated in Figure 6-12. Expression of ADORA2A, 
NOS2, NOSIP, PiT1 and PiT2 was not significantly different in HUVECs cultured in high 
phosphate medium and E-selectin was not expressed at either phosphate concentration 
(data not shown). However, in cells stimulated with IL1β for 6 hours, there was 
significantly increased expression of E-selectin and ADORA2A in HUVECs cultured in 
standard compared with high phosphate medium (Figure 6-13). 
6.3.4.5 Metacore™ network process analysis 
 Using Metacore™, it is possible to produce a series of ‘network processes’. These identify 
possible relationships between ‘objects’ of interest (including genes, enzymes, protein, 
transcription factors). The larger the number of ‘objects’ included then the more complex 
the resultant network becomes. It is possible to specify which ‘objects’ are to be included 
and also the degrees of separation between ‘objects’. I compiled several network processes 
and included ‘objects’ of interest from the microarray analysis: CCNA2, CCNB2, AURKA 
and AURKB, HSP6A (which encodes heat shock protein (HSP) 70 and was down-regulated 
in high phosphate conditions). Additionally, I elected to include additional ‘objects’ of 
interest to identify any possible associations: these included eNOS and PKG. Figure 6-14 
is an example of one of the obtained network processes and illustrates possible connections 
between ‘objects’ of interest in my microarray dataset and aspects of the NO pathway.  
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HSP 70 is down-regulated which may reduce activation of HSP 90, protein kinase B (Akt) 
and of transcription factor, CREB1 and thus of eNOS. Cyclin A is up-regulated which may 
enhance activation of transcription factor, SP1 and thus inhibition of PKG which is 
reduced in expression in high phosphate conditions (chapter 4). SP1 activates eNOS but 
this may not be its pre-dominant effect. Similarly, Aurora-A is up-regulated and activates 
Cyclin B which has an inhibitory effect on SP1, again this may not be a dominant effect. 
Up-regulation of Aurora-A and B may enhance inhibition of transcription factor, p53 
leading to reduced PKG. PP1-cat (a protein phosphatase) activity may also be reduced via 
Aurora-A with a knock on effect leading to reduced eNOS. The inhibitory effect of HSP 70 
on Aurora-A is reduced. 
Activation of the epidermal growth factor receptor (EGF-R) may be the stimulus for 
enhanced expression of Aurora-A and thus the trigger for the sequence of events described 
above.  
6.3.5 Summary of Results 
 HUVECs, rat ECs, human cardiac myocytes and rat VSMCs proliferate more when 
cultured in high phosphate concentration medium.  
 The addition of L-NAME, a NOS inhibitor, increases proliferation in HUVECs 
cultured in standard phosphate medium. FGF-23 and Klotho has no effect on 
proliferation. 
 Microarray analysis of HUVECs cultured in high phosphate concentration medium 
revealed that there was differential expression in 131 probes and the most 
significantly affected pathways were those involving the cell cycle. 
 RT-PCR confirmed differential expression of candidate genes involved in the cell 
cycle and showed no difference in expression of PiT1, PiT2, iNOS, NOSIP, E-
selectin or ADORA2A. When cells were stimulated with IL1β, cells cultured in high 
phosphate expressed significantly less E-selectin and ADORA2A. 
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Figure 6-12: BeadStudio candidate gene mRNA expression relative to GAPDH. 
(TaqMan® qRT-PCR). CCNA2 (top left), CCNB2 (top right), AURKA (bottom left) and AURKB 
(bottom right) mRNA expression was compared in HUVECs cultured in normal and high phosphate 
concentration medium (n=3).(CCNA2, Ct 1.86±0.05 vs., 0.15±0.02;p=0.02.CCNB2,Ct 
2.30±0.04 vs., 1.14±0.31;p=0.02. AURKA Ct 2.73±0.07 vs., 1.49±0.13; p=0.001. AURKB, Ct 
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Figure 6-13: Candidate gene mRNA expression relative to GAPDH. 
(TaqMan® qRT-PCR). E-selectin (left) and ADORA-2A (right) mRNA expression was compared in 
HUVECs cultured in normal and high phosphate concentration medium alone and in the presence 
of IL1β (n=3).(Ct values are for normal phosphate stimulated with IL1β vs., high phosphate 
stimulated with IL1β: E-selectin, Ct -5.6±0.01 vs -3.3±0.09;p<0.001 and ADORA2A, Ct 
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Figure 6-14: An example of a network process identifying possible relationships between 
objects of interest. 
The blue circles around objects identify objects of interest and the small red/blue circles identify 
genes which were up/ down regulated significantly in my dataset. Location of the objects of interest 
within the cell is indicated at the top of the figure. The legend is shown above; thin green arrows 
indicate activation of an object; thin red arrows inhibition. 
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6.4 Discussion 
LVH is a risk factor for cardiac arrhythmia and sudden cardiac death and it affects a 
significant proportion of patients with CKD (232;383;384). Phosphate and FGF-23 have 
been linked, independently and through an unknown mechanism, to the development of 
LVH in CKD (268;385). The work presented in this chapter lends support to the notion 
that phosphate may have direct effects on cell growth, rather than the prevailing view that 
such effects are mediated by FGF-23.  Moreover, I have identified a number of sub-cellular 
mechanisms through which phosphate may mediate cell growth.  
6.4.1 Direct effects of phosphate on cell growth 
Cells cultured in high phosphate medium are bigger and proliferate more rapidly than those 
cultured in normal phosphate concentration medium. This may reflect reduction of NO, 
and NO dependent growth inhibition, in high phosphate conditions. In support of this 
hypothesis, inhibition of NO synthesis by addition of L-NAME increased proliferation in 
HUVECs cultured in normal phosphate concentrations. There are several possible 
mechanisms by which the effect of phosphate on NO, and is actions, may result in 
increased growth. One possibility is that phosphate increases ROS and this inhibits NO. In 
chapter five, I showed higher levels of superoxide and nitrotyrosine and lower levels of 
NO in ECs cultured in high phosphate. The MTT assay has also been used to suggest the 
presence of ROS. Superoxide has been shown to reduce tetrazolium salts and this principal 
has been used to measure superoxide production in cellular assays (388;389). Thus the 
higher readings identified in high phosphate conditions in all cell lines might represent not 
only an increase in proliferation but also in superoxide generation. 
In high phosphate conditions, gene expression studies confirm up-regulation of genes 
involved in the cell cycle. Whilst analysis did not identify alterations in expression of 
genes directly involved in the NO pathway, microarray analysis did identify relationships 
between the NO pathway and the cell cycle. Possible connections are illustrated in Figure 
6-13. There are several identified transcription factors which connect the ‘objects’ of 
interest in the NO pathway and the microarray analysis. These include p53, CREB1 and 
SP1. Further exploration of the effect of phosphate on these factors is necessary by activity 
assays, gene and protein expression.  
Additionally the EGFR may be of importance; it has enzymatic activity and is activated 
through ligand binding including TGFα and EGF. High phosphate conditions may 
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stimulate production of TGFα and EGF; both are produced by macrophages. If in high 
phosphate conditions, there is a state of chronic inflammation with increased cell adhesion 
molecules (chapter 3) and down-regulation of ADORA2A, which is known to be 
protective against inflammation, there may be an increase in production of these molecules 
from activated macrophages. Further study of this receptor including studies where the 
receptor is blocked in the presence of high phosphate would be useful and provide insight 
into the mechanism of action of phosphate and also if the effects can be reversed.  
The phosphate transporters PiT1 and PiT2 are expressed on ECs but I did not demonstrate 
increased expression of either of these transporters in high phosphate conditions. This does 
not exclude the possibility of receptor dysfunction.  
6.4.2 FGF-23, Klotho and cell growth and proliferation. 
FGF-23 and Klotho are conventionally felt to mediate vascular cell growth and 
hypertrophy in CKD and phosphate has an acknowledged but undefined role. I have 
demonstrated that phosphate itself causes direct effects on cell growth. This leads to three 
key questions:  
1. Do FGF-23 and Klotho cause these same effects on growth in vitro? 
2. What are the precise mechanisms through which phosphate causes direct effects on 
growth? 
3. Do the pathophysiological effects of phosphate require the interaction between 
phosphate, Klotho and FGF-23? 
I provide some answers to question two in section 6.4.1 above. Further work is necessary 
but it is likely that the growth effects I demonstrate relate to effects of phosphate on gene 
and protein expression leading to disruption of the NO pathway, ED, inflammation and as 
a consequence dysregulation of cell growth. 
Question one is interesting. I confirmed that HUVECs express Klotho and the FGFR but I 
did not find an independent effect of FGF-23 or Klotho on proliferation of ECs or cardiac 
myocytes. I did not look at differences in expression of Klotho and FGFR between cells 
cultured in standard and high phosphate conditions. Until recently, ECs were not thought 
to express Klotho but my findings agree with other groups who have found Klotho to be 
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expressed on HUVECs. Klotho is down-regulated in CKD (390) and specifically it may be 
down regulated in the hyperphosphataemic environment, thereby contributing to the 
observed hypertrophy and proliferation via reduced NO. The secretion of Klotho by ECs is 
thought to induce NO production and thus reduce ROS release and oxidative stress 
(391;392) Expression of membranous and secreted Klotho should be quantified in all cell 
lines cultured in both normal and standard phosphate concentration medium and MTT 
assays should be repeated in the presence of FGF-23 and Klotho alone. 
I checked that the FGF-23 used was active by performing Western blot for MAPK (ERK1 
and 2) in ECs, cultured in standard and serum free medium, stimulated with FGF-23 for 
different time periods. This revealed an increase in ERK expression in standard conditions 
compared with serum free and maximal expression after 30 minutes of stimulation with 
FGF-23; thus confirming FGF-23 does have an effect on ECs (data not shown). Contrary 
to my findings, others have demonstrated that FGF-23 stimulates cell proliferation in ECs, 
via ERK (390).   
In observational human studies, FGF-23 is independently associated with LVH (sections 
1.7.2 and 1.7.3) and in animal studies there is some mechanistic evidence of an effect on 
cardiac cell growth and size; causing LVH in mice, mediated via the PLCγ pathway (201). 
This effect of FGF-23 was independent of Klotho which is not thought to be expressed on 
myocardial cells. 
Finally question three, do the pathophysological effects of phosphate require interaction 
between phosphate, FGF-23 and Klotho?  One key aim of this thesis was to attempt to 
separate the effects of chronic phosphate overload from those of other aspects of 
disordered homeostasis, eg elevated FGF-23, and the uraemic environment. This has been 
achieved and I have demonstrated in this chapter and the preceding chapters that phosphate 
disrupts the NO pathway, alters expression of cell adhesion molecules, causes ED and 
affects cell proliferation. In reality, however, the effects of phosphate on CV risk in CKD 
and the precise relationship between FGF-23, Klotho and phosphate is likely to be much 
more complex than we yet appreciate.  
Evidence of the complex interaction between these factors is seen when looking at effects 
on inflammation. ADORA2A is protective against inflammation and reduces ROS (393). 
In HUVECs cultured in high phosphate conditions, expression was unaltered. However 
when cells were stimulated, there was significantly reduced expression of ADORA-2A 
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suggesting a failure of innate protective mechanisms. Similarly E-selectin expression was 
significantly elevated in stimulated cells cultured in a normal phosphate concentration 
medium. In chapter three, I showed that in the high phosphate environment alone, E-
selectin expression was not increased but when cells were stimulated with FGF-23 in 
addition to IL1β, E-selectin expression was significantly higher in cells cultured in high 
phosphate medium. The addition of Klotho significantly reduced expression E-selectin, 
supporting an anti-inflammatory and anti-ageing role for Klotho.   
The directly detrimental and isolated effects seen in hyperphosphataemia may change in 
the presence of FGF-23 and Klotho and the predominant effect may differ between 
individuals and in the uraemic environment.  
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7 Chapter seven – Sustained phosphate loading 
and endothelial function: a cross over study 
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7.1 Introduction 
In vitro studies have been presented in the preceding chapters demonstrating that exposure 
to elevated concentrations of phosphate results in ED. This is evident both in cells and in 
resistance vessels from animals and from humans, with and without CKD. Furthermore, 
exposure to a high phosphate environment affects cell growth and exerts additional 
detrimental effects independently of any effect on the endothelium. This work adds to the 
mounting evidence that phosphate has direct, independent, detrimental effects on the 
function of the endothelium in vitro (6;249;250;368). The observed effects of phosphate on 
endothelial function are not limited to those with CKD but are also evident in the healthy 
population supporting a role for chronic long term phosphate overloading resulting in a 
detrimental effect on cardiovascular risk even in the face of a normal serum phosphate 
level (6). 
The details of the association between ED, serum phosphate and CV risk, in CKD and in 
other populations are not well understood. If exposure to elevated phosphate is sustained 
either through faulty homeostasis (CKD) or continued high exposure (elevated 
consumption; health and CKD) this may lead to a self-perpetuating cycle including 
oxidative stress, an imbalance in redox and thus ED. Phosphate may have direct effects in 
vitro and in vivo or other factors involved in phosphate homeostasis (eg FGF-23) may be 
involved. More detailed information may allow us to target increased CV risk more 
effectively. 
Clinical studies have tended to focus on the cardiac aspect, for example LVH, of the 
elevated cardiovascular risk seen with phosphate rather than the vascular effects 
(3;8;239;278). Since vascular effects by definition are widespread and not confined to one 
organ, these should have similar, if not predominant, focus in research studies with 
endothelial and vascular function as clinical endpoints. 
 Shuto et al., looked at the effect on endothelial function of a single high phosphate 
containing meal (1200mg) compared with a standard phosphate containing meal (400mg) 
and found that the meal containing high phosphate significantly reduced flow mediated 
dilatation in 11 healthy male volunteers (6). This is of interest but the relationship between 
ED, CV risk and serum phosphate is more complex than the effects seen following the 
ingestion of one phosphate rich meal. The effect of sustained phosphate loading on the 
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endothelium has never been studied. Therefore, the primary aims of the present study were 
in healthy volunteers: 
 To assess the effect of sustained phosphate loading on endothelial function. 
 To assess the effect of sustained phosphate loading on vascular function and 
vascular stiffness. 
Secondary aims were: 
 To study the relationships between endothelial and vascular function, sustained 
phosphate loading, serum phosphate, serum FGF-23 level and urinary phosphate 
and FGF-23 excretion. 
 To assess the effect of phosphate binding medication on serum and urinary 
phosphate and FGF-23 levels in the absence of CKD. 
 To assess the effect of sustained phosphate loading on endothelium independent 
vasodilatation. 
 
7.2 Materials and Methods 
These are explained in detail in section 2.6.2. Briefly, this was a single blind cross over 
study. Healthy volunteers attended for three visits. Prior to visits two and three, volunteers 
were randomised to receive phosphate supplements (three tablets daily, equivalent to 48.3 
mmol additional phosphate/day) or 3000mgs lanthanum carbonate daily for two weeks. 
After a two week wash out period, volunteers took the other drug. At each visit identical 
tests were carried out. Endothelial function was measured with FMD and vascular stiffness 
with PWV and PWA. Each FMD was performed and analysed by me and I was blinded to 
the order in which volunteers took each of the two drugs. PWV and PWA were carried out 
by one of a group of four trained individuals, also blinded to the order of drug ingestion. 
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7.3 Results 
7.3.1 Sample size and demographic data 
There were 20 participants. One was incidentally found to have CKD and was therefore 
excluded, leaving 19 volunteers, all of whom completed the study. 63% (n=12) were 
female and the mean age was 42.2±14.3 years. Participant demographics at baseline are 
illustrated in Table 7-1. At the baseline visit, mean eGFR was 102±10 mls/min, serum 
phosphate level was 1.05±0.18mmol/L and fractional excretion of urinary phosphate (FeP) 
was 14.3±3.4%. Participants were normotensive and normoglycaemic with mean lipid 
values (triglycerides, HDL and LDL cholesterol) within the normal range. Median FMD 
was 8.4, 6.2-11.6% post cuff inflation and median % vessel dilatation post GTN was 17.7, 
13.4-23.2%. 
7.3.2 Demographic data following each intervention 
The effect of each intervention on demographic data is presented in Table 7-2. Following 
phosphate supplementation and lanthanum carbonate there was no significant difference in 
mean serum phosphate, PTH, vitamin D, adjusted calcium or magnesium levels compared 
with values obtained at the baseline visit. Serum FGF-23 levels increased significantly 
following phosphate supplementation and fell, although not significantly, following 
lanthanum compared with the baseline value. Urinary phosphate levels increased 
significantly from baseline values following phosphate and reduced although not 
significantly with lanthanum. Figure 7-1 A, B and C illustrates serum phosphate, serum 
FGF-23 and FeP at baseline and following each intervention.  
Post cuff FMD decreased significantly following both interventions, although the effect 
was strongest following phosphate. There was a trend towards lower values for post GTN 
vessel dilatation, PWV and AI@75 following each intervention when compared with 
baseline values; this was particularly true for AI@75. These differences were not, 
however, statistically significant.  
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Table 7-1: Baseline demographics. 
 
Table 7-2: Participant demographics at baseline, following lanthanum and phosphate. 
Statistically significant differences (p<0.05) between baseline and subsequent measures are 
indicated in bold. % change refers to the % change in a particular parameter when compared with 
the value obtained at baseline. 
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Figure 7-1: Levels of serum phosphate (A) and FGF-23 (B) and fractional excretion of urinary 
phosphate (C) at baseline (green) and after lanthanum (blue) and phosphate (red) in the 
study population. Values are median and IQR. * denotes a significant change (p<0.05) 
compared with baseline values. 
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7.3.3 Determinants of vascular stiffness, endothelial function  
The following demographics were entered into a correlation matrix with PWV, 
AIx@75bpm, post cuff FMD and post GTN vessel dilatation: age, sex, BMI, systolic and 
diastolic blood pressure, eGFR, serum phosphate, serum FGF-23, triglycerides, total 
cholesterol, HDL, PTH, vitamin D, FeP, urinary sodium (fractional excretion), urinary 
FGF-23, and urinary cGMP. The results are presented in Table 7-3. 
There was significant correlation between PWV and age, sex, BMI, systolic and diastolic 
blood pressure and AIx@75bpm.There was a significant correlation between AIx@75bpm 
and age, systolic and diastolic blood pressure, eGFR, serum phosphate, HDL and PWV. 
Post cuff FMD correlated with urinary sodium, urinary phosphate and triglycerides. 
Serum FGF-23 correlated with sex, BMI, systolic blood pressure, eGFR, urinary FGF-23 
and post GTN vessel dilatation. Serum phosphate correlated with sex, BMI, systolic blood 
pressure, eGFR, triglycerides, HDL, AIx@75bpm, urinary FGF-23 and urinary cGMP. 
7.3.4 Flow mediated dilatation 
To assess reliability of image analysis, an intra-class correlation coefficient (ICC) was 
calculated on a selection of images from the total cohort; the raw data are presented 
alongside the ICC in Table 7-4. 
Using only data from the baseline visit (ie prior to any intervention), univariate analysis 
was performed by creating a general linear model (GLM) with baseline brachial artery 
diameter as the dependent variable and sex, age systolic and diastolic blood pressure as co-
variates. Women have smaller brachial arteries with a mean diameter of 3.69mm ±0.6mm 
compared with 4.77mm ±0.8mm in the male subjects. Blood pressure and age do not affect 
vessel diameter. The model was repeated with post cuff FMD and post GTN FMD as 
dependent variables and age, sex and blood pressure did not affect the ability of a vessel to 
dilate following cuff inflation or GTN administration. 
Increased phosphate intake was associated with a significant reduction in post cuff FMD. 
(3.38 (2.57-5.26)%, p<0.001) and with lanthanum, post cuff FMD also fell (6.6 (3.4-
10.3)%, p=0.033). There was no significant effect on post GTN FMD. This is illustrated in 
Figure 7-2. 
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Table 7-3: Significant correlations between PWV, AIx@75bpm, post cuff FMD, serum 
phosphate and serum FGF-23.  
Values are r,p. p<0.05 = significant. Fe sodium, fractional excretion of urinary sodium.  
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Table 7-4: The raw data used to calculate the ICC coefficient (top).  
The repeat measurements for baseline diameter, post cuff diameter and FMD are highlighted in 
yellow. ICC and confidence intervals are presented in the bottom table. 
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Figure 7-2: Change in post cuff FMD (top) and post GTN vessel dilatation (bottom). 
Following intervention with lanthanum (blue) and phosphate (red) expressed as a % change from 
the baseline visit. 
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To determine whether randomisation order had any effect, models were created using the 
entire dataset with post cuff FMD and post GTN FMD as the dependent variables. Various 
co-variates were added to the models including age, blood pressure, sex and measures of 
serum and urinary phosphate and FGF-23. Randomisation order was not a predictor of 
either post cuff FMD or post GTN vessel dilatation regardless of which co-variables were 
included in the model. 
On univariate analysis, by GLM, the change in serum phosphate level from baseline visit, 
the change in serum FGF-23 from baseline and fractional excretion of urinary phosphate 
were significant predictors of post cuff FMD. There were no significant predictors of post 
GTN vessel dilatation. A multiple regression model was created and is presented in Table 
7-5. The inclusion of serum FGF-23 and urinary FeP statistically significantly predicted a 
change in post cuff FMD compared with the baseline visit, F (2, 54) = 10.07, p<0.001, r
2
 
=0.28. Together both variables add statistically significantly to predict the change in FMD 
(p <0.05). Several models were tried to include the following variables: systolic blood 
pressure, serum phosphate, age, sex, urinary FGF-23, urinary calcium and urinary cGMP 
levels. None of these factors were significant predictors of the change in post cuff FMD 
after an intervention compared with the measures from the baseline. Including drug as a 
variable in the model increased the r
2 
value to 0.53 (F (4,52) = 15.2, p<0.001). However, 
this cancelled the predictive effect of FeP; since the study was not powered to examine the 
effect of the drugs on FMD, drug was excluded from the final model to produce a more 
statistically valid conclusion. However, following phosphate, post cuff FMD reduced 
significantly (3.38% (IQR 2.57-5.26%), p<0.001 ANOVA) and with lanthanum, post cuff 
FMD also fell (6.6% (IQR 3.4-10.3%), p=0.033 ANOVA).  By recoding the three drug 
categories (no drug, lanthanum, phosphate) into two rather than three variables, it was 
possible to add the effects of lanthanum on FMD compared to baseline measures and the 
effect of phosphate on FMD compared to baseline to a multivariate model with the change 
in post cuff FMD as a % of the baseline visit FMD as the dependent variable. The change 
in the FeP as a % from baseline and serum FGF-23 were included as co-variates. Now all 
four variables significantly predict the change in post cuff FMD compared with the 
baseline visit post cuff FMD, F (4,52)=18.31 p<0.001 r
2
 =0.59.  
Considering serum FGF-23 and fractional excretion of urinary phosphate in tertiles reveals 
that those in the highest tertiles for each measure had the lowest post cuff FMD. This 
relationship is illustrated in Figure 7-3. 
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Table 7-5: Multiple regression model with post cuff FMD as the outcome measure. 
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7.3.5 Urinary cGMP  
Urinary cGMP correlated negatively with serum phosphate (r = -0.392, p 0.003) as 
illustrated in Table 7-3. There was also a correlation with male sex (r = 0.329, p= 0.006). 
On univariate analysis, serum phosphate, age, male sex and FeP were predictive of urinary 
cGMP levels. A multivariate GLM was constructed to assess independent predictors of 
urinary cGMP. Serum phosphate was the only statistically significant predictor of urinary 
cGMP F (5,51) =2.5, p=0.043, r
2
 0.196.  
 
7.3.6 Side effects of lanthanum and phosphate 
Individuals were asked to comment on the taste and palatability of both drugs and on the 
presence of any gastrointestinal side effects (nausea, altered bowel habit, bloating). Five of 
the 19 participants commented on gastrointestinal side effects with phosphate 
supplementation, mostly abdominal bloating. Six participants commented on the salty taste 
and two individuals appreciated the orange flavour; otherwise it appeared to be well 
tolerated. Only one individual did not experience gastrointestinal side effects with 
lanthanum and eight participants commented on the large size of the tablets. Twelve 
participants commented on the chalk like taste. Interestingly eight participants volunteered 
that taking lanthanum with a meal rather than immediately after minimised the abdominal 
side effects when the predominant side effect was nausea. The manufacturer’s advice is 
that it be taken after a meal. 
7.3.7 Summary of results 
 Serum phosphate levels do not change significantly in healthy volunteers following 
lanthanum carbonate or phosphate supplementation. 
 Fractional excretion of urinary phosphate increases significantly following 
phosphate and falls significantly with lanthanum. 
 Serum FGF-23 rises by almost 20% when compared to baseline values following 
phosphate. It falls, although not significantly, following lanthanum. 
 Post cuff FMD reduces significantly compared to baseline measures following both 
phosphate and lanthanum. The effect was more marked with phosphate. 
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 FeP and serum FGF-23 level are independent predictors of post cuff FMD. The 
higher the serum FGF-23 and the higher the urinary excretion of phosphate, the 
lower the % FMD. 
 
7.4 Discussion 
This study has demonstrated for the first time that sustained phosphate loading causes ED; 
this effect is independent of serum phosphate level. Only around 1% of total body 
phosphate is found in the serum and thus it is perhaps not surprising that used alone this is 
not necessarily an accurate reflection of total body phosphate.  
7.4.1 Phosphate homeostasis and total body phosphate level 
The subjects did not have CKD and thus it is reasonable to expect that the homeostatic 
mechanisms to control serum phosphate within the physiological range should be intact. If, 
as the evidence increasingly suggests, FGF-23 is the first regulator to act when body 
phosphate increases, it is reasonable to expect that serum FGF-23 levels should rise 
following phosphate loading and as a consequence urinary phosphate excretion should 
increase; PTH would not be expected to rise significantly and vitamin D levels should be 
maintained.  
Against this background, in my study, serum phosphate was unchanged from baseline, 
serum FGF-23 level rose by around 20% compared with baseline visit measures following 
phosphate, and urinary phosphate excretion increased by 50% compared with baseline visit 
mean. This suggests compliance with the study medication and demonstrates phosphate 
homeostasis. Moreover, it highlights the inadequacies of serum phosphate as a measure of 
total body phosphate and suggests that other indices of phosphate metabolism may provide 
additional information pertaining to actual body phosphate level. In early CKD, serum 
phosphate is maintained within the reference range and rises consistently only when eGFR 
drops below 30ml/min/1.73m
2
. However, in CKD and in other populations, even in the 
face of a normal serum phosphate, CV risk seems to be increased and is linked 
independently to serum phosphate level. This may be explained by large elevations in total 
body phosphate which are not accurately represented by a single serum measure and it may 
be possible to further stratify and more precisely quantify risk by identifying those with 
higher total body phosphate using FGF-23 level and urinary phosphate levels. This is 
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supported by my findings associating elevated serum FGF-23 and urinary phosphate 
excretion with poorer endothelium function.  Twenty-four hour urinary phosphate level is 
likely to be superior reflection of phosphate intake and whole body phosphate, and thus 
increase when body phosphate levels rise in response to a rise in FGF-23. In the clinical 
setting, it may be possible to use a phosphate:creatinine ratio or a spot FeP to provide 
additional information about body phosphate levels. This would require to be validated in a 
clinical study. 
7.4.2 Associations with phosphate and FGF-23 
Several small studies have demonstrated an association between FGF-23 and dietary 
phosphate intake in healthy volunteers with increased phosphate intake over a few days 
resulting in increased levels of serum FGF-23 (394;395). Increased levels of FGF-23 have 
been shown to correlate with increased serum phosphate, increased urinary excretion of 
phosphate and increased vitamin D levels (394). We found that higher serum FGF-23 
correlated with female sex, higher BMI and lower systolic blood pressure. We also found 
that higher serum phosphate levels correlate with female sex and lower systolic blood 
pressure. Women have been shown to have lower systolic blood pressure than men and if 
phosphate levels are higher, this will trigger an increase in FGF-23 levels. In turn this will 
reduce the expression of the type 2 sodium phosphate co-transporter in the proximal tubule 
of the kidney and along with increasing urinary phosphate excretion, fewer sodium 
molecules will be absorbed, thus offering one possible mechanism for  the observed 
association between higher serum phosphate, FGF-23, lower systolic blood pressure and 
female sex.  
Both higher serum phosphate and higher FGF-23 correlate with lower eGFR and with 
higher urinary FGF-23 excretion. Serum FGF-23 also correlates positively with fractional 
excretion of urinary phosphate. Yet there was no significant correlation between serum 
phosphate and FGF-23; one explanation may be that serum phosphate is not an adequate 
marker of the total body phosphate content. There was no correlation between serum and 
urinary phosphate measures which lends weight to this argument. Urinary phosphate 
excretion alone or in combination with measures of FGF-23 may be a better surrogate for 
total body phosphate than serum phosphate level.  
The lack of a relationship between serum phosphate and serum FGF-23 and urinary 
phosphate, is an important observation regardless of the root cause. FGF-23 is being touted 
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as the earliest biomarker for excess total body phosphate and it is associated in my study 
with increased urinary phosphate excretion but not serum phosphate levels. This supports 
the notion that lowering CV risk may be dependent upon an intervention prior to a 
discernible rise in serum phosphate (even within the normal range).  
7.4.3 Vascular stiffness 
Phosphate loading did not alter PWV and thus vessel stiffness. PWV did correlate with 
several other demographic factors including age and BMI and this is similar to several 
other studies which have shown that male sex increasing BMI, age and blood pressure 
correlate closely with vessel stiffness (396).  This suggests that my study population is 
representative of the general population.   
AIx@75bpm is a further measure of arterial stiffness and is independently associated with 
CV risk. In my study population, increased arterial stiffness measured with AIx@75bpm 
did correlate with a higher serum phosphate level (within the physiological range) as well 
as with increasing age and blood pressure. The latter observations are in keeping with 
findings by other studies  but a correlation between serum phosphate and AIx@75bpm has 
not previously been observed (397). Houston et al., studied the relationship between 
AIx@75bpm and indices of phosphate metabolism, including serum phosphate and FGF-
23 level and urinary phosphate excretion in patients with CKD (398). They found no 
association between these measures of phosphate metabolism and arterial stiffness and 
confirmed that traditional measures including age and blood pressure are predictors of 
arterial stiffness in the CKD population. Their results may be explained by an inadequate 
study sample (n=74), the wide range of CKD (74% of study population had an eGFR 
≥30ml/min/1.73m2 and of them 30% had an eGFR >60ml/min/1.73m2. They also included 
subjects of black race, a factor which seemed to be associated with reduced urinary 
phosphate excretion and may contribute to the lack of relationship between measures of 
phosphate metabolism and AIx@75bpm. Other studies have linked serum phosphate and 
serum FGF-23 with other measures of vascular stiffness including ankle brachial index 
both in the presence and absence of CKD (399).   
In univariate and multivariate analysis, there was no relationship between serum 
phosphate, indices of phosphate metabolism and measures of vascular stiffness after either 
intervention. 
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7.4.4 Endothelial dysfunction 
Higher triglyceride levels, higher fractional excretion of urinary sodium and higher 
fractional excretion of urinary phosphate correlated with worse endothelial function. On  
univariate analysis, serum FGF-23 level, FeP and endothelial function differed between 
baseline and following intervention with phosphate and lanthanum. That lanthanum should 
also impair FMD was an unexpected finding and whilst the study was not powered to 
detect differences in the drugs themselves, it is an interesting observation. Further work is 
necessary to establish if this is an effect of lanthanum and if so the mechanism behind the 
observation. One explanation may be that enough lanthanum is absorbed to have a 
detrimental effect on the endothelium. The manufacturers quote up to 10% absorbance and 
there is increasing evidence that lanthanum accumulates in bone with long term usage. It is 
also possible that this effect would not be seen in CKD, the population of patients who are 
prescribed this medication.  
FeP and serum FGF-23 fell with lanthanum and rose with phosphate. On multivariate 
analysis, elevated serum FGF-23 and FeP were significant predictors of worse FMD and if 
examined in tertiles, those patients with the highest FGF-23 and highest FeP had the lowest 
FMD. Several observations can be made from these results:  
 Elevated serum FGF-23 and urinary phosphate excretion can be linked to ED. 
 Serum phosphate does not correlate with ED in my study population. 
 Phosphate loading results in ED and this is likely to be the result of increased total 
body phosphate. 
 I did not measure total body phosphate but it is likely that serum FGF-23 and FeP 
important and additive markers of total body phosphate and this hypothesis requires 
to be tested.  
 It may be that indices of phosphate metabolism are more important to the link 
between phosphate and CV risk than initially appreciated.  
 In the early stages of chronic phosphate overload (from diet or from reduced 
excretion), FGF-23 may be directly toxic to the endothelium thereby increasing CV 
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risk. If phosphate excess becomes chronic, then phosphate rises initially within the 
normal range and as it rises it may then become directly toxic.  
I measured urinary cGMP as an indirect marker of NO production. When ED is present, 
less NO is produced and plasma and urinary cGMP may fall. Urinary cGMP did not 
correlate with FMD but I did observe a correlation between urinary cGMP and serum 
phosphate levels. In a multivariate model, higher serum phosphate remained an 
independent predictor of lower urinary cGMP levels. That is to say serum phosphate may 
be related to low NO production and therefore ED. That there may be reduced NO 
produced in the presence of higher phosphate is in agreement with our observations from 
the in vitro work presented in chapters four, five and six. However, if we continue to assert 
that serum phosphate is not a good marker of total body phosphate excess, why then does it 
predict lower urinary cGMP levels? There are a few possibilities, the most plausible of 
which is that urinary cGMP may not be as sensitive a marker of ED as other measures – 
FMD is the “gold standard” measure and there was no correlation between urinary cGMP 
and FMD. 
 Whilst serum phosphate alone is perhaps not a good indicator of total body phosphate 
levels, this suggests there is an association between the serum phosphate values and 
adverse effects. In order to fully assess the effects of total body phosphate excess, it would 
be pragmatic to accept that we need to consider urinary phosphate losses and serum 
phosphate measures in combination. Ideally, serum FGF-23 measures should also be taken 
into consideration. I did not consider the type of phosphate consumed in our study but this 
may also be of relevance; specifically, phosphate from additives and processed foods 
compared with that in non-processed foods. 
 I also looked at the effects of phosphate loading on endothelium independent function 
(post GTN vessel dilatation). There were no differences between the interventions and the 
baseline values for this. Preserved endothelium independent vasodilation is in agreement 
with my myography data in rats and human vessels without CKD (chapters four and five). 
Interestingly, serum FGF-23 correlated positively with post GTN vessel dilatation. It may 
be that in a high phosphate environment which stimulates FGF-23 and perhaps reduces the 
level of available NO, the vessel becomes hyper-responsive to an exogenous source of NO. 
 The relationships between serum and urinary phosphate and other indices of phosphate 
metabolism are exceptionally complex and poorly understood. However, I demonstrate for 
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the first time that sustained phosphate loading is associated with ED not linked to serum 
phosphate but to urinary phosphate losses and serum FGF-23 level. This supports the 
concept that total body phosphate excess cannot be accurately quantified from a serum 
measure alone and that perhaps in the quest to modify CV risk by altering phosphate 
levels, we should focus on indices of phosphate metabolism, certainly initially, rather than 
on serum phosphate itself. 
7.4.5 Strengths and limitations 
This was a prospective cross over trial and was appropriately powered to detect a 
meaningful difference in the outcome measure - FMD. I performed and analysed all 
images in a single blind manner. The reproducibility of the analysis was excellent. 
Individuals were fasted and abstained from caffeine for 12 hours prior to study visits and 
attended for visits at the same time of day. The study participants have been closely 
phenotyped.  
Both sexes were included and it may be helpful to repeat this work in a single sex study to 
ameliorate possible effects of the female sex hormones. Dietary phosphate intake was not 
quantified.  Urinary cGMP was utilised as an indirect marker of NO production and 
therefore endothelial function, it may have been advantageous to have measured ROS 
directly in the serum of patients rather than make use of a by product. 
7.4.6 Conclusion 
Sustained phosphate loading results in ED, measured by post cuff FMD. Urinary phosphate 
excretion and serum FGF-23 are significant predictors of worse endothelial function and 
are likely to be useful markers of total body phosphate, providing more information in 
combination that serum phosphate or either measure alone. Whilst the study was not 
powered to study the direct effects of either phosphate supplementation or lanthanum, it is 
therefore difficult to draw a firm conclusion with regards to the effect of lanthanum on 
endothelial function. It is however worth noting that lanthanum certainly did not improve 
endothelial function and may in fact have a detrimental effect. I did not detect any 
independent effect of sustained phosphate loading on vascular stiffness measures in our 
study population.  
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7.5 Further work 
It is possible that patients with CKD may respond differently to sustained phosphate 
loading and thus these results cannot be extrapolated to the CKD population. This study 
should be repeated in a population with CKD, both pre dialysis and dialysis patients, to 
ascertain if the same relationships are present.   
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8 Chapter Eight – General discussion 
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8.1 Summary of findings 
The aim of this thesis was to study the mechanism of action of phosphate as a CV risk 
factor, particularly teasing out isolated effects of chronic exposure to phosphate, separate 
from other abnormalities of the uraemic environment. Whilst the prevalent view is that 
elevated serum phosphate increases CV risk by promoting vascular calcification, an 
alternative possibility is phosphate directly causes endothelial dysfunction. I have 
investigated this hypothesis by examining vascular function in vitro and in vivo, examining 
gene expression, and quantitative and functional changes in signal transduction pathways 
in the following systems: cell lines cultured in standard and high phosphate concentration 
medium; rat and human vessels, exposed to standard or high phosphate concentration PSS, 
in wire myography studies; and in a cross-over clinical study (with phosphate supplements 
and binders) with endothelial function as the outcome measure. The main findings were: 
 Evidence of disruption of the NO pathway, in the high phosphate environment, at 
several levels: 
o Reduced basal NO, reduced expression of phospho and total eNOS, reduced 
expression of PKG, lower concentrations of cGMP, increased expression of 
peroxynitrite and a trend towards increased superoxide levels. Some of 
these effects may be reversible. 
o Impaired function, in vitro, of human resistance vessels exposed to high 
phosphate. These effects differ between patients with and without CKD and 
suggest a degree of adaptability and reversibility of the effects of phosphate 
in CKD.   
o In rat resistance vessels, the impaired endothelium dependent and 
independent function observed in high phosphate conditions can be 
improved with ascorbic acid and ameliorated with the addition of zaprinast, 
a PDE5I. 
o In vivo, in the face of a normal serum phosphate, phosphate loading results 
in impaired post cuff FMD measures. 
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 Evidence that phosphate has direct effects on cell growth: 
o This may relate to reduced NO and increased ROS production. There is up-
regulation of several genes involved in the cell cycle and this may have a 
directly inhibitory effect on the NO pathway mediated by inhibition of 
transcription factors.  
o The relationship between phosphate and its regulators is complex. In cell 
culture, the addition of FGF-23 and Klotho did not have an additive effect 
on cell proliferation. However, FGF-23 is associated with LVH, measured 
by cardiac MRI, in CKD.  
 Evidence, in a high phosphate environment, of inflammation and impaired defence 
response in cells exposed to additional stress: 
o VEGF concentration in cells cultured in high phosphate does not increase 
significantly as would be expected on exposure to an hypoxic environment. 
o ADORA2A expression reduces significantly in cells cultured in high 
phosphate and stimulated with IL1β. 
o In combination with a high phosphate environment, FGF-23 increases 
expression of the cell adhesion molecules, E-selectin and VCAM.  
 
8.2 Strengths and limitations of these studies 
The described studies successfully identify isolated effects of phosphate in vitro and in 
vivo and particularly concentrate on the effects of sustained exposure to a high phosphate 
environment. This differs from other studies in this area where the focus has been on short 
term stimulation with elevated phosphate. In CKD, patients are exposed to higher 
phosphate concentrations for long, not short, time periods and thus laboratory and clinical 
studies looking at sustained exposure to high phosphate are more comparable with ‘real 
life’. In my studies, exposure to the high phosphate environment leads to inflammation, the 
generation of ROS, cell proliferation and impaired relaxation and each of these detrimental 
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effects contributes to ED in CKD. The mechanism underlying this is complex and is likely 
to involve multiple pathways. Figure 8-1 suggests possible pathways through which 
phosphate elevates CV risk, based upon the work presented in this thesis.  
FMD is the most accurate non-invasive measure of endothelial function and the patients in 
the clinical cross-over study underwent detailed analyses.  This study provided a unique 
opportunity to study the direct effects of sustained phosphate loading on endothelial and 
vascular function in vivo without confounders from the uraemic environment. 
The studies presented provide strong evidence of an effect of phosphate on endothelial 
function at every level from cell through to in vivo and suggest that the mechanism 
underlying the adverse effects and increased CV risk relates to effects on the NO pathway. 
The cell based studies consider both gene and protein expression as well as different 
aspects of the NO pathway, resulting in robust study of the whole NO pathway. The use of 
different cell lines also serves to provide more detailed and clinically relevant information 
on the effects of phosphate. 
Cultured cell lines may not represent the true in vivo phenotype and there is criticism of the 
HUVEC cell line in particular. However, HUVECs have been widely utilised in this area 
of research and thus I have adopted a pragmatic approach. Of interest, the concentration of 
phosphate in cell media varies enormously. The standard concentration in the media used 
in these experiments was 0.5 mM. This would represent a low phosphate in vivo although 
as discussed in chapter seven, the validity of serum phosphate as a marker of total body 
phosphate is unclear. Increasing to 3 mM for the high phosphate experiments seemed to be 
logical to mimic the in vivo environment. However, using a range of phosphate 
concentrations may have provided further information. Additionally, RPMI cell media is 
very widely used and it contains approximately 5mM phosphate, casting aspersions on the 
clinical applicability of studies making use of this media. 
Rat VSMCs are a myoblast cell line and share characteristics with VSMCs but they are not 
VSMCs and thus it is not possible to extrapolate the findings seen in my studies to 
VSMCs. Additionally, I did not use a human VSMC line which is a limitation. One option 
would have been to culture human VSMCs from the human resistance vessels and to 
undertake gene and protein expression studies in these cells. 
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In the rat resistance vessel work in chapter four, the rationale behind exposing the vessels 
to an elevated phosphate concentration was to try to tease out the isolated effects of 
phosphate from other effects of the uraemic environment. An alternative method would 
have been to have performed these experiments in rats fed on a normal and high phosphate 
diet: this may provide a more accurate reflection of the effects of long term exposure to 
phosphate on endothelial and vascular function. I demonstrate that the addition of PDE5I 
ameliorates the observed detrimental effects of the high phosphate environment. It would 
have been useful to have performed the same experiments in the presence of different 
concentrations of PDE5I and also to have incubated the drug for different time periods and 
compared these results. I measured cGMP in the rat vessels and I went on to use cell lines 
to measure eNOS, VEGF and NO. Culturing endothelial and smooth muscle cells from the 
actual resistance vessels and using these cells would have been more informative. 
Additionally, failure to measure gunaylate cyclase activity and expression is an important 
omission. I used the Griess reaction to measure NO and did not observe any difference in 
the rat VSMCs; one explanation for this might be that the cells were cultured on 96 well 
plates and thus the numbers of cells may have been too small. Furthermore, it is important 
to remember that these are rat resistance vessels from healthy rats, without CKD, and the 
results cannot therefore be extrapolated to CKD or to humans.  
In chapter five, I describe studies in human resistance vessels and although the results are 
interesting, there are a number of limitations. The small numbers of vessels is a major 
limitation. It is also impossible to allow for the many different confounders including mode 
and length of time on RRT of the patients included in the study. The observed 
improvement in the function of the CKD vessels when exposed to a normal concentration 
PSS is an interesting one and I hypothesise that this may relates to the presence of a 
circulating factor which is ‘washed out’. There are several possibilities including ADMA 
and ROS. Measuring the level of these both in the study participants and in the vessels 
would be informative. The linear nature of the relaxation curves (to both carbachol and 
SNP) seen in the vessels from living kidney donors was not expected and is difficult to 
explain but may relate to the length of time the vessels were ex-vivo. The studies should be 
repeated in vessels incubated for shorter time periods. Similarly to the rat studies in chapter 
four, performing the cell culture experiments from cells cultured from the resistance 
vessels themselves would have been more meaningful than using the HUVEC cell line. 
One main aim of this thesis was to study the isolated effects of phosphate, separate from 
other aspects of the uraemic environment. Whilst this has been achieved, in reality any 
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effects of phosphate, particularly in the setting of CKD, are in the presence of other 
abnormalities and are very likely to be intimately connected to phosphate regulators 
including FGF-23 and Klotho. Thus, more in depth study of the effects of FGF-23 and 
Klotho is desirable. Repetition of the cell studies described in chapters four and five in the 
presence of FGF-23 and Klotho, particularly with regards to eNOS expression would be of 
value. Similarly performing the myography experiments in the presence of FGF-23 and 
Klotho would be informative and may offer additional insight into the relationship between 
these factors, phosphate and endothelial function. I demonstrate in chapter six, that 
endothelial cells cultured in a normal phosphate environment express Klotho and the FGF 
receptor. Studying expression in cells cultured in high phosphate should also be undertaken 
and quantification and comparison of expression between the different phosphate 
concentrations would be informative. Measuring Klotho is difficult but it is possible to 
measure both the membrane bound and secreted forms of Klotho and this should have been 
attempted in blood samples from the human vessel study participants and also in extracted 
DNA. Similarly failure to measure eNOS gene expression in DNA from study participants 
is a flaw. 
In terms of the clinical studies undertaken, in chapter three, I studied the association of 
FGF-23 and vascular structure in CKD with additional in-vitro studies on the underlying 
mechanism. The study population comprised patients with CKD secondary to diabetic or 
IgA nephropathy and thus the findings of FGF-23 as an independent predictor of LVH 
cannot be extrapolated to patients with CKD from other aetiologies including inherited 
conditions. Furthermore this was a single centre pilot study and numbers were small and I 
did not prove causality with elevated FGF-23 and LVH. Whilst, I provide some evidence 
that in the hyperphosphataemic environment, FGF-23 stimulates the production of the cell 
adhesion molecules, E-selectin and VCAM. I measured these by ELISA and not Western 
blot. My findings require to be confirmed by Western blot. I did not perform gene 
expression studies and this is also necessary to ascertain what difference, if any, 
hyperphosphataemia and FGF-23 make to gene expression. Furthermore I used the 
HUVEC cell line and the above experiments should be performed in a cardiac myocyte cell 
line to ascertain if similar direct effects to those observed could be seen.  
In chapter seven, I describe a cross over trial in healthy volunteers without CKD looking at 
the effect of sustained phosphate loading on endothelial function. Both sexes were 
included and it may be helpful to repeat this work in a single sex study to ameliorate 
possible effects of the female sex hormones. Dietary phosphate intake was not quantified 
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and this can vary hugely depending upon the types of food consumed, particularly the 
consumption of foods containing preservatives.  Urinary cGMP was utilised as an indirect 
marker of NO production and therefore endothelial function, it may have been 
advantageous to have measured ROS directly in the serum of patients rather than make use 
of a by product. I demonstrate that urinary phosphate excretion and serum FGF-23 are 
significant predictors of worse endothelial function and are likely to be useful markers of 
total body phosphate, providing more information in combination that serum phosphate or 
either measure alone. However I did not measure total body phosphate nor intracellular 
phosphate and it would be informative to do this to determine if serum FGF-23 and urinary 
phosphate excretion correlate and are indeed markers of total body phosphate. Lastly, it is 
possible that patients with CKD may respond differently to sustained phosphate loading 
and thus these results cannot be extrapolated to the CKD population. This study should be 
repeated in a population with CKD, both pre dialysis and dialysis patients, to ascertain if 
the same relationships are present.   
8.3 Future work 
In vivo, the interaction between phosphate, FGF-23, Klotho and other aspects of the 
uraemic environment is complex. Furthermore, it is likely that effects differ between 
individuals and between organ systems. Phosphate causes ED and I provide strong 
evidence that this is why it is associated with CV risk. I have demonstrated that some of 
the effects of phosphate seem to be reversible and this may be a means to lower CV risk in 
CKD. Serum phosphate may not be a good marker of total body phosphate and other 
markers, including FeP should be considered. Phosphate binding medication is not well 
tolerated and there may be better ways in which to lower total body phosphate, e.g. a 
phosphate channel blocker, which would prevent phosphate entering an individual cell.  
There are several identified areas to expand upon the work contained within this thesis. 
Cell based studies focussing on transcription factor expression (p53, SP1 and CREB1) and 
effects of the high phosphate environment on expression of Klotho, the FGF-R and the 
EGF-R in the high phosphate environment. Intracellular phosphate should be measured and 






Figure 8-1: Effects of phosphate leading to ED, based on the findings in this thesis. 
Transcription factors which are likely to be key to the detrimental effects of phosphate are circled in 
red. Phosphate probably affects multiple pathways, with some overlap, causing inflammation via E-
selectin, VCAM, perhaps mediated via c-Fos; cell proliferation and impaired relaxation mediated via 
down-regulation of the NO pathway with the transcription factors SP1, CREB1, p53 and c-Fos 
being of importance. Phosphate also stimulates ROS mediated via the NO pathway. Green arrows 









In human resistance vessels, studies with larger numbers of vessels and to look at the effect 
of zaprinast, ascorbic acid and phosphate channel blockers are of interest. 
A repeat cross-over study in patients with CKD should be performed and additional 
measurements undertaken including intracellular phosphate, secreted Klotho and gene and 
protein expression studies following each intervention.  
A larger observational study looking at FeP and its correlation with serum phosphate and 
with CV outcome is of interest and ultimately an outcome study demonstrating that 
lowered phosphate translates to CV risk reduction and survival benefits.   
8.4 Conclusion 
Figure 8-2 shows possible mechanism of action as phosphate based on the main findings in 
this thesis. Long term exposure to elevated phosphate is associated with direct ED. It is 
likely to be ED which contributes to the elevated CV risk seen in those with CKD and not 
as convention has dictated, VC. In the high phosphate environment, endothelial and 
vascular dysfunction is evident in individual cell lines, in blood vessels and in humans 
exposed to prolonged oral phosphate loading. Strategies to block phosphate transport and 
reduce intracellular phosphate may have therapeutic potential. 
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Figure 8-2: Possible mechanism of action of phosphate resulting in endothelial dysfunction 
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The University of Glasgow, charity number   SC004401 
Dr Kate Stevens 
BHF Glasgow Cardiovascular Research Centre 
University of Glasgow 
126 University Avenue 
Glasgow G12 8TA 




Patient information sheet for patients undergoing abdominal 




Phosphate and endothelial function in human blood vessels 
 
Invitation 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it with 
others if you wish. Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you wish to take part. 
 
What is the Purpose of the Study? 
Patients with kidney disease are at increased risk of heart disease. Traditional risk 
factors for heart disease for example smoking do not adequately explain this increased 
risk. Phosphate, a salt naturally present in the body, is often elevated in patients with 
kidney disease because it is more difficult to excrete it in the urine. Whilst we know 
that high levels of phosphate are a risk factor for heart disease, we don’t understand 
why this should be. High levels of phosphate may interfere with the function of the 
body’s blood vessels making it more difficult for them to contract and relax 
appropriately. Increased phosphate may also cause different substances to be 
produced by cells within the blood vessel walls and may activate different genes 
causing the cells to behave differently to normal. All of this may increase the risk of 
heart disease. Some risk factors for heart disease for example sex cannot be altered 
but it is possible to modify phosphate levels in the body both with dietary measures 
and by taking tablets. It is important therefore that we try to establish why higher 
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levels of phosphate are linked with heart disease so that we can look at targeting 
phosphate as a way to lower the risks of heart disease. 
 
Why have I been chosen? 
We are planning to examine blood vessels from 20 patients who are known to have 
kidney disease and 20 patients who do not have kidney disease. You have been 
selected either because you have kidney disease or because you do not and because 
you are having an operation on your abdomen which involves your surgeon making an 
incision through adipose tissue (fat tissue).  
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do decide to take part 
you will be asked to sign two consent forms. If you decide to take part you are still 
free to withdraw at any time and without giving a reason. A decision to withdraw at 
any time, or a decision not to take part, will not affect the standard of care you 
receive. 
 
What will happen to me if I take part? 
We would like to use any left-over blood vessels from your operation for research. 
When the surgeon is performing your operation, it is necessary to cut through small 
amounts of adipose tissue (fat tissue) under the skin. This tissue is usually discarded 
during the operation. However, there are many small blood vessels contained within 
this tissue which we would like to use. Surgeons will not remove any extra tissue 
for this study. There will be no change to your operation or your treatment in any 
way. We would like to use your spare blood vessels for a number of examinations. For 
example we will examine how your blood vessels contract and relax when exposed to 
different levels of phosphate and which substances are produced by different layers of 
your vessels. We will also look at different genes within your blood sample to see if 
these are turned on or off when exposed to different levels of phosphate. 
 
We would also like to look at your medical notes and copy some of the information 
about any other medical conditions which you may have. Where available we will also 
take a copy of recent findings including blood results and other clinical data such as a 
current blood pressure reading. 
 
What do I have to do? 
To participate, we will ask you to sign three copies of a consent form; 1 copy of which 
you will be able to keep. We will take a blood sample from you and a urine specimen. 
During your operation if your surgeon has excess fat tissue, he will contact us. There 
will be no change to your operation or other treatment in any way. 
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What are the side effects of taking part? 
Your participation in this study will make no difference to your clinical treatment. 
 
What are the possible benefits of taking part? 
There is no direct benefit for you from taking part in this study. However, the 
information we get from this study may help us in the future to have a better 
understanding of the role phosphate plays in heart disease and it may allow us to 
better treat patients with kidney disease and heart disease.  
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone's negligence, then 
you may have grounds for a legal action for compensation against NHS Greater 
Glasgow and Clyde, but you may have to pay for it. Regardless of this, if you wish to 
complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms will be available to you. 
 
Will my taking part in this study be kept confidential? 
Your personal information will be kept on a file and stored in a secure place at the BHF 
Glasgow Cardiovascular Research Centre. The tissue specimens will be labelled with a 
code and not with any personal details so that all analyses will be carried out 
anonymously. All information which is collected about you during the course of the 
research will be kept strictly confidential. Any information about you which leaves the 
hospital will have your name and address removed so that you cannot be recognised 
from it. 
 
What will happen to the results of the research study? 
Results of this study will be published in scientific journals and thereby made available 
to the public. At BHF Glasgow Cardiovascular Research Centre we will have events to 
inform the public about our ongoing research and about results from this and other 
studies. 
 
What will happen to any samples I give? 
You will donate blood vessel samples for research purposes. Some examinations on 
these samples will be done straight away. Other examinations will be done at a later 
stage when we collect more samples from other patients. We will also store some of 
your samples or parts of them for up to 10 years to perform additional tests if 
required. The samples are treated as "gift"; this means you will not be entitled to any 
future financial reimbursement related to this study and related research. Similarly the 
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blood and urine specimens will also be examined straight away and a small amount 
will be stored for future analysis. 
 
Who is organising and funding the research? 
This study is organised by scientists from the BHF Glasgow Cardiovascular Research 
Centre at Glasgow University. The study is funded by charities and researchers will not 
receive any payment for conducting this research. 
 
Who has reviewed the study? 
The West of Scotland Research Ethics Committee 4 has reviewed this study. 
 
Contact for Further Information 
Should you have any further questions please feel free to call Dr K Stevens at the BHF 




Contact: Dr Kate Stevens, Rm 312, 126 University Place, University of Glasgow, G12 8TA 
Tel: +44(0)141-330-2409, email: k.stevens@clinmed.gla.ac.uk 
CONSENT FORM 
Version: 2.0     Date: 25 May 2010 
Title of Project:        Name of Researcher: 
Phosphate and endothelial function in human blood vessels  Dr K. Stevens 
Patient Identification Code for this Study:         
 
 I confirm that I have read and understand the information sheet dated 
31/03/2010 (v1.0) for the above study. I have had the opportunity to consider 
the information, ask questions and have had these answered satisfactorily. 
 
 I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal 
rights being affected. 
 
 I understand that sections of any of my medical notes and data collected 
during the study, may be looked at by members of the research team, where it 
is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
 I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by responsible individuals from regulatory 
authorities or from the NHS trust, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my records. 
 
 I agree to take part in the above project and to give any surplus pieces of 
adipose (fat) tissue removed during my operation for medical research. I agree 
to donate samples of blood and urine, for the purposes of the research project. 
I understand that samples will be examined for genes and proteins that may be 
related to the kidney and phosphate regulation. I agree that my samples will be 
retained for future use. 
 
 I understand that my surgeon will NOT be removing any extra tissue other 
than what is necessary as part of my care 
 
____________________________ ___________  _____________________ 
Name of Participant   Date  Signature 
____________________________ ___________  ____________________ 
Name of Person taking consent  Date  Signature 




The University of Glasgow, charity number   SC004401 
Dr Kate Stevens 
BHF Glasgow Cardiovascular Research Centre 
University of Glasgow 
Glasgow G12 8TA 
       Phone: 0141 330 2409.  Email: Kate.Stevens@Glasgow.ac.uk 
 
*For DRUG RELATED queries, please contact Professor Alan Jardine. Address as above. Phone: 0141-
330-2705.  Email: Alan.Jardine@Glasgow.ac.uk 
Patient information sheet  
 
Study Title: The physiological effects of altering phosphate concentration on the 
function of human blood vessels. 
 
Invitation 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it with 
others if you wish. Ask us if there is anything that is not clear or if you would like 
more information.  
 
What is the Purpose of the Study? 
Phosphate, a salt naturally present in the body, is known to be linked to an increased 
risk of cardiovascular disease. We know that higher levels of phosphate, even within 
the normal range, are a risk factor for heart disease but we don’t understand why. 
Phosphate may interfere with the function of blood vessels and may cause genes to be 
activated causing blood vessels to behave differently. This may increase the risk of 
heart disease. It is possible to reduce phosphate levels with dietary changes and 
medication. It is important to establish why higher levels of phosphate are linked with 
heart disease and then we can look at ways to reduce phosphate levels as a way to 
lower the risks of heart disease. We would like to alter the level of phosphate within 
the body to see how this affects blood vessel function. 
 
Why have I been chosen? 
We are planning to look at the effects of phosphate on blood vessels from 24 patients 
who have no known health problems.   
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do decide to take part 
you will be asked to sign three consent forms. If you decide to take part you are still 
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free to withdraw at any time and without giving a reason. A decision to withdraw at 
any time, or a decision not to take part, will not affect the standard of care you 
receive. 
 
What will happen to me if I take part? 
 
You will be invited to our research centre at The University of Glasgow for 3 90 minute 
appointments over a 6 week period. A taxi will pick you up and take you home. 
 
You are not required to do anything prior to attending for your initial visit (visit 1). 
Between visit 1 and visit 2 you will be given a phosphate binding medication 
(Lanthanum) or a phosphate supplement (Phosphate Sandoz) and asked to take 1 
tablet three times daily for two weeks. After visit 2, you will be given the other tablet 
to take for 2 weeks. You will then attend for visit 3. You will know which of the 2 drugs 
you have been taking but the doctor who sees you will not. This is to avoid any bias 
during the analysis of the results. We ask that you do not divulge which drug you have 
been taking. IF YOU HAVE ANY CONCERNS/QUESTIONS ABOUT THE DRUGS, 
PLEASE CONTACT PROFESSOR ALAN JARDINE (CONTACT DETAILS ABOVE) 
 
On each occasion, we ask you to come fasted and not to take any caffeine for 12 
hours beforehand. We will provide a urine specimen container and ask you to collect 
your urine for 24 hours before attending the appointment. At each visit, we will carry 
out the following tests: 
 
1. Height and weight and blood pressure ask you some simple questions about 
your health and the medication you are taking. This will take no more than 10 
minutes. 
2. Blood samples – about 2 tablespoons in total. We will do a number of different 
tests including phosphate level and kidney function. Some of the blood will be 
stored in our lab and we will use it to look at genes involved in the regulation 
of phosphate. We will also analyse and store your urine specimen. 
3. Examination of the blood vessels in your wrist with a pencil-like probe. It takes 
1 to 2 minutes and gives us useful information about the blood vessels. 
4. Function of the blood vessels. We will measure changes in blood flow with a 
probe on your upper arm. A blood pressure cuff will be placed around your 
forearm and inflated for 5 minutes and then deflated. We can then measure the 
changes in the size of and blood flow to the upper arm blood vessels. The final 
part of the test involves a spray of a medication called GTN spray under the 
tongue. GTN is a very short acting medication which dilates the blood vessels 
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and gives us additional information about the blood vessel function. The whole 
test takes about 20 to 25 minutes. 
 
What are the risks of taking part? 
We will take blood from the vein in your arm which in rare cases results in a small 
bruise. The amount of blood taken for this research does not place you at any risk. 
The other tests are ‘non-invasive’ – the probes are attached to the skin and no 
needles are involved. Measurement of the function of the blood vessels may lead to 
some numbness in the fingers when the blood pressure cuff is inflated. This will 
disappear when the cuff is deflated. A small bruise on your forearm may result from 
the cuff but will disappear within a couple of days. GTN spray is very short acting. In 
some people it can cause a headache will disappear within a few minutes. 
 
Lanthanum and Phosphate Sandoz are well tolerated tablets with few side effects. 
Lanthanum can cause constipation; diarrhoea; nausea; stomach pain; vomiting. 
Serious side effects are uncommon but include allergic reactions (rash; hives; itching; 
difficulty breathing; swelling of the mouth, face, lips, or tongue), dizziness and 
weakness  Phosphate sandoz are well tolerated; apart from nausea and diarrhoea, 
very few side effects have been reported. 
 
What are the possible benefits of taking part? 
There is no direct benefit for you from taking part in this study. However, the 
information we get from this study may help us in the future to have a better 
understanding of the role phosphate plays in heart disease and it may allow us to 
better treat patients who have heart disease or who are at risk of developing it.  
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone's negligence, then 
you may have grounds for a legal action for compensation against NHS Greater 
Glasgow and Clyde, but you may have to pay for it. Regardless of this, if you wish to 
complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms will be available to you. 
 
Will my taking part in this study be kept confidential? 
Your personal information will be kept on a file and stored in a secure place at the BHF 
Glasgow Cardiovascular Research Centre. The blood and urine specimens will be 
labelled with a code and not with any personal details so that all analyses will be 
carried out anonymously. All information which is collected about you during the 
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course of the research will be kept strictly confidential. Any information about you 
which leaves the hospital will have your name and address removed so that you 
cannot be recognised from it. 
 
What will happen to the results of the research study? 
Results of this study will be published in scientific journals and thereby made available 
to the public. At BHF Glasgow Cardiovascular Research Centre we will have events to 
inform the public about our ongoing research and about results from this and other 
studies. 
 
What will happen to any samples I give? 
You will donate blood and urine samples for research purposes. Some examinations on 
these samples will be done straight away. Other examinations will be done at a later 
stage when we collect more samples from other patients. We will also store some of 
your samples or parts of them for up to 10 years to perform additional tests if 
required. The samples are treated as "gift"; this means you will not be entitled to any 
future financial reimbursement related to this study and related research. 
 
Who is organising and funding the research? 
This study is organised by scientists from the BHF Glasgow Cardiovascular Research 
Centre at Glasgow University. The study is funded by charities and researchers will not 
receive any payment for conducting this research. 
 
Who has reviewed the study? 
The West of Scotland Research Ethics Commitee 2 has reviewed this study. 
 
Contact for Further Information 
Should you have any further questions please call Dr K Stevens at the BHF Glasgow 
Cardiovascular Research Centre, telephone 0141 330 2409. FOR DRUG RELATED 
QUERIES, PLEASE CONTACT PROFESSOR JARDINE, TELEPHONE 0141-330-
2705. 
 
If you wish to discuss the study with an independent contact person who is not 
involved in the study, please contact Dr Marie Freel via email on 







Contact: FOR DRUG RELATED QUERIES: Prof Alan Jardine, BHF GCRC, 126 University Place, G12 
8TA. Tel:0141-330-2705 .Email: Alan.Jardine@Glasgow.ac.uk For all other queries: Dr Kate Stevens, BHF 
GCRC, 126 University Place, G12 8TA. Tel:0141-330-2409. Email Kate.Stevens@Glasgow.ac.uk  
CONSENT FORM 
Version: 1.0     Date: 13 September 2011 
Title of Project: The physiological effects of altering phosphate concentration on the function of human 
blood vessels. Name of Researchers: Prof. A. Jardine and Dr K. Stevens 
Patient Identification Code for this Study:         
 
 I confirm that I have read and understand the information sheet dated 13/09/2011 
(v1.0) for the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
 I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affected. 
 
 I understand that sections of my medical notes and data collected during the study, 
may be looked at by members of the research team, where it is relevant to my taking 
part in this research. I give permission for these individuals to have access to my 
records. 
 
 I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by responsible individuals from regulatory authorities or from 
the NHS trust, where it is relevant to my taking part in this research. I give permission 
for these individuals to have access to my records. 
 
 I agree to take part in the above project and undergo the tests described in the 
information sheet. I agree to donate samples of blood and urine. I understand that 
samples will be examined for genes and proteins and agree that my samples will be 
retained for future use. 
 
 I understand that I will be asked to take a phosphate binder and a phosphate 
supplement during the study. 
 
 I agree to my General Practitioner being informed of my participation. 
 
 
___________________________  _________  _____________________ 
Name of Participant   Date         Signature 
 
____________________________  _________  _____________________ 
Name of Person taking consent  Date         Signature 






      GP Letter Version 1 Date 30/06/2011 
 
Study title: The physiological effects of altering phosphate concentration on 
the function of human blood vessels 
 
 






The above patient, who is not known to have chronic kidney disease, has agreed to 
participate in a research study looking at the effects of phosphate on endothelial 
function. Patients with and without chronic kidney disease will undergo a number of 
different tests on 3 separate occasions including non invasive pulse wave analysis, 
endothelial function testing and measures of vascular stiffness. Blood and urine will 
also be analysed. As part of the study patients will take a phosphate binder and 
phosphate supplement; each for a two week period.  
 
We will not routinely report results back to you. However should you wish further 












The physiological effects of altering phosphate concentration on the function of 
human blood vessels. 
 
I would be very grateful if you would consider volunteering for the above study. 
This projects aims to examine the effects of phosphate on the function of blood 
vessels and in particular the lining of the blood vessels. Phosphate is taken in 
through the diet and we have some evidence that levels at the high end of the 
normal range might be associated with an increased risk of cardiovascular 
disease. We do not fully understand why phosphate should increase 
cardiovascular risk but believe that it might be related to damaging effects on the 
blood vessel lining. We would like to alter your phosphate level with tablets and 
measure the effects this has on blood vessel function. Ultimately, we are looking 
to clarify the mechanism of phosphate as a cardiovascular risk factor because it 
can be modified with dietary intervention and drug therapy and therefore   
 
Further information is attached. If you would like to discuss the study further 
(with no obligation) or participate please contact me. 
 
Best Wishes,  
 
Dr Kate Stevens 
0141 330 2409 
Kate.Stevens@glasgow.ac.uk 
  
The ethics approval number for the study is 11/AL/0035  







Illumina® PID Gene Symbol FC Illumina® PID Gene Symbol FC 
ILMN_1806165 HSPA6 -25.3139 ILMN_1743445 FAM107A -2.03453 
ILMN_1789074 HSPA1A -11.4314 ILMN_2374865 ATF3 -2.02714 
ILMN_1729216 CRYAB -9.41668 ILMN_1764709 MAFB -2.02531 
ILMN_3235964 HSPA7 -7.65947 ILMN_1739428 IFIT2 -2.02522 
ILMN_1660436 HSPA1B -7.47329 ILMN_1738335 TNFSF18 -2.02355 
ILMN_1739423 RN7SK -7.24565 ILMN_1801584 CXCR4 -2.01862 
ILMN_3234762 RN5S9 -5.20804 ILMN_1712913 UNC5A -2.0181 
ILMN_3246273 RNU1-3 -5.17103 ILMN_1811472 KIF23 2.00272 
ILMN_3244646 RNU1G2 -5.04368 ILMN_1886655  2.00757 
ILMN_1658383 HSPA6 -4.80295 ILMN_1671843 PSRC1 2.00877 
ILMN_2086095 ID2 -4.77679 ILMN_1724407 TACC3 2.01981 
ILMN_3236653 RNU1-5 -4.704 ILMN_2222008 KIFC1 2.02306 
ILMN_3243644 LOC100132564 -4.51724 ILMN_2392472 CENPA 2.02325 
ILMN_1814221 NPTX1 -4.28743 ILMN_2409298 NUSAP1 2.03674 
ILMN_3239574 SNORD3A -4.24576 ILMN_1796949 TPX2 2.03907 
ILMN_1793990 ID2 -4.1334 ILMN_1700337 TROAP 2.06598 
ILMN_3242315 SNORD3D -4.09294 ILMN_3236160 C4orf49 2.07398 
ILMN_3241034 SNORD3C -3.95073 ILMN_1768097 RPGR 2.07443 
ILMN_1655595 SERPINE2 -3.93494 ILMN_1672611 CDH11 2.08778 
ILMN_3309453 RNU4-1 -3.77473 ILMN_2225718 CENPE 2.08879 
ILMN_1692938 PSAT1 -3.68627 ILMN_1801246 IFITM1 2.10152 
ILMN_1728785 GPR116 -3.56191 ILMN_1666305 CDKN3 2.10514 
ILMN_3240220 RNU1F1 -3.46815 ILMN_1680955 AURKA 2.12336 
ILMN_3245678 RNU1A3 -3.35049 ILMN_1753063 KIF15 2.14086 
ILMN_1746517 KYNU -3.24605 ILMN_2409220 HMMR 2.1558 
ILMN_2341229 CD34 -3.10609 ILMN_2163723 KRT7 2.17037 
ILMN_1751607 FOSB -3.01094 ILMN_1739645 ANLN 2.17495 
ILMN_1796417 ASNS -2.93579 ILMN_1685916 KIF2C 2.18083 
ILMN_1732799 CD34 -2.92934 ILMN_1786125 CCNA2 2.18388 
ILMN_3305273 LOC729779 -2.8901 ILMN_1747911 CDC2 2.18961 
ILMN_1669523 FOS -2.88802 ILMN_1737728 CDCA3 2.2138 
ILMN_2074860 RN7SK -2.88655 ILMN_1664516 CENPF 2.216 
ILMN_2150851 SERPINB2 -2.74696 ILMN_1788166 TTK 2.22291 
ILMN_1687757 AKR1C4 -2.71868 ILMN_2077550 RACGAP1 2.23268 
ILMN_1704537 PHGDH -2.67736 ILMN_1781943 FAM83D 2.25605 
Table A1: Differentially expressed probes identified by Illumina BeadStudio software in HUVECs 
culture in high phosphate.  
PID, probe identification; FC, fold change where the fold change is in cells cultured in high phosphate 
compared with cells cultured normal phosphate medium. Candidate genes are highlighted. 
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Illumina® PID Gene Symbol FC Illumina® PID Gene Symbol FC 
ILMN_1651498 GADD45G -2.58816 ILMN_1751776 CKAP2L 2.2712 
ILMN_1666733 IL8 -2.58615 ILMN_1753449 CST1 2.31416 
ILMN_1775304 DNAJB1 -2.56957 ILMN_1794539 KIF11 2.36294 
ILMN_3241878 RNU6ATAC -2.56502 ILMN_1793025 OSAP 2.37514 
ILMN_2120695 TSPAN7 -2.54602 ILMN_1716279 CENPE 2.37678 
ILMN_2184373 IL8 -2.51539 ILMN_2143155 KIF11 2.40801 
ILMN_2150856 SERPINB2 -2.44167 ILMN_1684217 AURKB 2.41338 
ILMN_1908824  -2.43835 ILMN_1751444 NCAPG 2.44288 
ILMN_1809291 TSPAN7 -2.418 ILMN_2162860 SLFN11 2.50444 
ILMN_1768139 RNU12 -2.37141 ILMN_1726720 NUSAP1 2.52074 
ILMN_2139761 LIMCH1 -2.36854 ILMN_1703906 HJURP 2.55119 
ILMN_1796179 HIST1H2BK -2.35807 ILMN_2072101 C4orf49 2.56007 
ILMN_2173611 MT1E -2.35039 ILMN_1747016 CEP55 2.56808 
ILMN_1798360 CXCR7 -2.33758 ILMN_1752520 SLFN11 2.58088 
ILMN_1775170 MT1X -2.32448 ILMN_1728934 PRC1 2.63054 
ILMN_1813314 HIST1H2BK -2.28837 ILMN_1801939 CCNB2 2.63694 
ILMN_1698725 FRMD3 -2.25119 ILMN_1749829 DLGAP5 2.66043 
ILMN_2371458 CXCR7 -2.21337 ILMN_2051373 NEK2 2.66356 
ILMN_3310351 RNU6-15 -2.19738 ILMN_2301083 UBE2C 2.67029 
ILMN_1910180  -2.17005 ILMN_2202948 BUB1 2.69462 
ILMN_2186137 RRAD -2.15489 ILMN_1801257 CENPA 2.74712 
ILMN_3247458 LOC652750 -2.15003 ILMN_1695658 KIF20A 2.7828 
ILMN_3308335 RNU6-1 -2.14885 ILMN_1714730 UBE2C 2.83813 
ILMN_1770152 ADAMTS18 -2.13135 ILMN_3239771 DLGAP5 2.94993 
ILMN_2412336 AKR1C2 -2.11502 ILMN_1673639 ABI3BP 3.07325 
ILMN_2398107 ASNS -2.0654 ILMN_1663390 CDC20 3.29585 
ILMN_1667081 CCND2 -2.05733 ILMN_1652826 LRRC17 3.48163 
ILMN_1662419 COX7A1 -2.0552 ILMN_1686097 TOP2A 3.48996 
ILMN_1651343 ITGA11 -2.05311 ILMN_2406815 LRRC17 3.85814 
ILMN_3268403 LOC100128252 -2.04976 ILMN_1815184 ASPM 3.99805 
ILMN_1694671 ZFAND2A -2.04516    
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